https://events.diabetes.org/p/s/certified-diabetes-care-and-education-specialist-certification-program-overview-227
https://events.diabetes.org/p/s/welcome-to-the-clinical-update-conference-228
https://events.diabetes.org/p/s/the-adas-standards-of-medical-care-in-diabetes-2023-summary-of-revisions-229
https://events.diabetes.org/p/s/updates-in-insulin-therapy-230
https://events.diabetes.org/p/s/updates-on-non-insulin-medications-for-diabetes-231
https://events.diabetes.org/p/s/heart-failure-and-diabetes-a-complicated-factor-232
https://events.diabetes.org/p/s/the-emotional-side-of-diabetes-messages-233
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-234
https://events.diabetes.org/p/s/stifling-weight-bias-and-stigma-235
https://events.diabetes.org/p/s/obesity-pharmacotherapy-236
https://events.diabetes.org/p/s/youth-onset-type-2-diabetes-237
https://events.diabetes.org/p/s/addressing-the-underlying-risk-factors-for-type-2-diabetes-238
https://events.diabetes.org/p/s/expert-huddle-tackling-obesity-now-speaker-roundtable-239
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-240
https://events.diabetes.org/p/s/nutrition-health-in-young-women-with-diabetes-241
https://events.diabetes.org/p/s/women-and-diabetes-boomers-and-beyond-242
https://events.diabetes.org/p/s/cardiovascular-health-in-women-with-diabetes-243
https://events.diabetes.org/p/s/eye-health-in-women-with-diabetes-244
https://events.diabetes.org/p/s/gestational-diabetes-mellitus-a-glimpse-into-the-future-245
https://events.diabetes.org/p/s/i-am-womanwith-diabetes-speaker-roundtable-246
https://events.diabetes.org/p/s/automated-insulin-delivery-the-ups-and-downs-248
https://events.diabetes.org/p/s/driving-technology-and-type-2-diabetes-249
https://events.diabetes.org/p/s/sustaining-behavioral-health-with-diabetes-technology-250
https://events.diabetes.org/p/s/diabetes-care-living-in-a-techno-world-speaker-panel-251
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-252
https://events.diabetes.org/p/s/product-theater-exploring-the-ada-2023-standards-of-care-recommendation-for-treating-diabetic-foot-ulcers-dfu-with-topical-oxygen-therapy-tot-257
https://events.diabetes.org/p/s/product-theater-find-the-clue-to-a-treatment-option-for-type-2-diabetes-258
https://events.diabetes.org/p/cf/2023-clinical-update-conference-on-demand-433
https://events.diabetes.org/p/s/certified-diabetes-care-and-education-specialist-certification-program-overview-434
https://events.diabetes.org/p/s/welcome-to-the-clinical-update-conference-435
https://events.diabetes.org/p/s/the-adas-standards-of-medical-care-in-diabetes-2023-summary-of-revisions-436
https://events.diabetes.org/p/s/updates-in-insulin-therapy-437
https://events.diabetes.org/p/s/updates-on-non-insulin-medications-for-diabetes-438
https://events.diabetes.org/p/s/heart-failure-and-diabetes-a-complicated-factor-439
https://events.diabetes.org/p/s/the-emotional-side-of-diabetes-messages-440
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-441
https://events.diabetes.org/p/s/stifling-weight-bias-and-stigma-442
https://events.diabetes.org/p/s/obesity-pharmacotherapy-443
https://events.diabetes.org/p/s/youth-onset-type-2-diabetes-444
https://events.diabetes.org/p/s/addressing-the-underlying-risk-factors-for-type-2-diabetes-445
https://events.diabetes.org/p/s/expert-huddle-tackling-obesity-now-speaker-roundtable-446
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-447
https://events.diabetes.org/p/s/nutrition-health-in-young-women-with-diabetes-448
https://events.diabetes.org/p/s/women-and-diabetes-boomers-and-beyond-449
https://events.diabetes.org/p/s/cardiovascular-health-in-women-with-diabetes-450
https://events.diabetes.org/p/s/eye-health-in-women-with-diabetes-451
https://events.diabetes.org/p/s/gestational-diabetes-mellitus-a-glimpse-into-the-future-452
https://events.diabetes.org/p/s/i-am-womanwith-diabetes-speaker-roundtable-453
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-454
https://events.diabetes.org/p/s/automated-insulin-delivery-the-ups-and-downs-455
https://events.diabetes.org/p/s/driving-technology-and-type-2-diabetes-456
https://events.diabetes.org/p/s/sustaining-behavioral-health-with-diabetes-technology-457
https://events.diabetes.org/p/s/diabetes-care-living-in-a-techno-world-speaker-panel-458
https://events.diabetes.org/p/s/hope-for-tomorrow-call-to-action-459
https://events.diabetes.org/p/s/product-theater-exploring-the-ada-2023-standards-of-care-recommendation-for-treating-diabetic-foot-ulcers-dfu-with-topical-oxygen-therapy-tot-460
https://events.diabetes.org/p/s/product-theater-find-the-clue-to-a-treatment-option-for-type-2-diabetes-461
https://events.diabetes.org/p/s/home-page-video-466
https://events.diabetes.org/p/cf/ada-83rd-scientific-sessions-467
https://events.diabetes.org/p/s/discussion-on-diabetes-and-cardiovascular-disease-sglt2-inhibitors-innovative-research-to-inform-clinical-practice-includes-livestream-468
https://events.diabetes.org/p/s/discussion-on-foot-care-includes-livestream-469
https://events.diabetes.org/p/s/discussion-on-eye-health-470
https://events.diabetes.org/p/s/enigma-no-more-recent-discoveries-in-diabetes-foot-management-471
https://events.diabetes.org/p/s/hypoglycemia-in-older-adults-with-diabetes-472
https://events.diabetes.org/p/s/mechanisms-linking-adipose-tissue-to-dyslipidemia-473
https://events.diabetes.org/p/s/dyslipidemia-in-diverse-patient-populations-includes-livestream-474
https://events.diabetes.org/p/s/the-kidneys-on-the-frontline-unraveling-the-kidneys-energetic-response-to-hypoxia-475
https://events.diabetes.org/p/s/balancing-the-scale-addressing-diabetic-kidney-disease-across-the-lifespan-through-weight-loss-with-ada-presidents-select-abstract-presentation-476
https://events.diabetes.org/p/s/emerging-techniques-and-treatments-in-diabetic-peripheral-neuropathy-477
https://events.diabetes.org/p/s/new-insights-in-epidemiology-and-clinical-implications-of-diabetic-neuropathy-with-ada-presidents-select-abstract-presentation-478
https://events.diabetes.org/p/s/retinopathy-risk-other-diseases-devices-disparities-includes-livestream-479
https://events.diabetes.org/p/s/of-mice-and-men-insights-into-diabetic-retinopathy-480
https://events.diabetes.org/p/s/the-future-is-now-artificial-intelligence-and-diabetes-foot-disease-481
https://events.diabetes.org/p/s/hypoglycemia-as-a-quality-measure-rationale-challenges-and-opportunities-482
https://events.diabetes.org/p/s/above-and-beyond-the-regular-lipid-panel-are-additional-measurements-really-needed-483
https://events.diabetes.org/p/s/beyond-antihyperglycemic-and-antihypertensive-agents-for-diabetic-kidney-disease-includes-livestream-484
https://events.diabetes.org/p/s/the-evolving-clinical-spectrum-of-diabetic-neuropathy-485
https://events.diabetes.org/p/s/doc-is-my-glp-1-med-making-my-sight-worse-new-considerations-in-management-of-diabetic-retinopathy-includes-livestream-486
https://events.diabetes.org/p/s/early-diagnosis-of-diabetes-cardiomyopathy-dbcm-what-can-be-done-487
https://events.diabetes.org/p/s/hypoglycemia-catecholamine-and-the-heart-488
https://events.diabetes.org/p/s/risk-factors-and-prevention-of-hypoglycemia-in-people-with-diabetes-or-after-bariatric-surgery-489
https://events.diabetes.org/p/s/stepping-ahead-new-concepts-in-diabetes-lower-extremities-complications-with-roger-pecoraro-award-lecture-includes-livestream-490
https://events.diabetes.org/p/s/emerging-biomarkers-and-omics-approaches-to-predict-cardiovascular-risk-in-diabetes-491
https://events.diabetes.org/p/s/emerging-clinical-risk-factors-that-predict-cardiovascular-disease-in-type-2-diabetes-492
https://events.diabetes.org/p/s/new-progress-in-defining-biological-mechanisms-of-cardiovascular-risk-and-protection-in-diabetes-with-edwin-bierman-award-lecture-includes-livestream-493
https://events.diabetes.org/p/s/current-controversies-in-the-primary-prevention-of-diabetes-macrovascular-complications-includes-livestream-494
https://events.diabetes.org/p/s/joint-adaasn-symposium-how-do-we-address-the-psychosocial-determinants-of-health-in-diabetes-and-kidney-disease-includes-livestream-495
https://events.diabetes.org/p/s/real-world-hypoglycemia-in-older-adults-with-diabetes-496
https://events.diabetes.org/p/s/the-goldilocks-paradigm-of-physical-activity-and-the-foot-in-persons-with-diabetes-includes-livestream-497
https://events.diabetes.org/p/s/new-treatment-possibilities-for-cardiovascular-residual-risk-in-diabetes-includes-livestream-498
https://events.diabetes.org/p/s/sglt2i-and-glp-1ra-in-cardiovascular-disease-an-update-for-clinical-practice-in-2023-includes-livestream-499
https://events.diabetes.org/p/s/implementation-of-guideline-directed-medical-therapy-for-cardiometabolic-disease-emerging-multidisciplinary-initiatives-500
https://events.diabetes.org/p/s/diabetes-kidney-disease-in-type-1-and-type-2-diabetes-the-same-disease-501
https://events.diabetes.org/p/s/what-is-the-best-approach-to-the-management-of-painful-diabetic-neuropathy-502
https://events.diabetes.org/p/s/creating-a-world-without-visual-loss-from-diabetes-503
https://events.diabetes.org/p/s/the-niddk-diabetic-foot-consortium-so-people-with-diabetes-may-stand-firm-504
https://events.diabetes.org/p/s/coordinate-diabetes-study-results-symposium-includes-livestream-505
https://events.diabetes.org/p/s/whats-the-verdict-on-telehealth-for-behavioral-and-psychological-diabetes-care-includes-livestream-506
https://events.diabetes.org/p/s/should-we-curb-the-carbs-includes-livestream-507
https://events.diabetes.org/p/s/to-eat-or-not-to-eat-fasted-vs-postprandial-exercise-for-glycemic-management-includes-livestream-508
https://events.diabetes.org/p/s/discussion-on-behavioral-markers-of-diabetes-self-management-perspectives-from-clinicians-and-people-with-diabetes-509
https://events.diabetes.org/p/s/discussion-on-exercise-physiology-lactate-reimagined-more-than-just-a-waste-product-510
https://events.diabetes.org/p/s/discussion-on-diabetes-self-management-education-and-support-dsmes-includes-livestream-511
https://events.diabetes.org/p/s/discussion-on-nutritional-sciences-and-metabolism-novel-methods-of-dietary-assessment-512
https://events.diabetes.org/p/s/discussion-on-womens-interprofessional-network-of-the-ada-win-ada-amplifying-womens-voices-in-the-diabetes-workforce-a-panel-discussion-includes-livestream-513
https://events.diabetes.org/p/s/is-it-all-about-the-food-514
https://events.diabetes.org/p/s/factors-beyond-the-food-in-clinical-nutrition-research-515
https://events.diabetes.org/p/s/expanding-the-delivery-and-perception-of-clinicians-providing-diabetes-self-management-education-516
https://events.diabetes.org/p/s/preventing-diabetes-lessons-learned-from-diabetes-prevention-programs-517
https://events.diabetes.org/p/s/muscle-metabolism-exercise-and-aging-in-diabetes-518
https://events.diabetes.org/p/s/managing-exercise-in-type-1-diabetes-519
https://events.diabetes.org/p/s/updates-in-diabetes-and-fasting-520
https://events.diabetes.org/p/s/demystifying-device-data-one-download-at-a-time-includes-livestream-521
https://events.diabetes.org/p/s/innovative-psychosocial-and-behavioral-medicine-interventions-in-type-1-diabetes-with-ada-presidents-select-abstract-presentation-includes-livestream-522
https://events.diabetes.org/p/s/behavioral-medicine-and-psychosocial-factors-implicated-in-type-1-diabetes-outcomes-523
https://events.diabetes.org/p/s/psychosocial-factors-in-type-2-diabetes-changing-individuals-and-structural-barriers-with-richard-r-rubin-award-lecture-includes-livestream-524
https://events.diabetes.org/p/s/behavioral-markers-of-diabetes-self-management-state-of-the-science-and-measurement-controversies-honoring-the-legacy-of-mark-peyrot-525
https://events.diabetes.org/p/s/lets-talk-treatment-discussing-options-for-weight-and-diabetes-management-526
https://events.diabetes.org/p/s/empowering-the-acute-care-team-to-optimize-diabetes-care-and-education-527
https://events.diabetes.org/p/s/efficacy-engagement-and-sustainability-of-dietary-management-options-in-type-2-diabetes-time-for-a-reappraisal-528
https://events.diabetes.org/p/s/translating-psychosocial-care-into-real-world-practice-settings-529
https://events.diabetes.org/p/s/hot-topics-in-nutrition-whats-the-evidence-includes-livestream-530
https://events.diabetes.org/p/s/joint-adaadces-symposium-implementing-technology-into-a-busy-practice-it-takes-a-village-includes-livestream-531
https://events.diabetes.org/p/s/able-bodied-aging-physical-activity-considerations-for-older-adults-with-diabetes-532
https://events.diabetes.org/p/s/exercise-as-medicine-physical-activity-for-preventing-and-managing-diabetes-complications-533
https://events.diabetes.org/p/s/ada-education-recognition-program-erp-impact-in-pregnancy-moms-in-control-of-diabetes-534
https://events.diabetes.org/p/s/improving-inclusive-care-in-pediatric-diabetes-clinics-ada-youth-strategies-committee-symposium-535
https://events.diabetes.org/p/s/moving-beyond-hba1c-new-standards-for-assessing-glycemic-control-the-evidence-and-role-of-sensor-based-continuous-glucose-monitoring-cgm-for-improving-patient-care-and-satisfaction-in-persons-with-typ-536
https://events.diabetes.org/p/s/managing-nafldnash-in-people-with-t2-diabetes-disease-burden-diagnosis-currentemerging-armamentarium-537
https://events.diabetes.org/p/s/real-time-continuous-glucose-monitoringgoing-beyond-the-obvious-538
https://events.diabetes.org/p/s/the-importance-of-weight-loss-quality-in-obesity-treatment-539
https://events.diabetes.org/p/s/nutrition-and-technology-for-diabetes-management-and-remission-540
https://events.diabetes.org/p/s/a-360-degree-examination-of-type-1-diabetes-from-patient-identification-to-treatment-and-prevention-541
https://events.diabetes.org/p/s/more-than-weight-treating-obesity-as-part-of-a-comprehensive-care-approach-to-cardiometabolic-disease-542
https://events.diabetes.org/p/s/beyond-the-scales-emerging-strategies-to-improve-metabolic-outcomes-for-people-with-obesity-543
https://events.diabetes.org/p/s/leading-the-charge-on-obesity-management-the-endocrinologists-role-in-empowering-community-providers-to-join-the-fight-cmece-544
https://events.diabetes.org/p/s/nutrition-in-pregnancy-is-low-carb-a-no-go-545
https://events.diabetes.org/p/s/dual-incretin-duel-includes-livestream-546
https://events.diabetes.org/p/s/are-two-better-than-one-initial-combination-therapy-in-type-2-diabetes-mellitus-includes-livestream-547
https://events.diabetes.org/p/s/do-it-yourself-diy-vs-commercial-closed-loop-systems-for-managing-type-1-diabetes-includes-livestream-548
https://events.diabetes.org/p/s/technology-or-immunomodulation-the-best-course-for-management-of-type-1-diabetes-549
https://events.diabetes.org/p/s/discussion-on-diabetes-technology-includes-livestream-550
https://events.diabetes.org/p/s/discussion-on-diabetes-in-primary-care-includes-livestream-551
https://events.diabetes.org/p/s/discussion-on-diabetes-in-youth-includes-livestream-552
https://events.diabetes.org/p/s/discussion-on-health-care-improvement-best-practices-in-implementing-adas-standards-of-care-in-diabetes-includes-livestream-553
https://events.diabetes.org/p/s/discussion-on-pregnancy-and-reproductive-health-metformin-use-in-type-2-diabetes-during-pregnancy-a-debate-includes-livestream-554
https://events.diabetes.org/p/s/discussion-on-clinical-centers-and-programs-555
https://events.diabetes.org/p/s/diabetes-is-costly-across-the-lifespan-and-around-the-world-556
https://events.diabetes.org/p/s/diabetes-treatment-and-the-kidney-557
https://events.diabetes.org/p/s/metabolic-effects-of-dual-incretin-agonism-558
https://events.diabetes.org/p/s/early-type-1-diabetes-with-ada-presidents-select-abstract-presentation-559
https://events.diabetes.org/p/s/type-2-diabetes-in-youth-560
https://events.diabetes.org/p/s/learn-how-to-pitch-your-entrepreneurial-idea-and-get-funding-561
https://events.diabetes.org/p/s/art-of-writing-a-winning-grant-562
https://events.diabetes.org/p/s/cultivating-provider-resiliency-and-preventing-burnout-includes-livestream-563
https://events.diabetes.org/p/s/what-can-diabetes-quality-teams-learn-from-engineers-and-designers-564
https://events.diabetes.org/p/s/overcoming-therapeutic-inertia-leveraging-the-diabetes-care-interprofessional-team-includes-livestream-565
https://events.diabetes.org/p/s/is-metabolic-surgery-or-lifestylemedical-management-of-type-2-diabetes-optimal-for-long-term-health-long-term-outcomes-of-the-armms-t2d-randomized-trial-after-7-12-years-of-follow-up-includes-livestre-566
https://events.diabetes.org/p/s/standardization-of-person-reported-outcomes-pros-a-consensus-statement-567
https://events.diabetes.org/p/s/management-of-the-athlete-with-diabetes-includes-livestream-568
https://events.diabetes.org/p/s/interactive-case-studies-optimizing-diabetes-technology-in-special-populations-includes-livestream-569
https://events.diabetes.org/p/s/interactive-case-studies-aid-systems-which-setting-would-you-change-includes-livestream-570
https://events.diabetes.org/p/s/innovation-challenge-includes-livestream-note-continuing-education-credit-is-not-awarded-for-this-session-571
https://events.diabetes.org/p/s/diabetes-in-the-hospital-hospitalization-early-consultation-and-optimizing-discharge-572
https://events.diabetes.org/p/s/evidence-for-reaching-out-to-overcome-barriers-and-achieve-goals-573
https://events.diabetes.org/p/s/insights-into-novel-determinants-of-outcomes-in-pregnancies-complicated-by-hyperglycemia-574
https://events.diabetes.org/p/s/advances-in-diagnosis-and-novel-treatments-for-diabetes-in-pregnancy-575
https://events.diabetes.org/p/s/advances-in-incretin-therapy-576
https://events.diabetes.org/p/s/early-intervention-577
https://events.diabetes.org/p/s/treatments-new-and-old-578
https://events.diabetes.org/p/s/sglt-inhibition-with-ada-presidents-select-abstract-presentation-579
https://events.diabetes.org/p/s/insulin-delivery-technologies-580
https://events.diabetes.org/p/s/insulin-delivery-technologies-581
https://events.diabetes.org/p/s/glucose-monitoring-technologies-582
https://events.diabetes.org/p/s/glucose-monitoring-technologies-583
https://events.diabetes.org/p/s/novel-approaches-to-characterization-and-treatment-of-diabetes-in-pregnancy-with-norbert-freinkel-award-lecture-includes-livestream-584
https://events.diabetes.org/p/s/do-quality-improvement-efforts-reduce-health-care-disparities-585
https://events.diabetes.org/p/s/remission-or-bust-586
https://events.diabetes.org/p/s/time-in-range-where-are-we-headed-in-2023-includes-livestream-587
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-includes-livestream-588
https://events.diabetes.org/p/s/extending-our-reach-using-technology-and-clinical-collaborations-to-improve-outcomes-589
https://events.diabetes.org/p/s/improving-outcomes-for-adolescents-with-type-2-diabetes-590
https://events.diabetes.org/p/s/automated-insulin-delivery-use-among-pregnant-women-with-type-1-diabetes-past-present-and-future-591
https://events.diabetes.org/p/s/genetics-of-glucose-metabolism-in-pregnancy-592
https://events.diabetes.org/p/s/the-heart-of-the-matter-cardiovascular-health-during-pregnancy-and-beyond-593
https://events.diabetes.org/p/s/transforming-therapy-with-ultra-long-acting-insulins-594
https://events.diabetes.org/p/s/addressing-context-to-facilitate-individualized-diabetes-management-595
https://events.diabetes.org/p/s/glucagon-fest-596
https://events.diabetes.org/p/s/continuous-glucose-monitoring-in-type-2-diabetes-are-we-there-yet-includes-livestream-597
https://events.diabetes.org/p/s/overcoming-barriers-to-diabetes-technology-598
https://events.diabetes.org/p/s/joint-adajdrf-symposium-global-perspective-on-population-level-type-1-diabetes-screening-and-monitoring-599
https://events.diabetes.org/p/s/joint-adaispad-symposium-why-arent-all-guidelines-the-same-a-focused-review-of-recommendations-from-ispad-2022-and-ada-2023-600
https://events.diabetes.org/p/s/ada-symposium-major-advances-and-discoveries-in-diabetes-the-year-in-review-includes-livestream-601
https://events.diabetes.org/p/s/diabetes-in-the-child-with-obesity-602
https://events.diabetes.org/p/s/retatrutide-ly3437943-a-novel-gipglp-1glucagon-receptor-triagonist-obesity-nafld-and-t2d-phase-2-trial-results-includes-livestream-603
https://events.diabetes.org/p/s/niddk-early-career-investigator-symposium-behavioral-and-physiological-adaptations-to-optimize-glucose-control-with-technology-what-is-needed-to-improve-outcomes-and-to-overcome-access-and-adoption-ba-604
https://events.diabetes.org/p/s/ada-diabetes-care-symposium-social-determinants-of-health-impact-on-diabetes-development-and-care-605
https://events.diabetes.org/p/s/joint-adaaacc-symposium-hyperglycemia-in-the-hospital-are-our-tools-for-measurement-accurate-enough-606
https://events.diabetes.org/p/s/joint-adaeasd-symposium-precision-medicine-in-diabetes-pmdi-includes-livestream-607
https://events.diabetes.org/p/s/oral-semaglutide-for-treatment-of-obesity-and-type-2-diabetes-results-from-oasis-1-and-pioneer-plus-trials-includes-livestream-608
https://events.diabetes.org/p/s/surmount-2-trial-results-and-potential-role-of-tirzepatide-in-treating-obesity-in-type-2-diabetes-includes-livestream-609
https://events.diabetes.org/p/s/where-lie-the-keys-to-type-2-diabetes-prevention-population-health-or-personalized-medicine-includes-livestream-610
https://events.diabetes.org/p/s/discussion-on-public-health-and-epidemiology-have-we-succeeded-in-type-2-diabetes-primary-prevention-a-debate-611
https://events.diabetes.org/p/s/kelly-west-award-for-outstanding-achievement-in-epidemiology-lecture-includes-livestream-612
https://events.diabetes.org/p/s/type-1-diabetes-genetic-risk-and-mechanisms-613
https://events.diabetes.org/p/s/prediabetes-diabetes-and-the-aging-brain-with-ada-presidents-select-abstract-presentation-614
https://events.diabetes.org/p/s/diabetes-endotypes-defined-by-dna-615
https://events.diabetes.org/p/s/microbiome-metabolome-lipidome-transcriptome-proteome-and-genome-oh-my-novel-insights-from-omics-based-biomarkers-616
https://events.diabetes.org/p/s/moving-beyond-simple-descriptions-of-race-disparities-structural-and-social-inequalities-and-diabetes-outcome-disparities-617
https://events.diabetes.org/p/s/multiancestry-and-longitudinal-type-2-diabetes-genetic-risk-618
https://events.diabetes.org/p/s/functional-characterization-of-type-2-diabetes-genetic-loci-with-ada-presidents-select-abstract-presentation-619
https://events.diabetes.org/p/s/immigration-and-diabetes-diabetes-risk-prevention-and-management-in-a-changing-american-landscape-includes-livestream-620
https://events.diabetes.org/p/s/real-world-data-in-diabetes-research-promise-or-peril-621
https://events.diabetes.org/p/s/the-road-less-traveled-us-rurality-and-diabetes-622
https://events.diabetes.org/p/s/multiancestry-genome-wide-association-studies-gwas-and-polygenic-risk-score-prs-includes-livestream-623
https://events.diabetes.org/p/s/all-the-omics-what-do-they-tell-us-about-diabetes-624
https://events.diabetes.org/p/s/the-ongoing-impact-of-the-dcctedic-study-at-40-years-625
https://events.diabetes.org/p/s/joint-adathe-lancet-symposium-global-inequity-in-diabetes-an-international-perspective-626
https://events.diabetes.org/p/s/ada-chief-executive-officer-remarks-president-health-care-and-education-address-and-outstanding-educator-in-diabetes-award-lecture-includes-livestream-627
https://events.diabetes.org/p/s/molecular-metabolism-628
https://events.diabetes.org/p/s/inflammatory-signaling-and-insulin-action-629
https://events.diabetes.org/p/s/twitter-bugs-dancing-between-the-carbohydrate-insulin-and-energy-balance-models-includes-livestream-630
https://events.diabetes.org/p/s/adipose-thermogenesis-and-body-weight-homeostasis-631
https://events.diabetes.org/p/s/hepatic-regulation-of-metabolism-includes-livestream-632
https://events.diabetes.org/p/s/regulation-of-insulin-signaling-633
https://events.diabetes.org/p/s/unraveling-novel-regulators-of-metabolism-634
https://events.diabetes.org/p/s/interoception-conversations-with-adipocytes-635
https://events.diabetes.org/p/s/cellular-cross-talk-regulating-insulin-action-636
https://events.diabetes.org/p/s/mitochondrial-metabolism-and-glucose-homeostasis-637
https://events.diabetes.org/p/s/its-about-time-eating-and-exercising-in-metabolic-health-638
https://events.diabetes.org/p/s/how-sex-shapes-metabolism-and-glucose-homeostasis-639
https://events.diabetes.org/p/s/observing-metabolism-through-new-lenses-includes-livestream-640
https://events.diabetes.org/p/s/is-it-time-to-revise-our-thinking-on-the-role-of-the-katp-channel-in-insulin-secretion-641
https://events.diabetes.org/p/s/discussion-on-islet-biology-development-and-function-alpha-beta-and-delta-cells-of-the-islets-more-than-just-neighbors-includes-livestream-642
https://events.diabetes.org/p/s/rescuing-islets-in-type-1-diabetes-with-ada-presidents-select-abstract-presentation-643
https://events.diabetes.org/p/s/beta-cell-stress-and-exit-644
https://events.diabetes.org/p/s/novel-insights-into-islet-development-includes-livestream-645
https://events.diabetes.org/p/s/insulin-secretion-646
https://events.diabetes.org/p/s/the-islet-neighborhood-includes-livestream-647
https://events.diabetes.org/p/s/endoplasmic-reticulum-er-stressed-out-beta-cells-648
https://events.diabetes.org/p/s/the-jekyll-and-hyde-of-inflammatory-signals-in-islets-includes-livestream-649
https://events.diabetes.org/p/s/beta-cell-identity-from-prenatal-life-to-death-650
https://events.diabetes.org/p/s/the-islet-cell-interactome-includes-livestream-651
https://events.diabetes.org/p/s/lets-talk-about-sex-differences-in-islet-biology-includes-livestream-652
https://events.diabetes.org/p/s/comparing-beta-cell-replacement-vs-artificial-pancreas-smart-insulins-with-a-focus-on-new-innovations-untested-technologies-includes-livestream-653
https://events.diabetes.org/p/s/discussion-on-immunology-immunogenetics-and-transplantation-engineering-islets-and-dealing-with-the-immune-system-includes-livestream-654
https://events.diabetes.org/p/s/cellular-and-molecular-mechanisms-of-type-1-diabetes-655
https://events.diabetes.org/p/s/islet-endocrine-cells-and-beta-cell-surrogates-656
https://events.diabetes.org/p/s/the-new-normal-perspectives-on-treatment-and-trials-as-immunotherapies-enter-the-type-1-diabetes-clinical-landscape-includes-livestream-657
https://events.diabetes.org/p/s/steps-to-better-treating-type-1-diabetes-658
https://events.diabetes.org/p/s/heterogeneity-in-type-1-diabetes-includes-livestream-659
https://events.diabetes.org/p/s/innovative-engineering-approaches-to-improve-isletbeta-cell-transplantation-660
https://events.diabetes.org/p/s/clinical-islet-cell-transplantation-includes-livestream-661
https://events.diabetes.org/p/s/controlling-the-communicators-cytokine-specific-therapies-to-preserve-beta-cell-function-in-type-1-diabetes-662
https://events.diabetes.org/p/s/the-quest-to-delay-or-prevent-type-1-diabetes-onset-recent-interventional-trials-includes-livestream-663
https://events.diabetes.org/p/s/type-1-diabetes-through-another-lens-lessons-from-other-disease-settings-includes-livestream-664
https://events.diabetes.org/p/s/clinical-cell-therapy-for-diabetes-665
https://events.diabetes.org/p/s/designer-beta-cells-666
https://events.diabetes.org/p/s/engineering-and-site-consideration-for-cell-therapy-667
https://events.diabetes.org/p/s/hope-or-hype-role-of-microbiome-in-obesity-includes-livestream-668
https://events.diabetes.org/p/s/aging-related-metabolic-disease-major-drivers-and-therapeutic-strategies-includes-livestream-669
https://events.diabetes.org/p/s/only-time-will-tell-early-eating-or-just-eating-includes-livestream-670
https://events.diabetes.org/p/s/new-insights-into-glucose-and-metabolic-regulation-671
https://events.diabetes.org/p/s/molecular-and-cellular-pathways-in-metabolic-control-672
https://events.diabetes.org/p/s/environmental-impacts-on-obesity-and-its-treatment-673
https://events.diabetes.org/p/s/metabolic-liver-disease-from-bench-to-bedside-674
https://events.diabetes.org/p/s/obesity-and-metabolic-disease-a-focus-on-females-675
https://events.diabetes.org/p/s/new-breakthrough-in-adipose-tissue-biology-676
https://events.diabetes.org/p/s/antiobesity-and-antidiabetes-therapeutics-targets-and-mechanistic-insights-677
https://events.diabetes.org/p/s/the-molecular-consequences-of-obesity-across-human-tissues-678
https://events.diabetes.org/p/s/bariatric-surgery-and-beyond-the-benefits-of-battling-obesity-679
https://events.diabetes.org/p/s/beyond-calories-in-calories-out-in-treating-obesity-includes-livestream-680
https://events.diabetes.org/p/s/nutrient-stimulated-hormones-anti-obesity-pharmacotherapy-game-changers-includes-livestream-681
https://events.diabetes.org/p/s/welcome-to-exosomes-their-role-in-obesity-682
https://events.diabetes.org/p/s/exercise-and-metabolic-health-insight-from-animal-studies-683
https://events.diabetes.org/p/s/single-cell-rnaseq-revolution-decipher-metabolism-one-cell-at-a-time-684
https://events.diabetes.org/p/s/chrononutrition-for-the-prevention-and-treatment-of-diabetes-685
https://events.diabetes.org/p/s/metabolic-adaptation-to-weight-loss-in-humans-686
https://events.diabetes.org/p/s/diabetic-myopathy-and-muscle-metabolism-687
https://events.diabetes.org/p/s/ada-diabetes-journal-symposium-staying-in-network-adipocyte-communication-in-regulation-of-energy-balance-688
https://events.diabetes.org/p/s/president-medicine-and-science-address-and-banting-medal-for-scientific-achievement-includes-livestream-689
https://events.diabetes.org/p/s/national-scientific-and-health-care-achievement-awards-presentation-and-outstanding-scientific-achievement-award-lecture-includes-livestream-690
https://events.diabetes.org/p/s/pathway-to-stop-diabetes-symposium-includes-livestream-691
https://events.diabetes.org/p/s/welcome-to-the-83rd-ada-scientific-sessions-keynote-address-by-francis-collins-md-phd-and-panel-discussion-includes-livestream-692
https://events.diabetes.org/p/s/sglt2-inhibitors-further-evidence-for-heart-failure-with-preserved-ejection-fraction-as-a-metabolic-disease-693
https://events.diabetes.org/p/s/sglt2-inhibitor-effects-on-inflammation-and-heart-disease-in-obesity-694
https://events.diabetes.org/p/s/sglt2-inhibitors-and-cardiac-remodeling-695
https://events.diabetes.org/p/s/welcome-and-introduction-696
https://events.diabetes.org/p/s/question-and-discussion-period-697
https://events.diabetes.org/p/s/toe-and-flow-plus-sodoh-preventing-amputations-via-social-determinants-of-health-in-diabetic-foot-care-698
https://events.diabetes.org/p/s/welcome-and-introduction-699
https://events.diabetes.org/p/s/when-resources-are-scarce-how-to-manage-pad-in-rural-and-underserved-communities-700
https://events.diabetes.org/p/s/diabetes-and-the-eye-701
https://events.diabetes.org/p/s/welcome-and-introduction-702
https://events.diabetes.org/p/s/diabetic-retinopathy-results-from-the-today-study-703
https://events.diabetes.org/p/s/a-novel-macrophage-regulation-drug-for-treating-diabetic-foot-ulcer-a-phase-iii-mrct-study-and-taiwan-experience-704
https://events.diabetes.org/p/s/systematic-intraoperative-bone-sampling-increases-healing-chances-in-diabetic-foot-osteomyelitis-705
https://events.diabetes.org/p/s/barriers-to-diabetic-foot-care-in-urban-safety-net-hospital-706
https://events.diabetes.org/p/s/outcomes-of-patients-with-and-without-severe-renal-impairment-admitted-with-moderate-and-severe-diabetic-foot-infections-707
https://events.diabetes.org/p/s/severe-hypoglycemia-among-older-adults-with-diabetes-inphorm-usa-708
https://events.diabetes.org/p/s/impaired-awareness-of-hypoglycemia-iah-in-older-adults-with-type-1-diabetes-in-the-wisdm-study-709
https://events.diabetes.org/p/s/burden-of-hypoglycemia-in-medicare-advantage-beneficiaries-with-type-2-diabetes-not-on-insulin-therapy-710
https://events.diabetes.org/p/s/risk-factors-for-continuous-glucose-monitoring-cgm-detected-hypoglycemia-in-very-old-adults-with-type-2-diabetes-711
https://events.diabetes.org/p/s/evaluation-of-saroglitazars-effects-on-small-dense-ldl-and-non-hdl-cholesterol-particles-in-diabetic-dyslipidemia-patients-712
https://events.diabetes.org/p/s/adipocyte-angptl8-regulates-insulin-sensitivity-and-thermogenic-programing-713
https://events.diabetes.org/p/s/novel-mechanism-of-lipoprotein-lipase-folding-and-maturation-in-adipocytes-714
https://events.diabetes.org/p/s/par2-downregulates-adipose-lpl-through-mif-a-novel-adipose-mechanism-contributing-to-the-development-of-hypertriglyceridemia-715
https://events.diabetes.org/p/s/effect-of-nutritional-ketosis-trajectory-on-change-in-glycemia-weight-and-atherogenic-dyslipidemia-over-two-years-in-people-with-type-2-diabetes-716
https://events.diabetes.org/p/s/the-triglyceride-glucose-index-may-be-a-surrogate-for-both-insulin-resistance-and-atherogenic-lipid-profile-in-africans-717
https://events.diabetes.org/p/s/diabetes-and-dyslipidemia-in-young-a-hidden-pandemic-real-world-multicentric-study-from-india-718
https://events.diabetes.org/p/s/the-efficacy-and-safety-of-glucagon-like-peptide-1-agonists-in-patients-with-familial-partial-lipodystrophy-719
https://events.diabetes.org/p/s/the-triple-roles-of-tubular-mitochondria-akt-in-the-regulation-of-renal-function-insulin-resistance-and-body-composition-during-development-of-diabetic-nephropathy-720
https://events.diabetes.org/p/s/insulin-resistance-ir-and-kidney-oxidative-metabolism-in-people-with-type-1-diabetes-t1d-721
https://events.diabetes.org/p/s/urine-lactate-is-a-disease-biomarker-for-diabetic-kidney-disease-722
https://events.diabetes.org/p/s/fetal-renal-hypoxia-response-to-maternal-overnutrition-723
https://events.diabetes.org/p/s/effect-of-vertical-sleeve-gastrectomy-vsg-on-the-kidney-transcriptome-of-youth-with-type-2-diabetes-t2d-724
https://events.diabetes.org/p/s/tirzepatide-reduces-albuminuria-in-patients-with-t2d-post-hoc-pooled-analysis-of-surpass-1-5-725
https://events.diabetes.org/p/s/metabolomic-analyses-identify-novel-predictors-of-diabetic-kidney-disease-in-youth-onset-type-2-diabetes-726
https://events.diabetes.org/p/s/ada-presidents-select-abstract-structural-lesions-on-kidney-biopsy-in-youth-onset-type-1-diabetes-t1d-and-type-2-diabetes-t2d-727
https://events.diabetes.org/p/s/identifying-painful-diabetic-neuropathy-subtypes-from-resting-state-functional-magnetic-resonance-brain-imaging-a-novel-unsupervised-machine-learning-approach-728
https://events.diabetes.org/p/s/omega-3-polyunsaturated-fatty-acids-in-the-treatment-of-diabetic-peripheral-neuropathy-is-the-source-important-729
https://events.diabetes.org/p/s/lx9211-an-orally-administered-non-opioid-aak1-inhibitor-for-painful-diabetic-peripheral-neuropathy-results-from-a-randomized-double-blind-placebo-controlled-parallel-group-multicenter-study-730
https://events.diabetes.org/p/s/degludec-like-insulin-analog-improves-peripheral-neuropathy-more-than-control-insulin-independent-of-glycemic-control-in-a-rat-model-of-type-2-diabetes-731
https://events.diabetes.org/p/s/differential-associations-of-obesity-and-metabolic-syndrome-with-polyneuropathy-in-early-type-2-diabetes-and-normal-glucose-tolerance-732
https://events.diabetes.org/p/s/proinflammatory-macrophage-infiltration-in-sural-nerve-is-associated-with-reduction-of-myelinated-nerve-fiber-density-but-not-ienfd-in-human-diabetic-subjects-733
https://events.diabetes.org/p/s/ada-presidents-select-abstract-risk-factors-for-distal-symmetrical-polyneuropathy-dspn-in-the-diabetes-prevention-program-dpp-and-the-dpp-outcomes-study-dppos-734
https://events.diabetes.org/p/s/association-of-silent-myocardial-infarction-with-cardiac-autonomic-neuropathy-among-asymptomatic-patients-with-type-2-diabetes-735
https://events.diabetes.org/p/s/autonomous-artificial-intelligence-diabetic-eye-exams-to-mitigate-disparities-in-screening-completion-736
https://events.diabetes.org/p/s/association-of-diabetic-retinopathy-with-a1c-and-glucose-management-indicator-discordance-737
https://events.diabetes.org/p/s/prior-cerebrovascular-disease-was-positively-associated-with-severe-diabetic-retinopathy-and-diabetic-macular-edema-in-type-2-diabetes-738
https://events.diabetes.org/p/s/clinical-and-biochemical-factors-are-inversely-correlated-in-diabetic-retinopathy-and-age-related-macular-degeneration-739
https://events.diabetes.org/p/s/rod-photoreceptor-contribution-to-inflammation-and-angiogenesis-in-diabetic-retinopathy-740
https://events.diabetes.org/p/s/smaller-hdl-particles-and-abca1-cholesterol-efflux-capacity-predict-incident-proliferative-retinopathy-only-among-men-with-type-1-diabetes-741
https://events.diabetes.org/p/s/glucagon-like-peptide-1-receptor-agonists-preserved-vascular-endothelial-junction-through-inhibition-of-sting-signaling-elicited-inflammation-in-diabetic-retinopathy-742
https://events.diabetes.org/p/s/vegf-is-a-contributing-factor-for-the-reduction-of-retinal-function-in-diabetic-retinopathy-and-hypoxic-retinal-disorders-743
https://events.diabetes.org/p/s/the-future-is-now-artificial-intelligence-and-diabetes-foot-disease-744
https://events.diabetes.org/p/s/the-future-is-now-artificial-intelligence-and-diabetes-foot-disease-745
https://events.diabetes.org/p/s/the-future-is-now-artificial-intelligence-and-diabetes-foot-disease-746
https://events.diabetes.org/p/s/the-future-is-now-artificial-intelligence-and-diabetes-foot-disease-747
https://events.diabetes.org/p/s/endocrinology-perspective-748
https://events.diabetes.org/p/s/ncqa-perspective-749
https://events.diabetes.org/p/s/ada-perspective-750
https://events.diabetes.org/p/s/hypoglycemia-among-medicare-beneficiaries-potential-opportunities-and-challenges-for-measurement-751
https://events.diabetes.org/p/s/primary-care-perspective-752
https://events.diabetes.org/p/s/commercial-insurance-perspective-753
https://events.diabetes.org/p/s/lipoprotein-disorders-when-do-we-need-genetic-testing-754
https://events.diabetes.org/p/s/when-to-use-coronary-artery-calcium-and-new-imaging-to-complement-lipid-panels-755
https://events.diabetes.org/p/s/more-specific-lipoprotein-measurements-are-they-a-waste-of-time-and-money-or-do-they-personalize-lipid-management-756
https://events.diabetes.org/p/s/future-therapies-targeting-mitochondrial-dysfunction-and-oxidative-stress-to-mitigate-diabetic-kidney-disease-intracellular-nad-plus-jak-stat-tgfbeta-757
https://events.diabetes.org/p/s/are-we-following-the-guidelines-and-using-the-newer-therapies-to-protect-against-diabetic-kidney-disease-758
https://events.diabetes.org/p/s/what-about-children-and-adolescents-with-diabetes-759
https://events.diabetes.org/p/s/question-and-discussion-period-760
https://events.diabetes.org/p/s/how-does-diabetic-peripheral-neuropathy-interconnect-with-autonomic-neuropathy-761
https://events.diabetes.org/p/s/update-on-mechanisms-762
https://events.diabetes.org/p/s/when-and-how-does-the-neuropathy-start-763
https://events.diabetes.org/p/s/new-therapies-for-diabetic-retinopathy-how-do-they-compare-with-what-we-already-have-764
https://events.diabetes.org/p/s/novel-diabetes-therapies-glp-1-sglt2-dpp-4s-and-diabetic-retinopathy-765
https://events.diabetes.org/p/s/question-and-discussion-period-766
https://events.diabetes.org/p/s/molecular-mechanisms-leading-to-diabetic-cardiomyopathy-767
https://events.diabetes.org/p/s/diagnosis-of-diabetic-cardiomyopathy-based-on-circulating-marker-of-disease-768
https://events.diabetes.org/p/s/cross-sectional-analysis-of-a-large-cohort-of-patients-with-dbcm-enrolled-in-a-longitudinal-study-the-baseline-results-of-the-arise-hf-trial-769
https://events.diabetes.org/p/s/norepinephrine-mediates-severe-hypoglycemia-induced-fatal-heart-block-in-rats-770
https://events.diabetes.org/p/s/prevailing-glucose-levels-alter-left-ventricular-contractions-pattern-myocardial-performance-and-myocardial-energy-efficiency-771
https://events.diabetes.org/p/s/causative-role-of-hypothalamic-ventromedial-glucose-inhibited-neurons-in-impaired-counterregulatory-responses-to-hypoglycemia-772
https://events.diabetes.org/p/s/revisiting-the-impact-of-opioid-receptor-blockade-on-hypoglycemia-associated-autonomic-failure-haaf-773
https://events.diabetes.org/p/s/counterregulatory-response-to-hypoglycemia-is-improved-with-serotonin-and-norepinephrine-reuptake-inhibitors-774
https://events.diabetes.org/p/s/cgm-time-below-range-predicts-epinephrine-response-to-hypoglycemia-in-patients-with-type-1-diabetes-775
https://events.diabetes.org/p/s/effects-of-roux-en-y-gastric-bypass-on-postprandial-glucose-turnover-assessed-through-the-single-tracer-oral-minimal-model-776
https://events.diabetes.org/p/s/continuous-glucose-monitoring-in-patients-with-post-bariatric-hypoglycemia-reduces-hypoglycemia-and-glycemic-variability-777
https://events.diabetes.org/p/s/predictors-of-impaired-awareness-of-hypoglycemia-in-adults-with-type-1-diabetes-778
https://events.diabetes.org/p/s/the-impact-of-identifying-sleep-with-a-fitbit-on-calculated-rates-of-nocturnal-hypoglycemia-the-hypo-metrics-study-779
https://events.diabetes.org/p/s/majority-of-sensor-hypoglycemia-is-not-detected-by-people-living-with-diabetes-hypo-metrics-study-780
https://events.diabetes.org/p/s/effect-of-continuous-glucose-monitoring-on-hypoglycemia-diet-liberalization-and-quality-of-life-in-post-bariatric-hypoglycemia-781
https://events.diabetes.org/p/s/social-determinants-of-health-predict-diabetic-foot-infection-development-782
https://events.diabetes.org/p/s/mean-hba1c-and-glycaemic-variability-are-associated-with-adverse-outcomes-following-infrainguinal-bypass-for-peripheral-arterial-disease-pad-a-retrospective-cohort-study-783
https://events.diabetes.org/p/s/the-infected-diabetic-foot-the-mrsa-incidence-conversion-of-non-mrsa-to-mrsa-pathogens-and-reinfection-in-soft-tissue-and-bone-infections-784
https://events.diabetes.org/p/s/roger-pecoraro-award-lecture-health-inequalities-and-limb-preservation-785
https://events.diabetes.org/p/s/metabolomics-analysis-reveals-links-between-stress-hyperglycemia-and-underlying-differences-in-branched-chain-amino-acid-metabolism-and-microbiome-host-interactions-786
https://events.diabetes.org/p/s/ceramides-predict-the-development-of-type-2-diabetes-787
https://events.diabetes.org/p/s/cystatin-c-predicts-major-cardiovascular-events-in-patients-with-coronary-artery-disease-both-among-patients-with-and-among-those-without-the-metabolic-syndrome-788
https://events.diabetes.org/p/s/remnant-cholesterol-predicts-major-cardiovascular-events-in-cardiovascular-disease-patients-with-nafld-789
https://events.diabetes.org/p/s/genetically-supported-therapeutic-targets-for-coronary-artery-disease-in-diabetes-evidence-from-proteome-wide-mendelian-randomization-790
https://events.diabetes.org/p/s/apolipoprotein-c-ii-posttranslational-truncation-is-associated-with-reduced-incident-cardiovascular-risk-in-multiethnic-study-of-atherosclerosis-mesa-791
https://events.diabetes.org/p/s/arterial-stiffness-and-diabetes-associated-complications-in-the-search-for-diabetes-in-youth-study-792
https://events.diabetes.org/p/s/the-apobldl-c-ratio-predicts-major-cardiovascular-events-in-cardiovascular-disease-patients-independent-of-type-2-diabetes-status-793
https://events.diabetes.org/p/s/postpartum-weight-retention-and-the-early-evolution-of-cardiovascular-risk-over-the-first-5-years-after-delivery-794
https://events.diabetes.org/p/s/hypoglycemia-effect-on-relationship-of-renal-andor-retinal-disease-with-cvd-and-vice-versa-795
https://events.diabetes.org/p/s/type-2-diabetes-and-chronic-kidney-disease-as-predictors-of-cardiovascular-mortality-in-patients-with-established-cardiovascular-disease-796
https://events.diabetes.org/p/s/diabetic-kidney-disease-dkd-and-nonalcoholic-fatty-liver-disease-nafld-confer-worsening-all-cause-mortality-and-cardiovascular-disease-cvd-risk-in-type-2-diabetes-t2d-797
https://events.diabetes.org/p/s/edwin-bierman-award-lecture-benefits-of-lowering-liver-fat-in-prediabetes-and-diabetes-798
https://events.diabetes.org/p/s/circulating-foamy-cd36hi-ly6clo-monocytes-in-mouse-models-of-diabetic-dyslipidemia-799
https://events.diabetes.org/p/s/insulin-prevents-palmitate-induced-stress-kinase-activation-autophagy-and-apoptosis-in-human-cardiac-progenitor-cells-800
https://events.diabetes.org/p/s/sglt2-inhibitors-exert-anti-inflammatory-and-antioxidant-effects-in-epicardial-adipose-tissue-of-severe-heart-failure-subjects-801
https://events.diabetes.org/p/s/insulin-stabilized-arterial-plaque-by-regulating-vascular-smooth-muscle-cell-metabolism-and-differentiation-802
https://events.diabetes.org/p/s/current-controversies-in-the-primary-prevention-of-diabetes-macrovascular-complications-803
https://events.diabetes.org/p/s/current-controversies-in-the-primary-prevention-of-diabetes-macrovascular-complications-804
https://events.diabetes.org/p/s/current-controversies-in-the-primary-prevention-of-diabetes-macrovascular-complications-805
https://events.diabetes.org/p/s/psychosocial-determinants-of-diabetic-kidney-disease-806
https://events.diabetes.org/p/s/representation-of-indigenous-and-underrepresented-groups-in-diabetic-kidney-disease-research-807
https://events.diabetes.org/p/s/race-racism-and-diabetic-kidney-disease-808
https://events.diabetes.org/p/s/real-world-epidemiology-and-diverse-impacts-of-hypoglycemia-in-older-adults-with-diabetes-809
https://events.diabetes.org/p/s/therapeutic-and-technological-approaches-to-prevent-hypoglycemia-in-older-adults-with-diabetes-gaps-and-opportunities-810
https://events.diabetes.org/p/s/system-level-intervention-to-improve-hypoglycemia-management-in-older-adults-with-diabetes-811
https://events.diabetes.org/p/s/every-step-matters-historical-perspective-on-the-association-between-physical-activity-and-diabetes-related-foot-ulcers-812
https://events.diabetes.org/p/s/psychological-considerations-and-physical-activity-goals-in-persons-with-diabetes-foot-disease-813
https://events.diabetes.org/p/s/how-much-is-too-much-physical-activity-recommendations-for-persons-with-diabetes-foot-disease-814
https://events.diabetes.org/p/s/do-triglycerides-contribute-to-residual-cardiovascular-disease-risk-in-diabetes-815
https://events.diabetes.org/p/s/what-is-the-evidence-that-lpa-is-significant-in-diabetes-risk-assessment-816
https://events.diabetes.org/p/s/angptl3-vs-apoc3-as-a-therapeutic-target-817
https://events.diabetes.org/p/s/question-and-discussion-period-818
https://events.diabetes.org/p/s/sglt2i-in-heart-failure-an-update-819
https://events.diabetes.org/p/s/sglt2iglp-1ra-in-cardiovascular-disease-overview-820
https://events.diabetes.org/p/s/glp-1ra-in-atherosclerotic-cardiovascular-disease-an-update-821
https://events.diabetes.org/p/s/question-and-discussion-period-822
https://events.diabetes.org/p/s/scaling-expertise-pharmacist-led-population-health-within-cardiology-823
https://events.diabetes.org/p/s/one-stop-shop-cardiometabolic-center-824
https://events.diabetes.org/p/s/where-we-fall-short-current-gaps-in-the-management-of-cardiometabolic-disease-825
https://events.diabetes.org/p/s/training-at-intersections-the-cardiometabolic-fellowship-826
https://events.diabetes.org/p/s/pharmacoequity-strategies-to-ensure-equitable-implementation-of-guideline-directed-medical-therapy-827
https://events.diabetes.org/p/s/question-and-discussion-period-828
https://events.diabetes.org/p/s/can-we-extrapolate-findings-from-type-2-diabetes-trials-to-type-1-diabetes-829
https://events.diabetes.org/p/s/histopathological-features-of-type-1-diabetes-resistors-in-the-kidney-precision-medicine-project-830
https://events.diabetes.org/p/s/structural-and-molecular-differences-from-kidney-biopsies-in-persons-with-type-1-diabetes-and-type-2-diabetes-831
https://events.diabetes.org/p/s/question-and-discussion-period-832
https://events.diabetes.org/p/s/the-pharmacological-approach-is-the-best-833
https://events.diabetes.org/p/s/the-neuromodulation-approach-is-the-best-834
https://events.diabetes.org/p/s/the-physical-activity-and-exercise-approach-is-the-best-835
https://events.diabetes.org/p/s/the-psychological-approach-is-the-best-836
https://events.diabetes.org/p/s/question-and-discussion-period-837
https://events.diabetes.org/p/s/designing-clinical-trials-based-on-advanced-understanding-of-diabetic-retinal-disease-838
https://events.diabetes.org/p/s/the-importance-of-studying-the-human-retinal-disease-839
https://events.diabetes.org/p/s/the-goal-of-eliminating-blindness-from-diabetic-retinal-disease-840
https://events.diabetes.org/p/s/structure-function-connections-in-human-diabetic-retinal-disease-841
https://events.diabetes.org/p/s/from-freezer-to-plates-metagenomics-technique-to-identify-foot-infection-and-move-beyond-the-culture-plate-842
https://events.diabetes.org/p/s/panel-discussion-843
https://events.diabetes.org/p/s/does-a-defect-in-barrier-function-of-the-repaired-skin-predict-diabetic-foot-ulcer-recurrence-844
https://events.diabetes.org/p/s/panel-discussion-845
https://events.diabetes.org/p/s/panel-discussion-846
https://events.diabetes.org/p/s/walking-in-someone-elses-shoes-health-disparities-in-diabetic-foot-ulcers-847
https://events.diabetes.org/p/s/circulating-proteome-leading-molecular-discoveries-of-the-diabetic-wound-healing-course-848
https://events.diabetes.org/p/s/panel-discussion-849
https://events.diabetes.org/p/s/panel-discussion-850
https://events.diabetes.org/p/s/the-diabetic-foot-consortium-the-scope-and-opportunities-for-diabetic-foot-ulcer-research-past-present-and-future-851
https://events.diabetes.org/p/s/panel-discussion-852
https://events.diabetes.org/p/s/participant-characteristics-853
https://events.diabetes.org/p/s/coordinate-diabetes-results-854
https://events.diabetes.org/p/s/endocrinology-perspective-855
https://events.diabetes.org/p/s/study-background-856
https://events.diabetes.org/p/s/commentary-857
https://events.diabetes.org/p/s/trial-design-and-conduct-858
https://events.diabetes.org/p/s/rebuttal-859
https://events.diabetes.org/p/s/telehealth-increases-access-fosters-innovations-and-achieves-at-least-equivalent-outcomes-to-in-person-care-860
https://events.diabetes.org/p/s/rebuttal-861
https://events.diabetes.org/p/s/something-and-someone-are-missing-gaps-in-telehealth-models-for-psychosocial-diabetes-care-862
https://events.diabetes.org/p/s/question-and-discussion-period-863
https://events.diabetes.org/p/s/moderate-carbohydrate-eating-is-best-864
https://events.diabetes.org/p/s/rebuttal-865
https://events.diabetes.org/p/s/rebuttal-866
https://events.diabetes.org/p/s/very-low-carbohydrate-eating-is-best-867
https://events.diabetes.org/p/s/question-and-discussion-period-868
https://events.diabetes.org/p/s/eat-postprandial-exercise-is-more-effective-for-blood-glucose-management-869
https://events.diabetes.org/p/s/rebuttal-870
https://events.diabetes.org/p/s/eat-not-fasted-exercise-is-more-effective-for-blood-glucose-management-871
https://events.diabetes.org/p/s/rebuttal-872
https://events.diabetes.org/p/s/question-and-discussion-period-873
https://events.diabetes.org/p/s/welcome-and-introduction-874
https://events.diabetes.org/p/s/measuring-diabetes-self-management-behaviors-perspectives-from-an-adult-clinician-875
https://events.diabetes.org/p/s/measuring-diabetes-self-management-behaviors-perspectives-from-people-with-diabetes-876
https://events.diabetes.org/p/s/measuring-diabetes-self-management-behaviors-perspectives-from-a-pediatric-clinician-877
https://events.diabetes.org/p/s/lactate-as-a-fulcrum-for-metabolism-878
https://events.diabetes.org/p/s/lactate-signaling-in-energy-metabolism-879
https://events.diabetes.org/p/s/welcome-and-introduction-880
https://events.diabetes.org/p/s/question-and-discussion-period-881
https://events.diabetes.org/p/s/tying-the-business-of-dsmes-together-dont-get-left-behind-882
https://events.diabetes.org/p/s/tying-the-business-of-dsmes-together-dont-get-left-behind-883
https://events.diabetes.org/p/s/tying-the-business-of-dsmes-together-dont-get-left-behind-884
https://events.diabetes.org/p/s/tying-the-business-of-dsmes-together-dont-get-left-behind-885
https://events.diabetes.org/p/s/recap-of-webinar-series-886
https://events.diabetes.org/p/s/question-and-discussion-period-887
https://events.diabetes.org/p/s/food-biomarkers-as-a-novel-tool-for-dietary-assessments-888
https://events.diabetes.org/p/s/welcome-and-introduction-889
https://events.diabetes.org/p/s/mhealth-technology-for-dietary-intake-measurements-890
https://events.diabetes.org/p/s/amplifying-womens-voices-in-the-diabetes-workforce-891
https://events.diabetes.org/p/s/amplifying-womens-voices-in-the-diabetes-workforce-892
https://events.diabetes.org/p/s/welcome-and-introduction-893
https://events.diabetes.org/p/s/amplifying-womens-voices-in-the-diabetes-workforce-894
https://events.diabetes.org/p/s/the-optifast-op-total-and-partial-meal-replacement-program-improves-cardiometabolic-risk-in-adults-with-obesity-secondary-and-exploratory-analysis-of-the-optiwin-study-895
https://events.diabetes.org/p/s/low-carbohydrate-vs-mediterranean-diets-in-adolescents-with-type-1-diabetes-a-randomized-control-trial-896
https://events.diabetes.org/p/s/genetic-variants-in-gipr-and-effects-of-dietary-carbohydrate-quantity-and-quality-on-glycemic-responses-to-an-oral-glucose-load-the-omnicarb-trial-897
https://events.diabetes.org/p/s/effect-of-dulaglutide-plus-calorie-restricted-diet-vs-calorie-restricted-diet-on-visceral-fat-and-metabolic-profiles-in-women-with-polycystic-ovary-syndrome-a-randomized-controlled-trial-898
https://events.diabetes.org/p/s/fasting-metabolic-flexibility-in-prediabetes-899
https://events.diabetes.org/p/s/effect-of-unblinded-vs-blinded-dexcom-g6-cgm-wear-in-outpatients-with-type-2-diabetes-real-world-data-900
https://events.diabetes.org/p/s/accuracy-of-dietary-records-dr-using-a-smartphone-app-is-greatly-improved-by-users-adjustments-compared-with-artificial-intelligence-ai-alone-901
https://events.diabetes.org/p/s/healthy-eating-index-correlates-with-better-glycemic-control-among-people-with-type-1-diabetes-902
https://events.diabetes.org/p/s/changing-how-we-talk-about-dsmes-applying-an-audience-driven-approach-903
https://events.diabetes.org/p/s/from-learning-to-planning-for-change-how-continuing-medical-education-drives-clinician-intention-to-implement-changes-in-diabetes-care-904
https://events.diabetes.org/p/s/improving-glycemic-outcomes-through-virtual-diabetes-self-management-education-pathway-905
https://events.diabetes.org/p/s/provider-perspectives-on-diabetes-education-for-emerging-adults-eas-906
https://events.diabetes.org/p/s/participant-engagement-and-weight-loss-in-the-national-diabetes-prevention-program-before-and-during-covid-907
https://events.diabetes.org/p/s/implementation-of-a-modified-diabetes-prevention-program-in-wic-clinics-a-pilot-study-908
https://events.diabetes.org/p/s/association-of-perceived-stress-and-weight-loss-in-the-national-diabetes-prevention-program-dpp-909
https://events.diabetes.org/p/s/what-motivates-people-to-enroll-in-the-national-diabetes-prevention-program-lifestyle-change-program-910
https://events.diabetes.org/p/s/fear-of-falling-and-its-relation-to-balance-task-performance-in-individuals-with-chronic-diabetes-911
https://events.diabetes.org/p/s/sex-and-diabetes-status-interact-to-affect-human-skeletal-muscle-mitochondrial-function-912
https://events.diabetes.org/p/s/muscle-lipid-turnover-predicts-aerobic-training-effects-on-body-composition-913
https://events.diabetes.org/p/s/what-are-the-barriers-and-facilitators-of-resistance-training-in-mildly-frail-older-adults-with-insulin-treated-diabetes-a-qualitative-analysis-using-the-capability-opportunity-motivation-and-behaviou-914
https://events.diabetes.org/p/s/hyperglycemia-lowers-lactate-clearance-during-exercise-in-type-1-diabetes-915
https://events.diabetes.org/p/s/timing-of-the-pre-exercise-temporary-target-with-advanced-hybrid-closed-loop-ahcl-and-hypoglycemia-risk-916
https://events.diabetes.org/p/s/increased-glucose-time-in-range-following-active-vs-sedentary-days-in-newly-diagnosed-youth-with-t1d-4t-exercise-results-917
https://events.diabetes.org/p/s/insulin-delivery-modality-does-not-impact-glycemic-change-during-physical-activity-in-youth-with-type-1-diabetes-t1d-results-from-the-real-world-t1dexi-pediatric-study-918
https://events.diabetes.org/p/s/question-and-discussion-period-919
https://events.diabetes.org/p/s/intermittent-fasting-and-diabetes-920
https://events.diabetes.org/p/s/diabetes-and-ramadan-fast-for-a-safer-journey-921
https://events.diabetes.org/p/s/question-and-discussion-period-922
https://events.diabetes.org/p/s/question-and-discussion-period-923
https://events.diabetes.org/p/s/the-clinicians-guide-to-data-review-getting-from-report-to-interpretation-to-data-driven-decision-making-924
https://events.diabetes.org/p/s/the-clinicians-guide-to-retrieving-data-getting-from-device-to-download-to-data-display-925
https://events.diabetes.org/p/s/ada-presidents-select-abstract-embark-a-randomized-controlled-trial-comparing-three-approaches-to-reducing-diabetes-distress-in-adults-with-type-1-diabetes-926
https://events.diabetes.org/p/s/predictors-of-young-adults-yas-engagement-in-a-type-1-diabetes-t1d-self-management-intervention-the-resilient-empowered-active-living-telehealth-real-t-diabetes-study-927
https://events.diabetes.org/p/s/results-from-the-promoting-resilience-in-stress-management-prism-intervention-a-multisite-randomized-controlled-trial-rct-for-teens-with-type-1-diabetes-t1d-928
https://events.diabetes.org/p/s/barriers-and-facilitators-of-implementing-a-pediatric-type-1-diabetes-psychosocial-intervention-provider-and-leader-perspectives-929
https://events.diabetes.org/p/s/the-supporting-emerging-adults-with-diabetes-sead-program-an-adult-based-clinical-model-that-improves-glycemic-control-and-diabetes-technology-uptake-in-underserved-young-adults-ya-with-type-1-diabete-930
https://events.diabetes.org/p/s/association-between-diabetes-distress-and-suicide-risk-in-emerging-adults-with-type-1-diabetes-931
https://events.diabetes.org/p/s/youth-with-t1d-and-elevated-a1c-pandemic-experiences-and-psychosocial-factors-932
https://events.diabetes.org/p/s/validation-of-the-short-type-1-diabetes-stigma-assessment-scale-dsas-1-and-its-association-with-affective-states-diabetes-distress-diabetes-self-management-and-glycemic-control-933
https://events.diabetes.org/p/s/factors-influencing-young-adults-rationing-insulin-and-diabetes-supplies-934
https://events.diabetes.org/p/s/diabetes-stigma-and-use-of-diabetes-technologies-among-us-adults-living-with-type-1-diabetes-935
https://events.diabetes.org/p/s/greater-sleep-variability-is-associated-with-less-time-in-range-of-glucose-levels-in-patients-with-type-1-diabetes-936
https://events.diabetes.org/p/s/richard-r-rubin-award-lecture-the-evolution-of-behavioral-diabetes-the-intersections-of-behavior-and-biology-937
https://events.diabetes.org/p/s/the-impact-of-a-digital-health-coaching-program-on-a-rural-population-938
https://events.diabetes.org/p/s/structural-racism-and-prevalence-of-diabetes-in-a-nationally-representative-sample-of-us-adults-939
https://events.diabetes.org/p/s/the-health-effects-of-a-behavior-change-program-for-prediabetes-quasi-experimental-evidence-from-21-million-primary-care-patients-in-england-940
https://events.diabetes.org/p/s/beliefs-about-medicines-self-efficacy-and-health-care-coverage-predict-glycemic-control-in-young-adults-with-youth-onset-type-2-diabetes-the-today2-icount-study-941
https://events.diabetes.org/p/s/question-and-discussion-period-942
https://events.diabetes.org/p/s/measuring-dietary-intake-and-dietary-quality-943
https://events.diabetes.org/p/s/honoring-the-legacy-of-mark-peyrot-944
https://events.diabetes.org/p/s/measuring-physical-activity-and-sedentary-behavior-with-actigraphy-945
https://events.diabetes.org/p/s/measuring-sleep-in-diabetes-946
https://events.diabetes.org/p/s/measuring-self-management-behaviors-via-ecological-momentary-assessment-947
https://events.diabetes.org/p/s/shared-decision-making-in-counseling-people-with-higher-weight-on-lifestyle-and-behavior-changes-948
https://events.diabetes.org/p/s/integrating-metabolic-surgery-into-the-conversation-when-counseling-people-with-higher-weight-949
https://events.diabetes.org/p/s/integration-of-glucose-lowering-and-weight-loss-medications-in-the-conversation-when-counseling-people-with-higher-weight-950
https://events.diabetes.org/p/s/question-and-discussion-period-951
https://events.diabetes.org/p/s/the-art-and-science-of-inpatient-subcutaneous-insulin-dosing-952
https://events.diabetes.org/p/s/the-good-the-bad-and-the-ugly-which-diabetes-meds-are-safe-and-effective-in-the-inpatient-setting-953
https://events.diabetes.org/p/s/creative-diabetes-orders-if-they-can-click-on-it-theyll-order-it-954
https://events.diabetes.org/p/s/teaching-diabetes-champions-to-improve-glycemic-outcomes-and-care-transitions-955
https://events.diabetes.org/p/s/glycemic-excursion-minimization-gem-a-paradigm-shift-in-the-management-of-type-2-diabetes-956
https://events.diabetes.org/p/s/very-low-carbohydrate-diets-for-management-of-type-2-diabetes-957
https://events.diabetes.org/p/s/weight-loss-via-low-calorie-diet-insight-into-the-causative-mechanisms-of-type-2-diabetes-using-mri-958
https://events.diabetes.org/p/s/question-and-discussion-period-959
https://events.diabetes.org/p/s/family-based-intervention-to-support-transitioning-from-pediatric-to-adult-type-1-diabetes-care-960
https://events.diabetes.org/p/s/intervening-to-improve-diabetes-distress-among-adults-with-type-1-and-type-2-diabetes-961
https://events.diabetes.org/p/s/psychosocial-and-behavioral-screening-in-real-world-pediatric-type-1-diabetes-care-962
https://events.diabetes.org/p/s/what-really-matters-effective-peer-support-models-in-any-setting-963
https://events.diabetes.org/p/s/how-to-talk-diabetes-nutrition-in-five-minutes-or-less-964
https://events.diabetes.org/p/s/binge-eating-disorder-and-weight-stigma-965
https://events.diabetes.org/p/s/food-as-medicine-966
https://events.diabetes.org/p/s/the-new-diabetes-technology-practice-competencies-validating-the-recommendations-967
https://events.diabetes.org/p/s/introduction-968
https://events.diabetes.org/p/s/question-and-discussion-period-led-by-kirsten-yehl-969
https://events.diabetes.org/p/s/question-and-discussion-period-led-by-paulina-duker-970
https://events.diabetes.org/p/s/professional-competencies-for-diabetes-technology-practice-who-should-do-what-971
https://events.diabetes.org/p/s/physical-activity-in-the-canadian-study-of-longevity-in-type-1-diabetes-972
https://events.diabetes.org/p/s/aging-body-composition-and-diabetes-the-role-of-physical-activity-in-the-prevention-of-sarcopenia-973
https://events.diabetes.org/p/s/drug-and-exercise-interactions-in-older-adults-with-diabetes-974
https://events.diabetes.org/p/s/prevention-of-microvascular-complications-in-prediabetes-epredice-study-975
https://events.diabetes.org/p/s/an-ounce-of-prevention-exercise-and-sedentary-behavior-in-youth-with-diabetes-976
https://events.diabetes.org/p/s/can-you-feel-hit-high-intensity-training-to-improve-hypoglycemia-unawareness-977
https://events.diabetes.org/p/s/question-and-discussion-period-978
https://events.diabetes.org/p/s/moms-in-control-team-based-approach-979
https://events.diabetes.org/p/s/moms-in-control-day-to-day-services-980
https://events.diabetes.org/p/s/moms-in-control-erp-expansion-981
https://events.diabetes.org/p/s/moms-in-control-medication-and-technology-management-982
https://events.diabetes.org/p/s/question-and-discussion-period-983
https://events.diabetes.org/p/s/minimizing-stigma-and-diabetes-management-barriers-through-inclusive-provider-communication-984
https://events.diabetes.org/p/s/implementation-of-inclusive-language-to-enhance-communication-in-the-pediatric-diabetes-clinic-setting-video-presentation-985
https://events.diabetes.org/p/s/lessons-learned-and-advice-for-best-practices-in-effective-communication-in-the-pediatric-diabetes-clinic-setting-986
https://events.diabetes.org/p/s/moving-beyond-hba1c-new-standards-for-assessing-glycemic-control-the-evidence-and-role-of-sensor-based-continuous-glucose-monitoring-cgm-for-improving-patient-care-and-satisfaction-in-persons-with-typ-987
https://events.diabetes.org/p/s/managing-nafldnash-in-people-with-t2-diabetes-disease-burden-diagnosis-currentemerging-armamentarium-988
https://events.diabetes.org/p/s/real-time-continuous-glucose-monitoring-going-beyond-the-obvious-989
https://events.diabetes.org/p/s/the-importance-of-weight-loss-quality-in-obesity-treatment-990
https://events.diabetes.org/p/s/nutrition-and-technology-for-diabetes-management-and-remission-991
https://events.diabetes.org/p/s/a-360-degree-examination-of-type-1-diabetes-from-patient-identification-to-treatment-and-prevention-992
https://events.diabetes.org/p/s/more-than-weight-treating-obesity-as-part-of-a-comprehensive-care-approach-to-cardiometabolic-disease-993
https://events.diabetes.org/p/s/beyond-the-scales-emerging-strategies-to-improve-metabolic-outcomes-for-people-with-obesity-994
https://events.diabetes.org/p/s/leading-the-charge-on-obesity-management-the-endocrinologists-role-in-empowering-community-providers-to-join-the-fight-cmece-995
https://events.diabetes.org/p/s/question-and-discussion-period-996
https://events.diabetes.org/p/s/pro-pregnant-persons-with-gestational-diabetes-should-follow-a-reduced-carbohydrate-meal-plan-997
https://events.diabetes.org/p/s/rebuttal-998
https://events.diabetes.org/p/s/con-there-is-no-role-for-reduced-carbohydrate-meal-plans-in-the-treatment-of-gestational-diabetes-999
https://events.diabetes.org/p/s/rebuttal-1000
https://events.diabetes.org/p/s/question-and-discussion-period-1001
https://events.diabetes.org/p/s/pro-how-can-we-not-afford-it-1002
https://events.diabetes.org/p/s/rebuttal-1003
https://events.diabetes.org/p/s/con-how-can-we-afford-it-1004
https://events.diabetes.org/p/s/rebuttal-1005
https://events.diabetes.org/p/s/question-and-discussion-period-1006
https://events.diabetes.org/p/s/con-1007
https://events.diabetes.org/p/s/rebuttal-1008
https://events.diabetes.org/p/s/pro-1009
https://events.diabetes.org/p/s/rebuttal-1010
https://events.diabetes.org/p/s/question-and-discussion-period-1011
https://events.diabetes.org/p/s/rebuttal-1012
https://events.diabetes.org/p/s/diy-is-an-essential-option-in-type-1-diabetes-management-1013
https://events.diabetes.org/p/s/diy-is-not-necessary-in-type-1-diabetes-management-1014
https://events.diabetes.org/p/s/rebuttal-1015
https://events.diabetes.org/p/s/question-and-discussion-period-1016
https://events.diabetes.org/p/s/rebuttal-1017
https://events.diabetes.org/p/s/technology-is-the-way-forward-1018
https://events.diabetes.org/p/s/lets-preserve-beta-cells-1019
https://events.diabetes.org/p/s/rebuttal-1020
https://events.diabetes.org/p/s/question-and-discussion-period-1021
https://events.diabetes.org/p/s/a-registry-study-of-hybrid-closed-loop-systems-during-pregnancy-maternal-and-fetal-medicine-perspective-1022
https://events.diabetes.org/p/s/a-registry-study-of-hybrid-closed-loop-systems-during-pregnancy-endocrine-perspective-1023
https://events.diabetes.org/p/s/welcome-and-introduction-1024
https://events.diabetes.org/p/s/breaking-the-cycle-of-hyperglycemia-new-themes-in-diabetes-prevention-in-the-real-world-practice-1025
https://events.diabetes.org/p/s/welcome-and-introduction-1026
https://events.diabetes.org/p/s/question-and-discussion-period-1027
https://events.diabetes.org/p/s/emerging-evidence-on-the-effects-of-sleep-in-youth-with-diabetes-1028
https://events.diabetes.org/p/s/welcome-and-introduction-1029
https://events.diabetes.org/p/s/question-and-discussion-period-1030
https://events.diabetes.org/p/s/approaches-to-effective-screening-for-prediabetes-and-diabetes-1031
https://events.diabetes.org/p/s/strategies-to-improve-the-use-of-sglt2-inhibitors-and-glp-1ras-in-primary-care-1032
https://events.diabetes.org/p/s/welcome-and-introduction-1033
https://events.diabetes.org/p/s/current-and-proposed-revisions-to-the-quality-measures-in-diabetes-care-1034
https://events.diabetes.org/p/s/question-and-discussion-period-1035
https://events.diabetes.org/p/s/patients-with-type-2-diabetes-should-not-take-metformin-during-pregnancy-1036
https://events.diabetes.org/p/s/rebuttal-1037
https://events.diabetes.org/p/s/welcome-and-introduction-1038
https://events.diabetes.org/p/s/patients-with-type-2-diabetes-should-take-metformin-during-pregnancy-1039
https://events.diabetes.org/p/s/rebuttal-1040
https://events.diabetes.org/p/s/welcome-and-introduction-1041
https://events.diabetes.org/p/s/question-and-discussion-period-1042
https://events.diabetes.org/p/s/welcome-and-introduction-1043
https://events.diabetes.org/p/s/a-model-for-future-clinical-diabetes-centers-of-excellence-1044
https://events.diabetes.org/p/s/the-impact-of-insulin-out-of-pocket-caps-among-commercially-insured-diabetes-patients-1045
https://events.diabetes.org/p/s/medication-use-among-youth-onset-diabetes-in-india-an-analysis-of-socioeconomic-factors-and-cost-of-care-1046
https://events.diabetes.org/p/s/cost-effectiveness-of-the-2017-hypertension-guidelines-among-us-adults-with-diabetes-results-from-a-simulation-study-1047
https://events.diabetes.org/p/s/lifetime-medical-spending-for-diabetes-among-medicare-beneficiaries-in-the-united-states-1048
https://events.diabetes.org/p/s/metformin-discontinuation-and-clinical-outcomes-in-patients-with-diabetes-and-advanced-chronic-kidney-disease-a-prospective-cohort-study-1049
https://events.diabetes.org/p/s/disparities-in-access-to-sodium-glucose-cotransporter-2-inhibitors-sglt2i-1050
https://events.diabetes.org/p/s/sglt2-inhibitors-are-associated-with-kidney-benefits-at-all-degrees-of-proteinuria-a-cohort-study-1051
https://events.diabetes.org/p/s/effects-of-dapagliflozin-therapy-on-renal-hemodynamics-in-type-2-diabetes-patients-1052
https://events.diabetes.org/p/s/the-effect-of-tirzepatide-during-weight-loss-on-food-intake-appetite-food-preference-and-food-craving-in-people-with-obesity-1053
https://events.diabetes.org/p/s/the-effect-of-tirzepatide-during-weight-loss-on-metabolic-adaption-fat-oxidation-and-food-intake-in-people-with-obesity-1054
https://events.diabetes.org/p/s/tirzepatide-attenuates-hepatic-insulin-resistance-and-glucagon-action-independent-of-weight-loss-and-gip-action-in-diet-induced-obese-mice-1055
https://events.diabetes.org/p/s/effect-of-tirzepatide-on-the-counterregulatory-response-to-hypoglycemia-during-a-hypoglycemic-clamp-in-people-with-type-2-diabetes-1056
https://events.diabetes.org/p/s/monitoring-stage-2-to-stage-3-transition-in-type-1-diabetes-using-continuous-glucose-monitoring-cgm-1057
https://events.diabetes.org/p/s/implementation-of-a-hybrid-screening-and-monitoring-model-in-colorado-autoimmunity-screening-for-kids-ask-1058
https://events.diabetes.org/p/s/ada-presidents-select-abstract-cgm-initiation-within-six-months-of-t1d-diagnosis-associated-with-lower-hba1c-at-3-years-1059
https://events.diabetes.org/p/s/loss-of-characteristic-ss-cell-function-in-autoantibody-positive-ab-plus-individuals-during-the-progression-to-type-1-diabetes-t1d-1060
https://events.diabetes.org/p/s/associations-of-growth-hormone-gh-mediators-with-loss-of-glycemic-control-in-youth-with-type-2-diabetes-t2d-1061
https://events.diabetes.org/p/s/glycemic-measures-in-childhood-as-predictors-of-future-diabetes-related-microvascular-complications-1062
https://events.diabetes.org/p/s/ten-year-evaluation-of-diabetes-categories-in-youth-shows-a-continuous-increase-in-frequency-of-newly-diagnosed-type-2-diabetes-results-from-the-worldwide-sweet-registry-1063
https://events.diabetes.org/p/s/insulin-dynamics-across-the-glucose-tolerance-spectrum-in-youth-with-obesity-1064
https://events.diabetes.org/p/s/learn-how-to-pitch-your-entrepreneurial-idea-and-get-funding-1065
https://events.diabetes.org/p/s/learn-how-to-pitch-your-entrepreneurial-idea-and-get-funding-1066
https://events.diabetes.org/p/s/learn-how-to-pitch-your-entrepreneurial-idea-and-get-funding-1067
https://events.diabetes.org/p/s/question-and-discussion-period-1068
https://events.diabetes.org/p/s/basic-science-perspective-1069
https://events.diabetes.org/p/s/clinicaltranslational-science-perspective-1070
https://events.diabetes.org/p/s/question-and-discussion-period-1071
https://events.diabetes.org/p/s/cultivating-provider-resiliency-1072
https://events.diabetes.org/p/s/addressing-provider-burnout-1073
https://events.diabetes.org/p/s/welcome-and-introduction-1074
https://events.diabetes.org/p/s/what-can-diabetes-quality-teams-learn-from-engineers-and-designers-1075
https://events.diabetes.org/p/s/what-can-diabetes-quality-teams-learn-from-engineer-and-designers-1076
https://events.diabetes.org/p/s/what-can-diabetes-quality-teams-learn-from-engineers-and-designers-1077
https://events.diabetes.org/p/s/question-and-discussion-period-1078
https://events.diabetes.org/p/s/overcoming-therapeutic-inertia-leveraging-the-diabetes-care-interprofessional-team-1079
https://events.diabetes.org/p/s/panel-discussion-1080
https://events.diabetes.org/p/s/panel-discussion-1081
https://events.diabetes.org/p/s/long-term-outcomes-and-diabetes-remission-at-7-12-years-1082
https://events.diabetes.org/p/s/the-case-for-an-rct-of-metabolic-surgery-and-type-2-diabetes-1083
https://events.diabetes.org/p/s/study-design-of-the-armms-t2d-randomized-trial-1084
https://events.diabetes.org/p/s/implications-for-clinical-management-of-type-2-diabetes-1085
https://events.diabetes.org/p/s/question-and-discussion-period-1086
https://events.diabetes.org/p/s/introduction-to-the-consensus-statement-and-what-it-will-achieve-1087
https://events.diabetes.org/p/s/pros-from-a-person-with-diabetes-perspective-1088
https://events.diabetes.org/p/s/what-to-look-for-in-a-pro-measure-1089
https://events.diabetes.org/p/s/core-psychosocial-domains-and-the-underpinning-science-of-pros-1090
https://events.diabetes.org/p/s/pros-and-what-matters-to-clinicians-1091
https://events.diabetes.org/p/s/clinical-strategies-to-support-the-developing-athlete-with-type-1-diabetes-1092
https://events.diabetes.org/p/s/physiology-metabolism-and-training-behaviors-of-the-competitive-athlete-living-with-type-1-diabetes-1093
https://events.diabetes.org/p/s/question-and-discussion-period-1094
https://events.diabetes.org/p/s/solutions-for-individuals-with-loss-of-dexterity-1095
https://events.diabetes.org/p/s/leveraging-accessibility-features-for-individuals-with-low-visionhearing-loss-1096
https://events.diabetes.org/p/s/optimizing-technology-for-individuals-with-intellectual-disability-1097
https://events.diabetes.org/p/s/is-continuous-glucose-monitoring-reliable-in-chronic-kidney-disease-1098
https://events.diabetes.org/p/s/question-and-discussion-period-1099
https://events.diabetes.org/p/s/how-to-get-the-best-of-aid-during-exercise-1100
https://events.diabetes.org/p/s/considerations-when-switching-between-aid-devices-1101
https://events.diabetes.org/p/s/steroids-sick-days-and-stress-1102
https://events.diabetes.org/p/s/introductory-lecture-on-systems-and-resources-1103
https://events.diabetes.org/p/s/innovation-challenge-1104
https://events.diabetes.org/p/s/innovation-challenge-1105
https://events.diabetes.org/p/s/innovation-challenge-1106
https://events.diabetes.org/p/s/marked-variability-of-starting-insulin-algorithms-for-noncritical-illness-a-survey-of-32-academic-hospitals-in-the-united-states-1107
https://events.diabetes.org/p/s/sglt2-inhibitor-prescribing-discrepancies-in-patients-with-diabetes-mellitus-type-2-and-heart-failure-at-an-academic-medical-center-1108
https://events.diabetes.org/p/s/hyperglycemia-in-patients-without-diabetes-in-the-emergency-department-and-subsequent-cascade-of-care-1109
https://events.diabetes.org/p/s/significant-differences-in-dka-outcomes-across-hospitals-despite-same-guidelines-highlights-the-need-for-better-implementation-strategies-results-from-dekode-initiative-1110
https://events.diabetes.org/p/s/early-electronic-consultation-reduces-glucose-and-health-care-associated-infection-in-hospital-the-stoic-d-surgery-randomised-controlled-trial-1111
https://events.diabetes.org/p/s/developing-a-fair-individualized-polysocial-risk-score-ipsrs-for-identifying-increased-social-risk-of-hospitalizations-in-patients-with-type-2-diabetes-t2d-1112
https://events.diabetes.org/p/s/effectiveness-of-a-virtual-diabetes-clinic-in-a-racially-diverse-population-1113
https://events.diabetes.org/p/s/use-of-cgm-adhesive-kits-increase-active-cgm-use-among-nhb-and-latinx-youth-with-t1d-1114
https://events.diabetes.org/p/s/incorporating-shared-decision-making-to-facilitate-equitable-insulin-pump-use-among-pediatric-patients-with-type-1-diabetes-1115
https://events.diabetes.org/p/s/older-adults-benefit-from-virtual-support-for-cgm-use-but-require-longer-visits-1116
https://events.diabetes.org/p/s/development-of-an-emr-dashboard-to-enable-remote-patient-monitoring-and-proactive-diabetes-care-1117
https://events.diabetes.org/p/s/autonomous-artificial-intelligence-ai-testing-for-diabetic-eye-disease-ded-closes-care-gap-and-improves-health-equity-on-a-systems-level-1118
https://events.diabetes.org/p/s/first-trimester-dietary-phenolic-compounds-and-lipids-are-associated-with-hyperinsulinism-at-birth-in-type-1-diabetes-pregnancy-1119
https://events.diabetes.org/p/s/amelioration-of-insulin-resistance-after-delivery-lowers-the-risk-of-postpartum-type-2-diabetes-in-women-with-gestational-diabetes-mellitus-1120
https://events.diabetes.org/p/s/newborn-adiposity-and-cord-blood-dna-methylation-an-epigenome-wide-association-study-in-hapo-with-validation-in-gen3g-1121
https://events.diabetes.org/p/s/association-of-early-pregnancy-triglycerides-and-hba1c-in-a-uk-multiethnic-cohort-1122
https://events.diabetes.org/p/s/genetic-variants-influencing-insulin-deficiency-and-resistance-are-associated-with-adverse-pregnancy-outcomes-1123
https://events.diabetes.org/p/s/maternal-triglycerides-in-diet-controlled-gdm-correlate-with-newborn-triglycerides-and-infant-fat-mass-at-four-months-of-life-1124
https://events.diabetes.org/p/s/normative-cgm-glucose-levels-throughout-gestation-in-patients-with-uncomplicated-pregnancies-1125
https://events.diabetes.org/p/s/cgm-measured-differences-in-pregnancies-with-vs-without-gestational-diabetes-gdm-and-adverse-perinatal-outcomes-apo-1126
https://events.diabetes.org/p/s/diagnosing-gdm-in-pregnancy-closing-the-door-after-the-horse-has-bolted-1127
https://events.diabetes.org/p/s/pregnancy-intervention-with-a-closed-loop-system-picls-study-1128
https://events.diabetes.org/p/s/copenfast-trial-fetal-growth-and-glycemic-control-in-pregnant-women-with-type-1-or-type-2-diabetes-using-faster-acting-insulin-aspart-or-insulin-aspart-a-randomized-controlled-trial-1129
https://events.diabetes.org/p/s/identification-of-gestational-diabetes-gdm-subtypes-via-machine-learning-and-associations-with-perinatal-complications-1130
https://events.diabetes.org/p/s/a-phase-2-randomized-double-blind-placebo-controlled-dose-finding-study-of-bi-456906-in-people-with-overweightobesity-1131
https://events.diabetes.org/p/s/effect-of-coadministered-sc-semaglutide-and-sc-cagrilintide-on-glycemic-levels-measured-by-cgm-1132
https://events.diabetes.org/p/s/a-long-acting-glucose-dependent-insulinotropic-polypeptide-receptor-agonist-shows-weight-loss-without-nausea-or-vomiting-1133
https://events.diabetes.org/p/s/efficacy-and-safety-of-coadministered-sc-semaglutide-and-sc-cagrilintide-in-type-2-diabetes-1134
https://events.diabetes.org/p/s/hsk7653-a-novel-ultralong-acting-dpp-4-inhibitor-as-monotherapy-in-patients-with-type-2-diabetes-a-randomized-double-blind-placebo-controlled-phase-iii-trial-1135
https://events.diabetes.org/p/s/effect-of-oral-nonpeptide-glp-1-receptor-agonist-orforglipron-ly3502970-in-participants-with-obesity-or-overweight-a-phase-2-study-1136
https://events.diabetes.org/p/s/worsening-insulin-resistance-is-key-pathological-contributor-to-dysglycemia-in-lean-koreans-a-longitudinal-validation-study-in-the-korean-genome-and-epidemiology-study-koges-1137
https://events.diabetes.org/p/s/pancreatic-gene-therapy-durably-improves-glycemia-and-delays-disease-progression-in-a-murine-model-of-type-2-diabetes-1138
https://events.diabetes.org/p/s/better-glycemic-control-with-once-weekly-insulin-icodec-vs-once-daily-insulin-degludec-in-insulin-naive-type-2-diabetes-onwards-3-1139
https://events.diabetes.org/p/s/improved-a1c-and-tir-with-once-weekly-insulin-icodec-vs-insulin-glargine-u100-in-insulin-naive-t2d-onwards-1-1140
https://events.diabetes.org/p/s/c-peptide-and-metabolic-outcomes-in-immunotherapy-studies-of-new-onset-type-1-diabetes-1141
https://events.diabetes.org/p/s/baseline-predictors-of-remission-of-type-2-diabetes-in-response-to-short-term-insulin-based-therapy-the-pivotal-role-of-beta-cell-function-1142
https://events.diabetes.org/p/s/glucagon-counterregulation-in-a-hypoglycemic-clamp-in-type-1-diabetes-is-increased-by-zt-01-a-novel-somatostatin-receptor-2-antagonist-a-phase-1b-study-1143
https://events.diabetes.org/p/s/retrospective-review-of-genetic-mutations-and-treatments-in-patients-with-monogenic-diabetes-of-the-youth-mody-1144
https://events.diabetes.org/p/s/first-in-human-study-of-a-pharmacological-duodenal-exclusion-therapy-mimics-a-roux-en-y-gastric-bypass-biomarker-signature-1145
https://events.diabetes.org/p/s/identification-of-novel-therapies-for-monogenic-diabetes-using-connectivity-map-cmap-1146
https://events.diabetes.org/p/s/metformin-reduces-fasting-glycemia-in-well-controlled-type-2-diabetes-by-promoting-aerobic-glycolysis-independent-of-decreasing-endogenous-glucose-production-1147
https://events.diabetes.org/p/s/the-efficacy-and-safety-of-hsk-16149-in-chinese-with-diabetic-peripheral-neuropathic-pain-a-randomized-double-blinded-placebo-and-pregabalin-controlled-phase-iiiii-study-1148
https://events.diabetes.org/p/s/capillary-blood-ketone-level-and-future-ketoacidosis-risk-in-type-1-diabetes-using-sodium-glucose-linked-transporter-inhibitors-1149
https://events.diabetes.org/p/s/empagliflozin-on-the-risk-of-retinopathy-in-patients-with-type-2-diabetes-results-from-the-emprise-study-1150
https://events.diabetes.org/p/s/health-care-utilization-and-cost-associated-with-empagliflozin-in-older-adults-with-type-2-diabetes-results-from-the-emprise-study-1151
https://events.diabetes.org/p/s/the-efficacy-of-sotagliflozin-on-heart-failure-related-outcomes-is-independent-of-baseline-a1c-1152
https://events.diabetes.org/p/s/the-combined-use-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on-the-risk-of-cardiovascular-events-among-patients-with-type-2-diabetes-1153
https://events.diabetes.org/p/s/ada-presidents-select-abstract-combining-an-sglt-inhibitor-with-a-glucagon-receptor-agonist-gra-in-subjects-with-type-1-diabetes-a-randomized-clinical-trial-1154
https://events.diabetes.org/p/s/six-months-experience-on-meal-announcement-with-three-personalized-presets-of-carbohydrates-vs-precise-carbohydrate-counting-in-adolescents-with-type-1-diabetes-using-the-minimed-780g-system-1155
https://events.diabetes.org/p/s/mobile-bolus-feature-improves-bolus-behavior-in-control-iq-users-who-bolus-3-timesday-1156
https://events.diabetes.org/p/s/a-pilot-study-evaluating-an-insulin-and-pramlintide-fully-closed-loop-delivery-system-1157
https://events.diabetes.org/p/s/glycemic-impact-of-meal-dosing-behavior-in-users-of-the-inpen-smart-insulin-pen-sip-paired-with-continuous-glucose-monitoring-cgm-1158
https://events.diabetes.org/p/s/glycemic-control-with-extended-use-of-automated-insulin-delivery-aid-in-children-age-2-6-years-with-type-1-diabetes-t1d-1159
https://events.diabetes.org/p/s/real-world-glycemic-outcomes-of-5900-adults-with-type-1-diabetes-using-the-omnipod-5-automated-insulin-delivery-aid-system-with-cloud-based-data-management-1160
https://events.diabetes.org/p/s/impact-of-a-parameter-change-in-dblg1-system-1161
https://events.diabetes.org/p/s/postprandial-hyper-and-hypoglycemia-are-related-to-injection-time-an-insulclock-connected-insulin-cap-based-real-world-study-1162
https://events.diabetes.org/p/s/aid-driven-tir-improvements-in-young-mdi-children-with-t1d-are-indistinguishable-from-their-pump-using-peers-a-pedap-subanalysis-1163
https://events.diabetes.org/p/s/hybrid-closed-loop-therapy-vs-other-modalities-of-therapy-during-ramadan-intermittent-fasting-in-adults-and-adolescents-with-type-1-diabetes-1164
https://events.diabetes.org/p/s/association-between-treatment-adherence-and-cgm-outcomes-in-people-with-t1d-using-smart-insulin-pens-in-a-real-world-setting-1165
https://events.diabetes.org/p/s/do-it-yourself-automated-insulin-delivery-aid-systems-are-noninferior-to-commercial-aid-systems-in-glucose-management-among-adults-with-type-1-diabetes-1166
https://events.diabetes.org/p/s/accuracy-and-reliability-of-real-time-continuous-glucose-monitoring-in-the-intensive-care-unit-after-major-abdominal-surgery-1167
https://events.diabetes.org/p/s/hybrid-continuous-glucose-monitoring-protocols-in-the-intensive-care-unit-multicenter-experience-1168
https://events.diabetes.org/p/s/a-calibration-protocol-for-continuous-glucose-monitor-accuracy-in-the-icu-1169
https://events.diabetes.org/p/s/the-effect-of-tirzepatide-vs-insulin-degludec-on-post-meal-glucose-control-in-patients-with-type-2-diabetes-surpass-3-cgm-1170
https://events.diabetes.org/p/s/increasing-quarterly-use-of-intermittent-cgm-among-individuals-with-t2d-is-associated-with-improved-glycemic-control-over-a-one-year-time-frame-1171
https://events.diabetes.org/p/s/time-in-range-is-associated-with-incident-diabetic-retinopathy-in-adults-with-type-1-diabetes-a-seven-year-longitudinal-study-1172
https://events.diabetes.org/p/s/hybrid-care-model-combining-telemedicine-and-office-visits-for-diabetes-management-is-effective-in-older-adults-with-type-1-diabetes-t1d-using-continuous-glucose-monitors-cgm-1173
https://events.diabetes.org/p/s/accuracy-evaluation-of-an-implantable-cgm-with-chemistry-improvements-in-a-365-day-feasibility-study-1174
https://events.diabetes.org/p/s/variation-in-utilization-of-continuous-glucose-monitoring-in-patients-with-type-1-diabetes-1175
https://events.diabetes.org/p/s/continuous-glucose-monitoring-in-diabetes-patients-with-cognitive-impairment-1176
https://events.diabetes.org/p/s/better-adherence-to-real-time-continuous-glucose-monitoring-rtcgm-than-to-intermittently-scanned-cgm-iscgm-among-people-with-type-2-diabetes-pwt2d-on-intensive-insulin-therapy-iit-1177
https://events.diabetes.org/p/s/continuous-glucose-monitoring-guided-insulin-administration-in-subjects-with-type-2-diabetes-in-long-term-care-facilities-a-randomized-clinical-trial-1178
https://events.diabetes.org/p/s/neonatal-outcomes-in-early-and-incident-gestational-diabetes-mellitus-are-they-normalized-with-treatment-from-24-28-weeks-gestation-1179
https://events.diabetes.org/p/s/metabolomic-signatures-of-excess-fetal-growth-in-pregnancies-complicated-by-type-1-diabetes-t1d-1180
https://events.diabetes.org/p/s/norbert-freinkel-award-lecture-a-diabetes-pregnancy-technology-road-map-1181
https://events.diabetes.org/p/s/closed-loop-insulin-delivery-postpartum-in-type-1-diabetes-1182
https://events.diabetes.org/p/s/placental-igfbp1-is-associated-with-insulin-sensitivity-during-pregnancy-and-is-an-early-biomarker-for-gestational-diabetes-1183
https://events.diabetes.org/p/s/do-quality-improvement-efforts-reduce-health-care-disparities-1184
https://events.diabetes.org/p/s/do-quality-improvement-efforts-reduce-health-care-disparities-1185
https://events.diabetes.org/p/s/remission-or-bust-1186
https://events.diabetes.org/p/s/remission-or-bust-1187
https://events.diabetes.org/p/s/remission-or-bust-1188
https://events.diabetes.org/p/s/question-and-discussion-period-1189
https://events.diabetes.org/p/s/time-in-range-in-clinical-decision-support-1190
https://events.diabetes.org/p/s/time-in-range-from-a-patient-perspective-1191
https://events.diabetes.org/p/s/time-in-range-from-a-regulatory-perspective-1192
https://events.diabetes.org/p/s/time-in-range-in-clinical-trials-1193
https://events.diabetes.org/p/s/question-and-discussion-period-1194
https://events.diabetes.org/p/s/ada-insights-and-initiatives-guidelines-dissemination-1195
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1196
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1197
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1198
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1199
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1200
https://events.diabetes.org/p/s/updates-in-adas-standards-of-care-in-diabetes-2023-1201
https://events.diabetes.org/p/s/question-and-discussion-period-1202
https://events.diabetes.org/p/s/a-unique-multi-and-interdisciplinary-clinic-experience-the-cardiology-renal-and-endocrinology-care-clinic-1203
https://events.diabetes.org/p/s/e-consults-and-professional-continuous-glucose-monitoring-with-recommendations-1204
https://events.diabetes.org/p/s/project-echo-to-support-best-practice-diabetes-care-1205
https://events.diabetes.org/p/s/medical-or-surgical-treatment-for-youth-onset-type-2-diabetes-1206
https://events.diabetes.org/p/s/interdisciplinary-team-approach-to-type-2-diabetes-management-1207
https://events.diabetes.org/p/s/developing-community-based-interventions-for-youth-with-obesity-and-diabetes-1208
https://events.diabetes.org/p/s/question-and-discussion-period-1209
https://events.diabetes.org/p/s/evaluation-of-a-pregnancy-specific-algorithm-in-the-us-its-about-time-1210
https://events.diabetes.org/p/s/looking-towards-the-future-ongoing-studies-1211
https://events.diabetes.org/p/s/where-we-started-and-where-we-are-now-1212
https://events.diabetes.org/p/s/evidence-and-practical-tools-for-using-commercially-available-systems-in-pregnancy-1213
https://events.diabetes.org/p/s/maternal-glucose-and-the-contribution-of-fetal-insulin-mediated-growth-to-birthweight-what-have-we-learned-from-genetics-1214
https://events.diabetes.org/p/s/controversies-in-clinical-management-of-monogenic-diabetes-in-pregnancy-1215
https://events.diabetes.org/p/s/genetics-of-gestational-glucose-homeostasis-an-overview-1216
https://events.diabetes.org/p/s/breastfeeding-and-future-cardiometabolic-health-1217
https://events.diabetes.org/p/s/hypertension-in-pregnancy-updates-and-controversies-1218
https://events.diabetes.org/p/s/hypertriglyceridemia-in-pregnancy-pathophysiology-monitoring-and-treatment-1219
https://events.diabetes.org/p/s/question-and-discussion-period-1220
https://events.diabetes.org/p/s/clinical-perspectives-patient-and-provider-1221
https://events.diabetes.org/p/s/clinical-trials-update-1222
https://events.diabetes.org/p/s/rationale-and-proof-of-concept-1223
https://events.diabetes.org/p/s/future-outlook-for-ultra-long-acting-insulins-1224
https://events.diabetes.org/p/s/question-and-discussion-period-1225
https://events.diabetes.org/p/s/personalizing-care-for-eating-disorders-with-diabetes-1226
https://events.diabetes.org/p/s/food-and-housing-insecurity-1227
https://events.diabetes.org/p/s/use-of-antipsychotic-medications-1228
https://events.diabetes.org/p/s/physical-and-cognitive-impairment-1229
https://events.diabetes.org/p/s/glucagon-in-a-bihormonal-bionic-pancreas-system-1230
https://events.diabetes.org/p/s/new-glucagon-formulations-1231
https://events.diabetes.org/p/s/glucagon-use-during-exercise-1232
https://events.diabetes.org/p/s/is-there-a-role-for-cgm-in-prediabetes-and-obesity-1233
https://events.diabetes.org/p/s/iscgm-vs-rtcgm-in-insulin-treated-type-2-diabetes-1234
https://events.diabetes.org/p/s/role-of-continuous-glucose-monitoring-in-non-insulin-requiring-type-2-diabetes-1235
https://events.diabetes.org/p/s/the-ehr-and-data-integration-1236
https://events.diabetes.org/p/s/psychological-considerations-in-technology-adoption-1237
https://events.diabetes.org/p/s/overcoming-barriers-to-technology-in-primary-care-1238
https://events.diabetes.org/p/s/screening-and-monitoring-perspectives-from-germany-1239
https://events.diabetes.org/p/s/screening-and-monitoring-perspectives-from-the-united-states-1240
https://events.diabetes.org/p/s/screening-and-monitoring-perspectives-from-northern-europe-1241
https://events.diabetes.org/p/s/diabetes-technologies-with-a-global-perspective-1242
https://events.diabetes.org/p/s/looking-through-the-ada-lens-2023-ada-guidelines-for-pediatrics-1243
https://events.diabetes.org/p/s/an-approach-to-the-stages-of-diabetes-the-ispad-approach-1244
https://events.diabetes.org/p/s/question-and-discussion-period-1245
https://events.diabetes.org/p/s/translational-1246
https://events.diabetes.org/p/s/clinical-1247
https://events.diabetes.org/p/s/basic-1248
https://events.diabetes.org/p/s/management-of-youth-with-obesity-and-type-1-diabetes-1249
https://events.diabetes.org/p/s/the-latest-outcomes-from-the-today-study-1250
https://events.diabetes.org/p/s/new-onset-diabetes-in-adolescents-is-it-type-1-type-2-or-another-type-1251
https://events.diabetes.org/p/s/question-and-discussion-period-1252
https://events.diabetes.org/p/s/retatrutide-obesity-efficacy-and-safety-results-of-the-48-week-obesity-phase-2-trial-1253
https://events.diabetes.org/p/s/retatrutide-nafld-phase-2-trial-results-in-subset-of-patients-with-obesity-and-nafld-1254
https://events.diabetes.org/p/s/why-three-leveraging-the-metabolic-action-of-glucagon-in-retatrutide-a-novel-gipglp-1glucagon-receptor-triagonist-1255
https://events.diabetes.org/p/s/retatrutide-t2d-efficacy-and-safety-results-of-the-36-week-t2d-phase-2-trial-1256
https://events.diabetes.org/p/s/question-and-discussion-period-1257
https://events.diabetes.org/p/s/what-is-needed-to-improve-outcomes-more-physiological-delivery-of-hormone-replacement-in-diabetes-1258
https://events.diabetes.org/p/s/welcome-remarks-from-the-niddk-director-1259
https://events.diabetes.org/p/s/strategies-to-improve-usability-and-overcome-access-and-adoption-barriers-the-importance-of-context-and-social-connections-in-optimizing-device-use-for-youth-living-with-type-1-diabetes-1260
https://events.diabetes.org/p/s/what-is-needed-to-improve-outcomes-technological-and-physiological-adaptations-needed-for-more-automated-systems-1261
https://events.diabetes.org/p/s/remote-glucose-monitoring-among-patients-with-type-1-diabetes-strategies-to-improve-usability-and-overcome-access-and-adoption-barriers-1262
https://events.diabetes.org/p/s/question-and-discussion-period-1263
https://events.diabetes.org/p/s/overview-of-social-determinants-of-health-in-the-development-of-diabetes-1264
https://events.diabetes.org/p/s/neighborhood-physical-environment-and-social-cohesion-and-diabetes-prevalence-and-care-1265
https://events.diabetes.org/p/s/economic-adversity-as-a-driver-of-outcomes-for-individuals-with-diabetes-1266
https://events.diabetes.org/p/s/food-insecurity-and-diabetes-1267
https://events.diabetes.org/p/s/blood-glucose-meters-in-the-hospital-are-they-good-enough-1268
https://events.diabetes.org/p/s/continuous-glucose-monitors-in-the-hospital-are-they-good-enough-1269
https://events.diabetes.org/p/s/what-should-glucose-targets-be-1270
https://events.diabetes.org/p/s/question-and-discussion-period-1271
https://events.diabetes.org/p/s/precision-medicine-in-type-1-diabetes-1272
https://events.diabetes.org/p/s/precision-medicine-in-monogenic-diabetes-1273
https://events.diabetes.org/p/s/precision-medicine-in-type-2-diabetes-1274
https://events.diabetes.org/p/s/precision-medicine-in-gestational-diabetes-1275
https://events.diabetes.org/p/s/question-and-discussion-period-1276
https://events.diabetes.org/p/s/oasis-1-results-1277
https://events.diabetes.org/p/s/introduction-1278
https://events.diabetes.org/p/s/oasis-1-trial-design-and-baseline-characteristics-1279
https://events.diabetes.org/p/s/placing-oasis-1-and-pioneer-plus-into-current-context-independent-discussant-1280
https://events.diabetes.org/p/s/pioneer-plus-trial-design-and-baseline-characteristics-1281
https://events.diabetes.org/p/s/pioneer-plus-results-1282
https://events.diabetes.org/p/s/rationale-for-evaluating-higher-dose-glp-1ras-1283
https://events.diabetes.org/p/s/question-and-discussion-period-1284
https://events.diabetes.org/p/s/putting-surmount-2-results-in-context-and-implications-regarding-treatment-of-patients-having-both-obesity-and-type-2-diabetes-1285
https://events.diabetes.org/p/s/surmount-2-rationale-hypotheses-and-study-design-1286
https://events.diabetes.org/p/s/tirzepatide-and-the-rationale-pharmacology-and-mechanism-of-multifunctional-peptides-1287
https://events.diabetes.org/p/s/surmount-2-safety-data-1288
https://events.diabetes.org/p/s/current-therapeutic-landscape-for-treating-obesity-in-type-2-diabetes-two-diseases-each-requiring-optimal-therapy-1289
https://events.diabetes.org/p/s/surmount-2-efficacy-data-1290
https://events.diabetes.org/p/s/question-and-discussion-period-1291
https://events.diabetes.org/p/s/population-health-approaches-1292
https://events.diabetes.org/p/s/rebuttal-1293
https://events.diabetes.org/p/s/personalized-medicine-approaches-1294
https://events.diabetes.org/p/s/rebuttal-1295
https://events.diabetes.org/p/s/question-and-discussion-period-1296
https://events.diabetes.org/p/s/have-we-succeeded-in-type-2-diabetes-primary-prevention-con-1297
https://events.diabetes.org/p/s/welcome-and-introduction-1298
https://events.diabetes.org/p/s/have-we-succeeded-in-type-2-diabetes-primary-prevention-pro-1299
https://events.diabetes.org/p/s/kelly-west-award-for-outstanding-achievement-in-epidemiology-diabetes-in-south-asians-uncovering-novel-risk-factors-with-longitudinal-epidemiologic-data-1300
https://events.diabetes.org/p/s/characterization-and-prediction-of-genetic-risk-of-t1d-in-individuals-without-hla-dr3-or-hla-dr4-1301
https://events.diabetes.org/p/s/mapping-cis-regulatory-programs-affecting-diabetes-risk-in-pancreatic-islet-cell-types-using-single-cell-multimodal-profiling-1302
https://events.diabetes.org/p/s/the-mda5627x-variant-is-associated-with-type-1-diabetes-protection-via-attenuated-inflammatory-antiviral-responses-1303
https://events.diabetes.org/p/s/metabolite-ratios-and-development-of-type-1-diabetes-1304
https://events.diabetes.org/p/s/the-impact-of-insulin-secretion-and-insulin-sensitivity-on-cognition-in-adults-with-prediabetes-the-diabetes-prevention-program-outcomes-study-dppos-1305
https://events.diabetes.org/p/s/health-care-utilization-in-older-adults-with-diabetes-and-dementia-medical-expenditure-panel-survey-2000-2020-1306
https://events.diabetes.org/p/s/ada-presidents-select-abstract-structural-neuroimaging-and-cognitive-function-in-long-duration-type-1-diabetes-1307
https://events.diabetes.org/p/s/association-between-age-at-diagnosis-of-type-2-diabetes-and-subsequent-risk-of-dementia-and-its-major-subtypes-1308
https://events.diabetes.org/p/s/question-and-discussion-period-1309
https://events.diabetes.org/p/s/endotypes-of-ketosis-prone-diabetes-1310
https://events.diabetes.org/p/s/endotypes-of-type-2-diabetes-1311
https://events.diabetes.org/p/s/monogenic-diabetes-endotypes-1312
https://events.diabetes.org/p/s/endotypes-of-prediabetes-1313
https://events.diabetes.org/p/s/machine-learning-approach-reveals-microbiome-metabolome-lipidome-and-their-interaction-in-type-1-diabetes-mellitus-1314
https://events.diabetes.org/p/s/circulating-metabolites-and-type-2-diabetes-t2d-risk-an-integrated-metabolomics-and-genetics-study-of-23000-adults-1315
https://events.diabetes.org/p/s/genetic-variants-that-lower-hemoglobin-a1c-independently-of-glycemia-are-associated-with-higher-diabetic-retinopathy-risk-in-diverse-ancestries-1316
https://events.diabetes.org/p/s/metabolic-signatures-of-type-2-diabetes-subtypes-in-uk-biobank-1317
https://events.diabetes.org/p/s/circulating-micrornas-predict-weight-loss-in-participants-from-the-diabetes-prevention-program-1318
https://events.diabetes.org/p/s/digital-divide-and-medicare-diabetes-prevention-program-of-beneficiaries-with-elevated-bmi-1319
https://events.diabetes.org/p/s/examining-the-association-between-health-care-utilization-and-raceethnicity-in-us-adults-with-diabetic-kidney-disease-2000-2020-1320
https://events.diabetes.org/p/s/differences-in-the-use-of-diabetes-medications-with-cardiorenal-benefits-between-rural-and-urban-america-1321
https://events.diabetes.org/p/s/trends-in-racial-ethnic-and-socioeconomic-inequalities-in-diagnosed-diabetes-prevalence-and-incidence-among-us-adults-2008-2021-1322
https://events.diabetes.org/p/s/the-lasting-effects-of-redlining-on-diabetes-rates-a-tri-city-statistical-analysis-1323
https://events.diabetes.org/p/s/the-contribution-of-social-needs-factors-to-racial-differences-in-type-2-diabetes-1324
https://events.diabetes.org/p/s/improving-performance-of-type-2-diabetes-polygenic-scores-in-african-and-hispanic-ancestries-1325
https://events.diabetes.org/p/s/the-landscape-of-pharmacogenetic-variants-associated-with-noninsulin-antidiabetic-drugs-in-the-indian-population-1326
https://events.diabetes.org/p/s/higher-genetic-risk-for-type-2-diabetes-is-associated-with-faster-decline-of-beta-cell-function-1327
https://events.diabetes.org/p/s/multiancestry-genome-wide-association-study-reveals-distinct-biological-pathways-and-cell-types-driving-type-2-diabetes-risk-with-heterogeneous-effects-across-diverse-populations-1328
https://events.diabetes.org/p/s/multiancestry-genetic-clustering-of-type-2-diabetes-loci-highlights-the-contribution-of-non-european-variants-to-disease-heterogeneity-1329
https://events.diabetes.org/p/s/identification-of-489-type-2-diabetes-shared-and-tissue-specific-effector-genes-by-integrating-eqtl-data-with-a-multiancestry-gwas-of-25-million-individuals-1330
https://events.diabetes.org/p/s/using-ipsc-derived-islets-to-model-the-effect-of-an-abcc8-arg1420his-mutation-in-fetal-and-adult-islets-1331
https://events.diabetes.org/p/s/ada-presidents-select-abstract-an-isogenic-hpsc-based-platform-for-functional-interrogation-of-the-role-of-multiple-t2d-associated-genes-in-pancreatic-beta-cell-failure-1332
https://events.diabetes.org/p/s/surveying-specific-and-shared-responses-of-human-islets-to-t2d-associated-stressors-1333
https://events.diabetes.org/p/s/an-abcc8-r1420h-loss-of-function-variant-affects-insulin-secretory-function-and-microvascular-disease-in-american-indians-1334
https://events.diabetes.org/p/s/an-alternative-downstream-translational-start-site-in-pparg-produces-a-novel-protein-that-rescues-loss-of-function-mutations-in-humans-1335
https://events.diabetes.org/p/s/question-and-discussion-period-1336
https://events.diabetes.org/p/s/english-proficiency-and-diabetes-care-challenges-and-opportunities-1338
https://events.diabetes.org/p/s/the-importance-and-influence-of-culture-on-diabetes-prevention-and-management-how-to-tailor-the-intervention-to-the-lifestyle-1339
https://events.diabetes.org/p/s/diabetes-risk-and-resilience-the-immigrant-generation-gap-1340
https://events.diabetes.org/p/s/question-and-discussion-period-1341
https://events.diabetes.org/p/s/practical-tools-for-evaluation-of-real-world-evidence-in-diabetes-research-1342
https://events.diabetes.org/p/s/diabetes-surveillance-using-ehr-data-the-dicaya-study-1343
https://events.diabetes.org/p/s/real-world-data-and-regulatory-decision-making-in-diabetes-therapeutics-highlights-from-rct-duplicate-1344
https://events.diabetes.org/p/s/question-and-discussion-period-1345
https://events.diabetes.org/p/s/burden-and-epidemiology-of-diabetes-in-rural-america-1346
https://events.diabetes.org/p/s/neighborhood-socioeconomic-environment-and-influence-on-diabetes-1347
https://events.diabetes.org/p/s/rural-urban-trends-in-diabetes-management-1348
https://events.diabetes.org/p/s/risks-underlying-rural-areas-longitudinal-rural-study-collaborative-effort-to-understand-rural-health-1349
https://events.diabetes.org/p/s/d-prism-prs-of-diabetes-and-related-traits-1350
https://events.diabetes.org/p/s/utilizing-multiancestry-gwas-to-elucidate-biological-mechanisms-for-type-2-diabetes-1351
https://events.diabetes.org/p/s/multiancestry-gwas-for-glycemic-traits-1352
https://events.diabetes.org/p/s/single-nucleus-multi-omic-profiling-in-human-islets-under-basal-and-proinflammatory-conditions-nominates-diabetes-gene-regulatory-mechanisms-1353
https://events.diabetes.org/p/s/integrated-and-diverse-omics-and-data-science-1354
https://events.diabetes.org/p/s/integrated-single-nucleus-omics-across-pancreas-development-1355
https://events.diabetes.org/p/s/question-and-discussion-period-1356
https://events.diabetes.org/p/s/what-can-edic-still-contribute-future-directions-1357
https://events.diabetes.org/p/s/clinical-perspective-how-dcctedic-changed-the-care-of-type-1-diabetes-1358
https://events.diabetes.org/p/s/functional-impact-of-long-standing-type-1-diabetes-cognition-physical-function-hearing-and-skeletal-health-1359
https://events.diabetes.org/p/s/overview-and-design-of-dcct-and-edic-from-clinical-trial-to-epidemiology-1360
https://events.diabetes.org/p/s/functional-impact-of-long-standing-type-1-diabetes-cognition-physical-function-hearing-and-skeletal-health-1361
https://events.diabetes.org/p/s/cardiovascular-disease-in-type-1-diabetes-1362
https://events.diabetes.org/p/s/clinical-perspective-how-dcctedic-changed-the-care-of-type-1-diabetes-1363
https://events.diabetes.org/p/s/the-amelioration-of-microvascular-complications-and-their-major-risk-factors-in-dcctedic-1364
https://events.diabetes.org/p/s/frameworks-and-real-world-international-case-studies-to-address-global-inequity-in-diabetes-1365
https://events.diabetes.org/p/s/panel-discussion-1366
https://events.diabetes.org/p/s/panel-discussion-1367
https://events.diabetes.org/p/s/panel-discussion-1368
https://events.diabetes.org/p/s/structural-racism-and-geographic-inequity-in-diabetes-1369
https://events.diabetes.org/p/s/panel-discussion-1370
https://events.diabetes.org/p/s/addressing-racial-inequity-in-the-us-1371
https://events.diabetes.org/p/s/panel-discussion-1372
https://events.diabetes.org/p/s/frameworks-and-real-world-international-case-studies-to-address-global-inequity-in-diabetes-1373
https://events.diabetes.org/p/s/panel-discussion-1374
https://events.diabetes.org/p/s/structural-racism-and-geographic-inequity-in-diabetes-1375
https://events.diabetes.org/p/s/panel-discussion-1376
https://events.diabetes.org/p/s/outstanding-educator-in-diabetes-award-lecture-optimal-diabetes-care-through-listening-to-multiple-voices-1377
https://events.diabetes.org/p/s/ada-chief-executive-officer-remarks-1378
https://events.diabetes.org/p/s/president-health-care-and-education-address-improving-diversity-in-clinical-trials-1379
https://events.diabetes.org/p/s/augmented-heparanase-secretion-in-diabetes-regulates-development-of-cardiac-hypertrophy-1380
https://events.diabetes.org/p/s/high-glucose-metabolism-fuels-cathepsin-l-maturation-to-promote-sars-cov-2-infection-in-patients-with-diabetes-1381
https://events.diabetes.org/p/s/reduction-in-insulin-uncovers-a-novel-effect-of-vegfb-on-cardiac-substrate-utilization-1382
https://events.diabetes.org/p/s/insulin-and-glucagon-regulate-a-novel-bidirectional-long-noncoding-rnaprotein-coding-gene-pair-that-control-cell-sensitivity-to-metabolic-stress-1383
https://events.diabetes.org/p/s/methionine-restriction-differentially-protects-against-high-fat-diet-induced-neuroinflammation-and-central-insulin-resistance-in-male-and-female-mice-1384
https://events.diabetes.org/p/s/il-10-treated-adipose-stromal-vascular-fractions-reverse-insulin-resistance-in-a-type-2-diabetes-mellitus-mouse-model-1385
https://events.diabetes.org/p/s/post-translational-modification-of-shda-regulating-macrophage-polarization-and-inflammation-in-obesity-1386
https://events.diabetes.org/p/s/carbohydrate-insulin-model-cim-1387
https://events.diabetes.org/p/s/energy-balance-eb-model-1388
https://events.diabetes.org/p/s/a-new-cytoskeleton-based-mechanism-for-regulating-brown-adipose-tissue-physiology-1389
https://events.diabetes.org/p/s/targeted-erasure-of-dna-methylation-by-tet3-with-cebpd-rewires-adipogenic-execution-for-energy-metabolism-1390
https://events.diabetes.org/p/s/axon-guidance-molecule-slit3-is-essential-for-cold-induced-remodeling-of-bat-neurovasculature-and-thermogenesis-1391
https://events.diabetes.org/p/s/cold-responsive-proteolytic-rewiring-of-mitochondria-safeguards-white-fat-thermogenic-remodeling-1392
https://events.diabetes.org/p/s/targeting-junb-induces-a-shift-from-low-to-high-thermogenic-adipocytes-and-ameliorates-diet-induced-insulin-resistance-1393
https://events.diabetes.org/p/s/adipose-lysosomal-acid-lipase-is-indispensable-for-starvation-and-cold-induced-lipolysis-1394
https://events.diabetes.org/p/s/defining-pathway-selective-insulin-resistance-in-type-2-diabetes-using-ips-cell-derived-hepatocytes-1395
https://events.diabetes.org/p/s/hepatic-integrin-ss1-subunit-is-required-for-liver-insulin-resistance-but-not-fatty-liver-in-diet-induced-obese-mice-1396
https://events.diabetes.org/p/s/macrophage-derived-interleukin-12-regulates-obesity-mediated-insulin-resistance-in-the-liver-1397
https://events.diabetes.org/p/s/foxk1-associated-gene-regulatory-network-a-new-transcriptional-regulator-of-hepatic-insulin-action-1398
https://events.diabetes.org/p/s/high-fat-diets-containing-sucrose-and-fructose-but-not-glucose-induce-obesity-and-hepatic-insulin-resistance-via-accumulation-of-diacylglycerols-1399
https://events.diabetes.org/p/s/creg1-regulates-hepatic-insulin-sensitivity-and-insulin-receptor-trafficking-1400
https://events.diabetes.org/p/s/muscle-a-parvin-deletion-results-in-insulin-resistance-by-impairing-glut4-translocation-and-hexokinase-ii-association-with-mitochondria-in-mice-1401
https://events.diabetes.org/p/s/lower-insulin-sensitivity-before-the-onset-of-type-2-diabetes-is-associated-with-increased-risk-of-albuminuria-after-diabetes-onset-1402
https://events.diabetes.org/p/s/deletion-of-the-type-2-diabetes-candidate-gene-slc16a11-reduces-peripheral-insulin-sensitivity-in-mice-1403
https://events.diabetes.org/p/s/fgf21-mediated-signaling-defects-and-their-effects-on-insulin-resistance-in-insulin-mediated-pseudoacromegaly-1404
https://events.diabetes.org/p/s/lipid-induced-insulin-resistance-in-brown-adipose-tissue-is-mediated-by-the-sn-12-dag-pkce-irkt1150-phosphorylation-pathway-1405
https://events.diabetes.org/p/s/lrtm1-a-novel-regulator-of-insulin-signaling-and-metabolism-1406
https://events.diabetes.org/p/s/unsupervised-approach-systematically-analyzes-the-multiomics-profiles-associated-with-t2d-insulin-insensitivity-an-imi-rhapsody-study-1407
https://events.diabetes.org/p/s/regulation-of-metabolite-pools-influences-adipocyte-differentiation-and-antioxidant-capacity-1408
https://events.diabetes.org/p/s/e-cigarette-vaping-exposure-increases-adipose-11ss-hsd1-expression-and-disturbs-glucose-homeostasis-in-mice-1409
https://events.diabetes.org/p/s/brown-adipose-tissue-m6a-mrna-methylation-regulates-systemic-insulin-sensitivity-via-a-prostaglandin-interorgan-axis-1410
https://events.diabetes.org/p/s/a-machine-learning-approach-to-estimate-insulin-resistance-from-untargeted-metabolomics-data-1411
https://events.diabetes.org/p/s/question-and-discussion-period-1412
https://events.diabetes.org/p/s/neuronal-control-of-thermogenesis-1413
https://events.diabetes.org/p/s/role-of-the-brain-1414
https://events.diabetes.org/p/s/energy-balance-and-metabolic-set-points-1415
https://events.diabetes.org/p/s/question-and-discussion-period-1416
https://events.diabetes.org/p/s/spatial-compartmentation-of-protein-and-metabolites-1417
https://events.diabetes.org/p/s/interorgan-cross-talk-and-tissue-microenvironment-in-metabolic-liver-disease-1418
https://events.diabetes.org/p/s/changing-the-conversation-how-ptms-moderate-organellar-cross-talk-1419
https://events.diabetes.org/p/s/question-and-discussion-period-1420
https://events.diabetes.org/p/s/mitochondrial-pyruvate-uptake-and-hepatic-metabolism-1421
https://events.diabetes.org/p/s/mitochondrial-metabolic-flux-and-fatty-acid-metabolism-1422
https://events.diabetes.org/p/s/insulin-signaling-and-muscle-mitochondrial-function-1423
https://events.diabetes.org/p/s/mitochondrial-fatty-acid-synthesis-1424
https://events.diabetes.org/p/s/question-and-discussion-period-1425
https://events.diabetes.org/p/s/circadian-rhythm-and-metabolism-1426
https://events.diabetes.org/p/s/time-restricted-feeding-improves-cardiometabolic-profiles-1427
https://events.diabetes.org/p/s/forget-about-calories-lets-focus-on-time-the-role-of-time-restricted-eating-on-weight-loss-and-metabolic-health-1428
https://events.diabetes.org/p/s/question-and-discussion-period-1429
https://events.diabetes.org/p/s/hormonal-control-over-energy-balance-1430
https://events.diabetes.org/p/s/liver-lipid-metabolism-intersecting-with-hormones-to-regulate-sex-differences-in-immunity-1431
https://events.diabetes.org/p/s/sex-specific-adipose-depot-development-1432
https://events.diabetes.org/p/s/estrogen-rewiring-of-the-neural-circuitry-controlling-energy-balance-1433
https://events.diabetes.org/p/s/question-and-discussion-period-1434
https://events.diabetes.org/p/s/watching-multienzyme-complexes-and-metabolism-1435
https://events.diabetes.org/p/s/metabolic-signaling-pathways-in-real-time-1436
https://events.diabetes.org/p/s/intensity-based-fluorosensors-1437
https://events.diabetes.org/p/s/real-time-single-cell-imaging-of-circadian-rhythms-the-cell-cycle-and-cell-differentiation-1438
https://events.diabetes.org/p/s/question-and-discussion-period-1439
https://events.diabetes.org/p/s/evidence-for-a-new-spatially-and-temporally-compartmentalized-model-1440
https://events.diabetes.org/p/s/rebuttal-1441
https://events.diabetes.org/p/s/evidence-for-the-canonical-model-1442
https://events.diabetes.org/p/s/rebuttal-1443
https://events.diabetes.org/p/s/question-and-discussion-period-1444
https://events.diabetes.org/p/s/emerging-roles-and-interactions-of-alpha-cells-in-islet-function-1445
https://events.diabetes.org/p/s/trouble-in-the-neighborhood-emerging-roles-for-beta-cell-mirnas-in-type-1-diabetes-pathogenesis-and-risk-stratification-1446
https://events.diabetes.org/p/s/welcome-and-introduction-1447
https://events.diabetes.org/p/s/emerging-roles-and-interactions-of-delta-cells-in-islet-function-1448
https://events.diabetes.org/p/s/residual-beta-cell-function-associates-with-lower-glycaemic-variability-and-more-time-in-range-in-individuals-with-type-1-diabetes-1449
https://events.diabetes.org/p/s/ada-presidents-select-abstract-preclinical-evaluation-of-tyk2-inhibitors-in-type-1-diabetes-1450
https://events.diabetes.org/p/s/a-novel-drug-that-normalizes-hyperglycemia-in-type-1-diabetes-1451
https://events.diabetes.org/p/s/characterising-a-novel-peptide-that-inhibits-and-reverses-type-1-diabetes-1452
https://events.diabetes.org/p/s/chronic-pancreatitis-does-not-induce-specific-alterations-in-beta-cell-function-1453
https://events.diabetes.org/p/s/stabilizing-14-3-3-and-chrebp-cytoplasmic-interaction-to-rescue-ss-cells-from-glucolipotoxicity-1454
https://events.diabetes.org/p/s/exercise-training-decreases-ss-cell-senescence-in-mice-and-humans-1455
https://events.diabetes.org/p/s/epigenetic-control-of-beta-cell-stress-response-and-senescence-1456
https://events.diabetes.org/p/s/defining-the-transcriptome-and-epitranscriptome-of-the-ss-cell-compensation-to-insulin-resistance-1457
https://events.diabetes.org/p/s/structure-function-analysis-of-p57kip2-in-the-human-pancreatic-beta-cell-reveals-a-canonical-bipartite-nuclear-localization-sequence-nls-1458
https://events.diabetes.org/p/s/swisnf-controls-transcriptional-programs-required-for-ss-cell-development-and-postnatal-islet-function-1459
https://events.diabetes.org/p/s/nrf2-regulates-neonatal-ss-cell-mass-expansion-1460
https://events.diabetes.org/p/s/the-rnf20-ubiquitin-ligase-is-required-for-beta-cell-identity-and-function-1461
https://events.diabetes.org/p/s/self-organized-insulin-producing-ss-cells-differentiated-from-human-omentum-derived-stem-cells-1462
https://events.diabetes.org/p/s/myc-activity-is-required-for-mitochondrial-function-and-glucose-stimulated-insulin-secretion-gsis-in-pancreatic-ss-cells-1463
https://events.diabetes.org/p/s/pancreatic-ss-cell-trapd-deficiency-reduces-insulin-production-but-improves-insulin-sensitivity-1464
https://events.diabetes.org/p/s/succinate-potentiates-insulin-secretion-through-sucnr1-1465
https://events.diabetes.org/p/s/stim1-interacts-with-g-protein-coupled-estrogen-receptor-signaling-to-maintain-ss-cell-identity-in-female-mice-1466
https://events.diabetes.org/p/s/the-beta-cell-specific-deletion-of-complement-1q-like-3-secreted-protein-improves-beta-cell-function-and-glucose-homeostasis-1467
https://events.diabetes.org/p/s/reduced-nkx2-2-expression-enhances-insulin-secretion-by-primary-human-ss-cells-1468
https://events.diabetes.org/p/s/pancreatic-elastase-regulates-human-beta-cell-viability-by-impairing-the-par2-pathway-1469
https://events.diabetes.org/p/s/optogenetic-control-of-pancreatic-delta-cells-reveals-their-central-role-in-hormone-release-from-pancreatic-islets-1470
https://events.diabetes.org/p/s/role-of-insulin-degrading-enzyme-ide-in-the-tubulin-primary-cilium-axis-to-regulate-glucagon-secretion-1471
https://events.diabetes.org/p/s/the-long-chain-fatty-acid-receptor-ffa4-stimulates-insulin-secretion-via-inhibition-of-somatostatin-release-from-the-delta-cell-1472
https://events.diabetes.org/p/s/dynorphin-a-novel-paracrine-factor-that-regulates-insulin-secretion-1473
https://events.diabetes.org/p/s/to-which-degree-do-alpha-cells-shape-the-role-of-the-beta-cells-first-responders-1474
https://events.diabetes.org/p/s/genetic-evidence-for-beta-cell-er-stress-in-diabetes-1475
https://events.diabetes.org/p/s/pharmacological-targeting-of-er-stress-in-diabetes-1476
https://events.diabetes.org/p/s/genetic-targeting-of-beta-cell-upr-in-type-1-diabetes-1477
https://events.diabetes.org/p/s/novel-insights-into-tumor-necrosis-factor-tnf-receptor-signaling-and-beta-cell-death-1478
https://events.diabetes.org/p/s/effect-of-gut-derived-bacteria-on-beta-cell-inflammation-and-dysfunction-1479
https://events.diabetes.org/p/s/il-1v-stimulates-insulin-secretion-via-neuronal-transmission-1480
https://events.diabetes.org/p/s/postnatal-beta-cells-1481
https://events.diabetes.org/p/s/beta-cell-aging-1482
https://events.diabetes.org/p/s/fetal-beta-cells-in-the-human-pancreas-1483
https://events.diabetes.org/p/s/question-and-discussion-period-1484
https://events.diabetes.org/p/s/sensory-modulation-of-pancreatic-v-cells-1485
https://events.diabetes.org/p/s/the-role-of-endocrine-cross-talk-in-nutrient-homeostasis-1486
https://events.diabetes.org/p/s/understanding-contributions-of-vasculature-to-islet-function-1487
https://events.diabetes.org/p/s/delta-cell-regulation-of-beta-cell-function-1488
https://events.diabetes.org/p/s/sex-differences-in-the-islet-stress-response-1489
https://events.diabetes.org/p/s/sex-differences-in-islet-dna-methylation-1490
https://events.diabetes.org/p/s/sex-differences-in-the-beta-cell-response-to-maternal-obesity-1491
https://events.diabetes.org/p/s/question-and-discussion-period-1492
https://events.diabetes.org/p/s/for-emerging-innovations-1493
https://events.diabetes.org/p/s/rebuttal-1494
https://events.diabetes.org/p/s/for-beta-cell-replacement-1495
https://events.diabetes.org/p/s/rebuttal-1496
https://events.diabetes.org/p/s/question-and-discussion-period-1497
https://events.diabetes.org/p/s/biomaterial-based-approaches-to-reduce-the-immunorejection-of-islets-1498
https://events.diabetes.org/p/s/engineering-islets-1499
https://events.diabetes.org/p/s/welcome-and-introduction-1500
https://events.diabetes.org/p/s/immune-modifying-therapies-1501
https://events.diabetes.org/p/s/reduction-of-macrophage-ipla2ss-derived-proinflammatory-lipids-inhibit-type-1-diabetes-development-1502
https://events.diabetes.org/p/s/sex-specific-differences-in-subcutaneous-adipose-tissue-in-persons-with-hiv-may-contribute-to-diabetes-risk-1503
https://events.diabetes.org/p/s/sirtuin-1-dysfunction-underlies-the-pathological-upregulation-of-netosis-in-diabetes-1504
https://events.diabetes.org/p/s/diabetic-wound-keratinocytes-induce-macrophage-jmjd3-mediated-nlrp3-expression-1505
https://events.diabetes.org/p/s/two-different-ways-to-replace-beta-cell-mass-after-partial-pancreatectomy-1506
https://events.diabetes.org/p/s/differentiation-of-adult-islet-cell-precursors-into-ss-and-a-like-cells-for-islet-transplantation-1507
https://events.diabetes.org/p/s/selected-dyrk1a-inhibitors-simultaneously-drive-both-human-beta-cell-proliferation-and-differentiation-1508
https://events.diabetes.org/p/s/transcriptomics-identification-of-a-cell-subpopulations-in-human-islets-using-integrated-scrna-seq-and-snrna-seq-1509
https://events.diabetes.org/p/s/patient-advocate-1510
https://events.diabetes.org/p/s/midsize-practice-representative-1511
https://events.diabetes.org/p/s/teplizumab-in-the-prevention-and-delay-of-type-1-diabetes-1512
https://events.diabetes.org/p/s/smallerprivate-practice-representative-1513
https://events.diabetes.org/p/s/consortia-representative-1514
https://events.diabetes.org/p/s/a-combinatorial-approach-with-monoclonal-antibodies-to-serpinb13-and-cd3-is-therapeutically-superior-to-single-antibody-use-in-autoimmune-diabetes-1515
https://events.diabetes.org/p/s/safety-and-efficacy-of-immunomodulatory-therapy-using-antithymocyte-globulin-and-pegfilgrastim-in-japanese-patients-with-type-1-diabetes-a-pilot-randomized-clinical-trial-1516
https://events.diabetes.org/p/s/mechanisms-of-antigen-specific-immunotherapy-following-tolerance-induction-to-a-cd4-hybrid-insulin-peptide-epitope-and-the-impact-on-cd8-t-cell-dysfunction-1517
https://events.diabetes.org/p/s/submicron-ultrasound-contrast-agents-as-therapeutic-delivery-vehicles-in-type-1-diabetes-1518
https://events.diabetes.org/p/s/systematic-review-of-immune-interventions-trials-in-recent-onset-type-1-and-effect-on-hba1c-1519
https://events.diabetes.org/p/s/stage-transitions-in-preclinical-type-1-diabetes-protective-effect-of-ia2-variant-autoantibody-positivity-1520
https://events.diabetes.org/p/s/automated-multiplex-antibody-detection-by-agglutination-pcr-adap-compared-with-gold-standard-radiobinding-assays-of-autoantibodies-in-type-1-diabetes-1521
https://events.diabetes.org/p/s/characterization-of-type-1-diabetes-t1d-endotypes-1522
https://events.diabetes.org/p/s/a-human-gut-commensal-parabacteroides-distasonis-stimulates-an-inflammatory-response-specific-to-the-pancreas-but-not-to-the-intestines-and-induces-type-1-diabetes-1523
https://events.diabetes.org/p/s/an-early-immune-signature-in-prediabetes-can-predict-progression-to-type-2-diabetes-1524
https://events.diabetes.org/p/s/automated-cluster-analysis-by-machine-learning-reveals-important-dissimilarities-in-the-immune-phenotype-of-t1d-ms-and-sle-1525
https://events.diabetes.org/p/s/features-of-human-th-like-regulatory-t-cells-in-the-pathogenesis-of-type-1-diabetes-1526
https://events.diabetes.org/p/s/immunoprivileged-hydrogels-extend-functionality-of-islets-in-immunocompetent-animals-1527
https://events.diabetes.org/p/s/targeted-drug-delivery-to-human-ss-cells-using-novel-nanocapsule-delivery-vehicle-for-t1d-treatment-1528
https://events.diabetes.org/p/s/the-survival-and-function-of-whole-or-dissociated-islet-transplants-are-improved-by-immunomodulatory-microporous-annealed-particle-map-gel-1529
https://events.diabetes.org/p/s/3d-bioprinting-of-a-bionic-pancreas-with-a-vascular-system-results-of-transplantation-in-large-animals-1530
https://events.diabetes.org/p/s/adoshell-islet-a-new-biomaterial-for-allogenic-islet-encapsulation-shows-six-months-insulin-secretion-in-diabetic-immunocompetent-rats-1531
https://events.diabetes.org/p/s/glycemic-control-after-total-pancreatectomy-with-islet-autotransplantation-results-from-a-single-center-with-large-cohort-of-patients-1532
https://events.diabetes.org/p/s/changes-in-renal-function-after-islet-transplantation-in-a-single-centre-cohort-in-canada-over-20-years-1533
https://events.diabetes.org/p/s/gastrin-improves-single-islet-transplant-outcomes-1534
https://events.diabetes.org/p/s/islet-allotransplantation-into-prevascularized-sernova-cell-pouch-early-results-from-the-university-of-chicago-1535
https://events.diabetes.org/p/s/preservation-of-islet-graft-function-and-blood-glucose-control-after-total-pancreatectomy-with-islet-autotransplantation-in-patients-with-chronic-pancreatitis-and-intractable-pain-nine-year-follow-up-1536
https://events.diabetes.org/p/s/defining-targets-for-continuous-glucose-monitoring-cgm-after-total-pancreatectomy-with-islet-autotransplantation-tpiat-1537
https://events.diabetes.org/p/s/il-2-in-the-preservation-of-beta-cell-function-1538
https://events.diabetes.org/p/s/ustekinumab-in-the-treatment-of-type-1-diabetes-1539
https://events.diabetes.org/p/s/treatment-of-type-1-diabetes-with-il-2-1540
https://events.diabetes.org/p/s/perspective-on-cytokine-specific-therapies-in-type-1-diabetes-1541
https://events.diabetes.org/p/s/jakinibs-in-the-treatment-of-type-1-diabetes-1542
https://events.diabetes.org/p/s/question-and-discussion-period-1543
https://events.diabetes.org/p/s/oh-the-place-well-go-reflections-of-past-experience-and-future-opportunities-and-challenges-1544
https://events.diabetes.org/p/s/hydroxychloroquine-in-the-prevention-of-type-1-diabetes-1545
https://events.diabetes.org/p/s/prevention-trials-in-type-1-diabetes-1546
https://events.diabetes.org/p/s/abatacept-in-the-prevention-of-type-1-diabetes-1547
https://events.diabetes.org/p/s/question-and-discussion-period-1548
https://events.diabetes.org/p/s/type-1-diabetes-pathology-revealed-through-ici-t1d-animal-models-1549
https://events.diabetes.org/p/s/type-1-diabetes-and-celiac-disease-partners-in-crime-make-good-research-partners-1550
https://events.diabetes.org/p/s/type-1-diabetes-pathology-revealed-through-checkpoint-inhibition-in-cancer-1551
https://events.diabetes.org/p/s/type-1-diabetes-in-primary-immunodeficiencies-1552
https://events.diabetes.org/p/s/question-and-discussion-period-1553
https://events.diabetes.org/p/s/introduction-clinical-islet-transplantation-where-are-we-now-1554
https://events.diabetes.org/p/s/current-state-of-stem-cell-based-islet-therapies-in-patients-progress-and-challenges-1555
https://events.diabetes.org/p/s/islet-auto-transplant-lessons-learned-for-cell-therapy-in-diabetes-1556
https://events.diabetes.org/p/s/is-there-a-role-for-cadaveric-islet-transplantation-at-academic-centers-in-the-future-and-in-what-settings-1557
https://events.diabetes.org/p/s/question-and-discussion-period-1558
https://events.diabetes.org/p/s/how-do-we-manage-immunogenicity-1559
https://events.diabetes.org/p/s/designing-a-cell-source-for-the-future-1560
https://events.diabetes.org/p/s/introduction-current-state-and-future-needs-of-beta-cell-replacement-in-diabetes-1561
https://events.diabetes.org/p/s/are-there-other-cell-sources-beyond-esc-and-ipsc-1562
https://events.diabetes.org/p/s/the-pro-and-cons-of-open-scaffolds-vs-encapsulation-1563
https://events.diabetes.org/p/s/introduction-with-what-where-and-how-1564
https://events.diabetes.org/p/s/monitoring-of-patients-post-transplant-1565
https://events.diabetes.org/p/s/cotransplantation-of-other-cell-types-to-influence-engraftment-1566
https://events.diabetes.org/p/s/question-and-discussion-period-1567
https://events.diabetes.org/p/s/microbiome-is-all-hype-1568
https://events.diabetes.org/p/s/rebuttal-1569
https://events.diabetes.org/p/s/microbiome-is-key-for-obesity-1570
https://events.diabetes.org/p/s/rebuttal-1571
https://events.diabetes.org/p/s/question-and-discussion-period-1572
https://events.diabetes.org/p/s/rebuttal-1573
https://events.diabetes.org/p/s/senescent-cells-coordinate-an-immune-response-in-health-but-that-malfunctions-in-disease-1574
https://events.diabetes.org/p/s/fundamental-aging-mechanisms-as-drivers-of-metabolic-disease-future-potential-for-gerotherapeutic-interventions-1575
https://events.diabetes.org/p/s/rebuttal-1576
https://events.diabetes.org/p/s/question-and-discussion-period-1577
https://events.diabetes.org/p/s/rebuttal-1578
https://events.diabetes.org/p/s/the-value-of-eating-early-1579
https://events.diabetes.org/p/s/a-calorie-is-a-calorie-regardless-of-timing-1580
https://events.diabetes.org/p/s/rebuttal-1581
https://events.diabetes.org/p/s/the-effect-of-glucagon-like-peptide-1-receptor-blockade-on-the-ss-cell-response-to-glucagon-bolus-in-people-with-and-without-type-2-diabetes-1582
https://events.diabetes.org/p/s/postprandial-glucagon-action-in-the-human-brain-1583
https://events.diabetes.org/p/s/incretin-production-is-impaired-in-atypical-low-bmi-diabetes-mellitus-1584
https://events.diabetes.org/p/s/epigenetic-reader-brd4-directs-fast-twitch-myofiber-gene-programs-influencing-skeletal-muscle-endurance-capacity-and-systemic-glucose-homeostasis-1585
https://events.diabetes.org/p/s/attenuation-of-obesity-induced-vascular-inflammation-by-microrna-485-in-endothelial-cells-1586
https://events.diabetes.org/p/s/targeting-a-lipid-droplet-hydrolase-mediated-lipid-signaling-for-treatment-of-type-2-diabetes-1587
https://events.diabetes.org/p/s/regulation-of-melanocortin-receptor-4-mc4r-ciliary-trafficking-1588
https://events.diabetes.org/p/s/cdkn2a-regulates-beige-fat-maintenance-through-becn1-mediated-autophagy-1589
https://events.diabetes.org/p/s/an-obesity-centric-approach-with-and-without-antiobesity-medications-compared-with-the-usual-care-approach-to-management-of-patients-with-obesity-and-type-2-diabetes-in-an-employer-setting-a-pragmatic-1590
https://events.diabetes.org/p/s/adoption-of-state-level-complete-streets-legislations-and-us-prevalence-of-obesity-1591
https://events.diabetes.org/p/s/discrepancy-between-genetically-predicted-and-actual-body-mass-index-predicts-incident-diabetes-mellitus-1592
https://events.diabetes.org/p/s/adiposity-and-mortality-among-us-hispaniclatino-adults-1593
https://events.diabetes.org/p/s/a-new-composite-blood-biomarker-performs-well-in-the-diagnosis-of-nash-advanced-hepatic-fibrosis-and-high-risk-nash-1594
https://events.diabetes.org/p/s/myeloid-specific-era-deletion-disrupts-mitochondrial-function-driving-iron-accumulation-and-cardiometabolic-disease-1595
https://events.diabetes.org/p/s/oral-insulin-alleviates-liver-fibrosis-and-reduces-fat-in-patients-with-nash-and-type-2-diabetes-results-of-phase-ii-clinical-trial-1596
https://events.diabetes.org/p/s/hepatic-acyl-protein-thioesterases-prevent-insulin-resistance-1597
https://events.diabetes.org/p/s/antidiabetic-tix100-improves-nafldnash-in-mice-with-and-without-diabetes-and-obesity-1598
https://events.diabetes.org/p/s/liver-fibrosis-scores-in-novel-subclusters-of-patients-at-risk-for-type-2-diabetes-1599
https://events.diabetes.org/p/s/how-menstrual-cycle-impacts-brain-insulin-action-results-from-young-women-1600
https://events.diabetes.org/p/s/reduced-vdac1-limits-ros-release-to-restrain-oxidative-damage-in-muscle-of-3-year-old-nonhuman-primates-with-early-life-exposure-to-maternal-western-diet-or-obesity-1601
https://events.diabetes.org/p/s/maternal-high-fat-diet-alters-the-gut-microbiota-liver-circadian-rhythms-and-results-in-metabolic-dysfunction-in-offspring-1602
https://events.diabetes.org/p/s/short-term-hyperglycemia-impacts-mouse-skeletal-muscle-in-a-sex-specific-manner-1603
https://events.diabetes.org/p/s/pea15-regulates-metabolism-and-adiposity-in-a-sex-dependent-manner-through-alterations-in-metabolic-flexibility-1604
https://events.diabetes.org/p/s/estrogen-signaling-in-the-ventromedial-hypothalamus-modulates-adipose-tissue-metabolic-adaptation-1605
https://events.diabetes.org/p/s/role-of-pcpe2-in-adipose-tissue-remodeling-and-expansion-1606
https://events.diabetes.org/p/s/delineating-the-origin-of-supraclavicular-brown-adipocytes-1607
https://events.diabetes.org/p/s/adipose-rna-n6-methyladenosine-m6a-modification-promotes-obesity-and-insulin-resistance-through-suppressing-lipolysis-1608
https://events.diabetes.org/p/s/hippo-yaptaz-signaling-coordinates-adipose-plasticity-and-energy-balance-by-uncoupling-leptin-expression-from-fat-mass-1609
https://events.diabetes.org/p/s/fbf1-deficiency-promotes-ciliary-cold-sensing-trp-channel-activation-in-thermogenesis-1610
https://events.diabetes.org/p/s/dual-amylin-and-calcitonin-receptor-agonists-increase-mitochondrial-respiratory-capacity-in-adipose-tissues-of-obese-rat-1611
https://events.diabetes.org/p/s/myostatin-inhibition-synergizes-with-glp-1r-agonism-to-accelerate-weight-loss-in-male-obese-nonhuman-primates-1612
https://events.diabetes.org/p/s/comparable-improvement-in-nafld-weight-loss-and-lipid-metabolism-in-rats-treated-with-dual-glp-1-gip-receptor-agonist-tirzepatide-and-gastric-sleeve-1613
https://events.diabetes.org/p/s/djb-surgery-improves-oxidative-stress-and-alleviates-neuron-cell-injury-of-hypothalamus-in-t2dm-rats-by-nrf2ho-1-signal-1614
https://events.diabetes.org/p/s/leptin-reduction-as-a-required-component-for-weight-loss-1615
https://events.diabetes.org/p/s/long-acting-gipr-agonism-enhances-body-weight-regulation-of-multiple-weight-reducing-agents-in-diet-induced-obese-mice-1616
https://events.diabetes.org/p/s/dapagliflozin-counteracts-the-proapoptotic-effects-of-the-secretome-of-visceral-adipose-cells-from-obese-subjects-in-human-cardiac-progenitor-cells-via-the-sglt2-cotransporter-1617
https://events.diabetes.org/p/s/signs-of-glucagon-resistance-after-a-two-week-hypercaloric-diet-intervention-1618
https://events.diabetes.org/p/s/diabetes-remission-after-gastric-bypass-is-characterized-by-upregulation-of-lxr-and-antioxidant-related-pathways-in-jejunum-1619
https://events.diabetes.org/p/s/positive-effects-of-bariatric-surgery-are-associated-with-attenuation-of-cellular-senescence-1620
https://events.diabetes.org/p/s/a-novel-platform-for-genetic-screening-of-nafld-associated-genes-identifies-ube2g2-and-other-genes-that-alter-hepatic-lipid-accumulation-1621
https://events.diabetes.org/p/s/impaired-mitochondrial-respiration-in-peripheral-blood-mononuclear-cells-is-associated-with-increased-obesity-classified-by-waist-to-hip-ratio-in-nondiabetes-egat-population-1622
https://events.diabetes.org/p/s/repetitive-transcranial-magnetic-stimulation-a-potential-antiobesity-approach-for-long-term-maintenance-of-weight-loss-1623
https://events.diabetes.org/p/s/continued-weight-loss-with-semaglutide-once-weekly-in-patients-without-type-2-diabetes-and-postbariatric-treatment-failure-1624
https://events.diabetes.org/p/s/life-expectancy-and-causes-of-death-after-bariatric-surgery-or-usual-care-in-patients-stratified-by-baseline-type-2-diabetes-in-the-swedish-obese-subjects-study-1625
https://events.diabetes.org/p/s/mortality-in-the-swedish-obese-subjects-study-over-up-to-30-years-in-relation-to-two-year-diabetes-remission-after-bariatric-surgery-or-usual-care-1626
https://events.diabetes.org/p/s/optimized-weight-loss-with-bimagrumab-reduced-fat-mass-with-increased-muscle-mass-by-appetite-independent-mechanisms-1627
https://events.diabetes.org/p/s/long-term-outcomes-of-metabolic-surgery-vs-medicallifestyle-therapy-on-nonalcoholic-fatty-liver-disease-in-adults-with-obesity-and-type-2-diabetes-1628
https://events.diabetes.org/p/s/question-and-discussion-period-1629
https://events.diabetes.org/p/s/food-properties-that-drive-intake-1630
https://events.diabetes.org/p/s/animal-vs-vegetable-does-food-type-matter-1631
https://events.diabetes.org/p/s/highly-processed-foods-tipping-the-scale-of-energy-balance-1632
https://events.diabetes.org/p/s/question-and-discussion-period-1633
https://events.diabetes.org/p/s/clinical-implications-of-nutrient-stimulated-hormone-pharmacotherapy-1634
https://events.diabetes.org/p/s/role-for-amylin-in-monotherapy-and-combination-therapy-1635
https://events.diabetes.org/p/s/contribution-of-gastric-inhibitory-peptide-and-glucagon-in-dual-and-triple-agonism-1636
https://events.diabetes.org/p/s/contribution-of-pyy-in-combination-treatment-with-glp-1-1637
https://events.diabetes.org/p/s/question-and-discussion-period-1638
https://events.diabetes.org/p/s/introduction-to-exosomes-production-and-cargo-1639
https://events.diabetes.org/p/s/exosomes-and-insulin-action-in-people-with-obesity-1640
https://events.diabetes.org/p/s/adipocyte-exosomes-and-metabolic-function-1641
https://events.diabetes.org/p/s/adipose-tissue-macrophage-exosomes-and-adipogenesis-1642
https://events.diabetes.org/p/s/question-and-discussion-period-1643
https://events.diabetes.org/p/s/microbiome-regulation-of-exercise-1644
https://events.diabetes.org/p/s/cellular-and-synaptic-reorganization-of-hypothalamic-neurons-after-exercise-1645
https://events.diabetes.org/p/s/lysine-acetylation-as-a-critical-regulator-of-glucose-uptake-during-exercise-1646
https://events.diabetes.org/p/s/energy-metabolism-in-skeletal-muscle-and-exercise-capacity-1647
https://events.diabetes.org/p/s/question-and-discussion-period-1648
https://events.diabetes.org/p/s/single-cell-analysis-of-the-aging-mouse-hypothalamus-1649
https://events.diabetes.org/p/s/understanding-liver-functions-and-diseases-by-scrnaseq-1650
https://events.diabetes.org/p/s/a-single-cell-atlas-of-white-adipose-tissue-1651
https://events.diabetes.org/p/s/new-insight-on-cns-regulation-of-energy-balance-using-scrnaseq-approach-1652
https://events.diabetes.org/p/s/the-impact-of-time-restricted-eating-on-cardiometabolic-health-in-shift-workers-the-healthy-heroes-rct-1653
https://events.diabetes.org/p/s/feasibility-of-time-restricted-eating-for-prevention-and-treatment-of-type-2-diabetes-1654
https://events.diabetes.org/p/s/time-restricted-eating-to-prevent-and-treat-metabolic-disease-from-rodents-to-humans-1655
https://events.diabetes.org/p/s/the-role-of-adaptive-thermogenesis-in-weight-loss-and-regain-1656
https://events.diabetes.org/p/s/adaptations-to-changes-in-weight-1657
https://events.diabetes.org/p/s/metabolic-flexibility-to-weight-loss-1658
https://events.diabetes.org/p/s/question-and-discussion-period-1659
https://events.diabetes.org/p/s/muscle-health-and-recovery-from-exercise-in-type-1-diabetes-1660
https://events.diabetes.org/p/s/impact-of-diabetes-and-metformin-on-muscle-quality-and-fibro-adipogenic-progenitor-function-1661
https://events.diabetes.org/p/s/sex-differences-in-muscle-insulin-resistance-1662
https://events.diabetes.org/p/s/question-and-discussion-period-1663
https://events.diabetes.org/p/s/adipsin-and-beta-cell-function-1664
https://events.diabetes.org/p/s/exercise-induced-mediators-of-body-adiposity-1665
https://events.diabetes.org/p/s/fat-brain-communication-across-scales-1666
https://events.diabetes.org/p/s/mitochondrial-dynamics-adipose-tissue-function-and-metabolic-regulation-1667
https://events.diabetes.org/p/s/banting-medal-for-scientific-achievement-overcoming-obesity-the-discovery-of-multi-receptor-drugs-1668
https://events.diabetes.org/p/s/president-medicine-and-science-address-my-journey-in-diabetes-care-research-and-complications-1669
https://events.diabetes.org/p/s/national-scientific-and-health-care-achievement-awards-presentation-includes-livestream-1670
https://events.diabetes.org/p/s/outstanding-scientific-achievement-award-lecture-includes-livestream-the-ailing-beta-cell-in-diabetes-insights-from-a-trip-to-the-er-1671
https://events.diabetes.org/p/s/unseen-allies-how-bacterial-speak-to-our-immune-system-to-tackle-type-1-diabetes-1672
https://events.diabetes.org/p/s/whole-person-care-identifying-and-treating-diabetes-distress-as-part-of-routine-type-1-diabetes-care-1673
https://events.diabetes.org/p/s/hiding-in-plain-sight-cloaking-beta-cells-from-immune-mediated-damage-1674
https://events.diabetes.org/p/s/the-brain-on-sugar-investigating-neural-changes-that-promote-obesity-and-diabetes-1675
https://events.diabetes.org/p/s/branched-chain-amino-acids-and-diabetes-a-closer-look-1676
https://events.diabetes.org/p/s/introduction-1677
https://events.diabetes.org/p/s/keynote-address-the-omics-revolution-provides-new-insights-for-diabetes-1678
https://events.diabetes.org/p/s/panel-discussion-1679
https://events.diabetes.org/p/s/panel-discussion-1680
https://events.diabetes.org/p/s/panel-discussion-1681
https://events.diabetes.org/p/s/welcome-to-the-83rd-ada-scientific-sessions-1682
https://events.diabetes.org/p/s/panel-discussion-1683
https://events.diabetes.org/p/s/glucose-dependent-insulin-production-and-insulin-independence-in-type-1-diabetes-from-stem-cell-derived-fully-differentiated-islet-cells-updated-data-from-the-vx-880-clinical-trial-1684
https://events.diabetes.org/p/s/introducing-dexcom-g7-simplicity-solutions-and-success-for-your-patients-and-your-practice-presented-by-dexcom-includes-live-video-1696
https://events.diabetes.org/p/s/evolving-perspectives-in-hypercortisolism-a-panel-discussion-presented-by-corcept-therapeutics-includes-livestream-1701
https://events.diabetes.org/p/s/omnipod-r-5-clinical-pearls-for-pediatrics-1702
https://events.diabetes.org/p/s/omnipod-r-5-clinical-pearls-for-pediatrics-1703
https://events.diabetes.org/p/s/inserter-network-for-eversense-r-e3-cgm-system-prescribe-eversense-with-confidence-presented-by-asencia-diabetes-center-1704
https://events.diabetes.org/p/s/the-role-of-inflammation-and-interleukin-8-in-patients-with-type-1-diabetes-clinical-trial-update-ongladiator-1705
https://events.diabetes.org/p/s/exploring-the-ada-2023-standards-of-care-a-grade-recommendation-for-treating-diabetic-foot-ulcers-dfu-with-topical-oxygen-therapy-tot-presented-by-advanced-oxygen-therapy-1706
https://events.diabetes.org/p/s/how-to-easily-incorporate-eversense-into-your-practice-and-learn-how-chris-ruden-inspires-others-on-managing-diabetes-differently-with-the-eversense-r-e3-cgm-system-presented-by-asencia-diabetes-care-1707
https://events.diabetes.org/p/s/how-to-easily-incorporate-eversense-into-your-practice-and-learn-how-chris-ruden-inspires-others-on-managing-diabetes-differently-with-the-eversense-r-e3-cgm-system-presented-by-asencia-diabetes-care-1708
https://events.diabetes.org/p/s/ai-strategies-for-easing-burden-from-diabetes-technology-systems-presented-by-tandem-diabetes-care-inc-1709
https://events.diabetes.org/p/s/ai-strategies-for-easing-burden-from-diabetes-technology-systems-presented-by-tandem-diabetes-care-inc-1710
https://events.diabetes.org/p/s/ai-strategies-for-easing-burden-from-diabetes-technology-systems-presented-by-tandem-diabetes-care-inc-1711
https://events.diabetes.org/p/s/get-ready-for-bigfoots-expanded-access-identifying-candidates-for-bigfoot-unity-presented-by-bigfoot-biomedical-1712
https://events.diabetes.org/p/s/rethinking-treatment-limits-expanding-cgm-to-improve-outcomes-in-glucose-management-presented-by-abbott-1713
https://events.diabetes.org/p/s/rethinking-treatment-limits-expanding-cgm-to-improve-outcomes-in-glucose-management-presented-by-abbott-1714
https://events.diabetes.org/p/s/rethinking-treatment-limits-expanding-cgm-to-improve-outcomes-in-glucose-management-presented-by-abbott-1715
https://events.diabetes.org/p/s/jardiance-r-empagliflozin-tablets-a-review-of-multiple-clinical-trials-and-approved-indications-presented-by-boehringer-ingelheim-pharmaceuticals-inc-and-lilly-usa-1716
https://events.diabetes.org/p/s/jardiance-r-empagliflozin-tablets-a-review-of-multiple-clinical-trials-and-approved-indications-presented-by-boehringer-ingelheim-pharmaceuticals-inc-and-lilly-usa-1717
https://events.diabetes.org/p/s/global-experience-success-for-all-on-the-minimed-780g-system-presented-by-medtronic-1718
https://events.diabetes.org/p/s/global-experience-success-for-all-on-the-minimed-780g-system-presented-by-medtronic-1719
https://events.diabetes.org/p/s/global-experience-success-for-all-on-the-minimed-780g-system-presented-by-medtronic-1721
https://events.diabetes.org/p/s/please-join-provention-bio-for-a-product-theater-to-learn-more-about-an-approved-therapy-presented-by-provention-bio-1722
https://events.diabetes.org/p/s/introducing-dexcom-g7-simplicity-solutions-and-success-for-your-patients-and-your-practice-presented-by-dexcom-1723
https://events.diabetes.org/p/s/introducing-dexcom-g7-simplicity-solutions-and-success-for-your-patients-and-your-practice-presented-by-dexcom-1724
https://events.diabetes.org/p/s/one-year-of-omnipod-r-5-real-world-learnings-for-optimized-care-presented-by-insulet-makers-of-omnipod-1725
https://events.diabetes.org/p/s/one-year-of-omnipod-r-5-real-world-learnings-for-optimized-care-presented-by-insulet-makers-of-omnipod-1727
https://events.diabetes.org/p/s/pathophysiological-impact-of-nevro-hfx-high-frequency-10-khz-spinal-cord-stimulation-for-painful-diabetic-neuropathy-presented-by-nevro-1728
https://events.diabetes.org/p/s/pathophysiological-impact-of-nevro-hfx-high-frequency-10-khz-spinal-cord-stimulation-for-painful-diabetic-neuropathy-presented-by-nevro-1729
https://events.diabetes.org/p/s/elevating-the-standard-of-care-for-hypoglycemia-readiness-presented-by-xeris-pharmaceuticals-1730
https://events.diabetes.org/p/s/elevating-the-standard-of-care-for-hypoglycemia-readiness-presented-by-xeris-pharmaceuticals-1731
https://events.diabetes.org/p/s/a-dual-dilemma-navigating-cardiorenal-risk-in-ckd-associated-with-t2d-in-clinical-practice-presented-by-bayer-1732
https://events.diabetes.org/p/s/a-dual-dilemma-navigating-cardiorenal-risk-in-ckd-associated-with-t2d-in-clinical-practice-presented-by-bayer-1733
https://events.diabetes.org/p/s/evolving-perspectives-in-hypercortisolism-a-panel-discussion-presented-by-corcept-therapeutics-1734
https://events.diabetes.org/p/s/evolving-perspectives-in-hypercortisolism-a-panel-discussion-presented-by-corcept-therapeutics-1735
https://events.diabetes.org/p/s/global-experience-success-for-all-on-the-minimed-780g-system-presented-by-medtronic-1746
https://events.diabetes.org/p/s/one-year-of-omnipod-r-5-real-world-learnings-for-optimized-care-presented-by-insulet-makers-of-omnipod-1747
https://events.diabetes.org/p/s/pathophysiological-impact-of-nevro-hfx-high-frequency-10-khz-spinal-cord-stimulation-for-painful-diabetic-neuropathy-presented-by-nevro-1748
https://events.diabetes.org/p/s/evolving-perspectives-in-hypercortisolism-a-panel-discussion-presented-by-corcept-therapeutics-1749
https://events.diabetes.org/p/s/83rd-scientific-sessions-1751
https://events.diabetes.org/p/s/pre-conference-workshop-certification-board-for-diabetes-care-and-education-certified-diabetes-care-and-education-specialist-r-cdces-r-credentialingpractice-integration-1757
https://events.diabetes.org/p/s/welcome-and-innovations-in-diabetes-care-1758
https://events.diabetes.org/p/s/standards-of-care-2024-select-updates-and-practice-implications-presentation-and-panel-discussion-1759
https://events.diabetes.org/p/s/case-study-workshop-primary-care-education-diabetes-specialty-1760
https://events.diabetes.org/p/s/group-discussion-1761
https://events.diabetes.org/p/s/new-medications-for-weight-management-glp-1gip-1762
https://events.diabetes.org/p/s/psychological-implications-of-weight-management-is-lifestyle-dead-in-the-age-of-incretin-therapy-1763
https://events.diabetes.org/p/s/panel-discussion-1764
https://events.diabetes.org/p/s/call-to-action-1765
https://events.diabetes.org/p/s/managing-a-patient-with-nash-and-type-2-diabetes-a-case-based-approach-1767
https://events.diabetes.org/p/s/obesity-related-heart-disease-1768
https://events.diabetes.org/p/s/management-of-chronic-kidney-disease-in-type-2-diabetes-so-many-drugs-how-to-choose-1769
https://events.diabetes.org/p/s/break-1771
https://events.diabetes.org/p/s/break-1773
https://events.diabetes.org/p/s/amputation-prevention-strategies-and-foot-care-1774
https://events.diabetes.org/p/s/complication-prevention-and-panel-discussion-1775
https://events.diabetes.org/p/s/break-1776
https://events.diabetes.org/p/s/why-the-national-diabetes-prevention-program-lifestyle-change-program-should-matter-to-you-how-you-can-integrate-the-program-into-your-practice-1777
https://events.diabetes.org/p/s/practice-integration-panel-1778
https://events.diabetes.org/p/s/break-1779
https://events.diabetes.org/p/s/diabetes-and-aging-treatment-goals-and-therapies-1780
https://events.diabetes.org/p/s/fasting-practices-and-diabetes-management-1781
https://events.diabetes.org/p/s/nutrition-and-lifestyle-recommendations-building-blocks-for-a-healthy-future-1782
https://events.diabetes.org/p/s/break-1783
https://events.diabetes.org/p/s/2024-technology-updates-continuous-glucose-monitoring-pumps-smart-pens-and-more-1784
https://events.diabetes.org/p/s/using-technology-in-primary-care-the-time-is-now-1785
https://events.diabetes.org/p/s/apps-and-wearables-1786
https://events.diabetes.org/p/s/panel-discussion-1787
https://events.diabetes.org/p/s/call-to-action-1788
https://events.diabetes.org/p/s/landmines-in-communication-during-clinic-visits-1790
https://events.diabetes.org/p/s/advancing-health-equity-in-diabetes-tools-to-help-remove-barriers-to-health-1791
https://events.diabetes.org/p/s/5-in-5-effective-behavioral-strategies-for-anyone-working-in-diabetes-1792
https://events.diabetes.org/p/s/break-1793
https://events.diabetes.org/p/s/building-the-ideal-team-models-of-care-delivery-1794
https://events.diabetes.org/p/s/hot-topics-in-inpatient-diabetes-care-and-education-and-telehealth-1795
https://events.diabetes.org/p/s/billing-and-reimbursement-for-education-and-technology-1796
https://events.diabetes.org/p/s/putting-the-puzzle-together-who-what-when-how-creating-the-best-pwds-and-call-to-action-1797
https://events.diabetes.org/p/s/committee-members-1804
https://events.diabetes.org/p/s/product-theater-sponsored-by-medtronic-breaking-barriers-in-diabetes-management-with-the-minimed-780g-system-1805
https://events.diabetes.org/p/s/sulfonylureas-in-type-2-diabetes-management-should-they-stay-or-should-they-go-includes-livestream-1814
https://events.diabetes.org/p/s/discussion-on-diabetes-and-cardiovascular-disease-obesity-and-diabetes-innovative-research-to-inform-clinical-practice-1815
https://events.diabetes.org/p/s/discussion-on-foot-care-lower-extremity-complications-1816
https://events.diabetes.org/p/s/discussion-on-eye-health-novel-diabetes-therapies-in-diabetic-retinopathy-a-basic-science-and-preclinical-perspective-1817
https://events.diabetes.org/p/s/lower-extremity-complications-with-systemic-effects-1818
https://events.diabetes.org/p/s/cell-and-molecular-approaches-to-diabetes-related-foot-complications-with-roger-pecoraro-award-lecture-includes-livestream-1819
https://events.diabetes.org/p/s/hypoglycemia-in-the-real-world-whos-really-at-risk-1820
https://events.diabetes.org/p/s/continuous-glucose-monitoring-can-it-reduce-hypoglycemia-burden-includes-livestream-1821
https://events.diabetes.org/p/s/physiologic-responses-to-hypoglycemia-new-insights-1822
https://events.diabetes.org/p/s/multiorgan-cross-talk-in-lipid-metabolism-1823
https://events.diabetes.org/p/s/new-biomarkers-to-inform-lipid-therapies-in-diabetes-with-ada-presidents-select-abstract-presentation-1824
https://events.diabetes.org/p/s/clinical-biomarkers-of-ascvd-risk-progression-in-diabetes-mellitus-and-metabolic-disease-1825
https://events.diabetes.org/p/s/emerging-small-molecule-biomarkers-of-ascvd-risk-in-metabolic-disease-1826
https://events.diabetes.org/p/s/emerging-molecular-mechanisms-of-ascvd-progression-in-cardiometabolic-disease-with-edwin-bierman-award-lecture-includes-livestream-1827
https://events.diabetes.org/p/s/metabolic-pathways-to-protection-innovative-approaches-in-diabetes-induced-kidney-disease-1828
https://events.diabetes.org/p/s/diabetic-kidney-disease-includes-livestream-1829
https://events.diabetes.org/p/s/innovative-approaches-in-diagnosing-and-managing-diabetic-neuropathy-with-ada-presidents-select-abstract-presentation-includes-livestream-1830
https://events.diabetes.org/p/s/unraveling-molecular-signatures-biomarkers-and-methods-for-neuropathy-cognitive-decline-and-foot-ulcers-1831
https://events.diabetes.org/p/s/innovations-in-diabetic-eye-care-advancements-therapeutic-strategies-and-disease-associations-1832
https://events.diabetes.org/p/s/insights-into-diabetic-retinopathy-from-molecular-characterization-to-therapeutic-considerations-1833
https://events.diabetes.org/p/s/from-the-cutting-room-floor-semi-live-surgery-for-healing-diabetic-foot-ulcers-for-the-referring-practitioner-1834
https://events.diabetes.org/p/s/diabetic-foot-disparities-treatment-with-and-without-a-multidisciplinary-team-1835
https://events.diabetes.org/p/s/beyond-statins-treating-and-evaluating-residual-atherosclerotic-cardiovascular-disease-risk-1836
https://events.diabetes.org/p/s/a-multidisciplinary-approach-challenging-cases-from-the-cardiometabolic-clinic-includes-livestream-1837
https://events.diabetes.org/p/s/systemic-medications-for-diabetic-retinopathy-protective-and-risk-factors-1838
https://events.diabetes.org/p/s/diabetic-retinopathy-care-and-screening-is-artificial-intelligence-changing-the-future-1839
https://events.diabetes.org/p/s/demystifying-impaired-awareness-of-hypoglycemia-diagnosis-experience-and-treatment-in-the-real-world-1840
https://events.diabetes.org/p/s/sex-and-gender-dimorphism-in-cardiovascular-disease-risk-in-diabetes-1841
https://events.diabetes.org/p/s/select-trial-new-looks-at-glycemia-inflammation-and-heart-failure-includes-livestream-1842
https://events.diabetes.org/p/s/cardiovascular-disease-risk-prediction-in-obesity-and-type-2-diabetes-emerging-tools-for-the-clinician-1843
https://events.diabetes.org/p/s/navigating-the-spatial-landscape-omics-in-diabetic-kidney-disease-1844
https://events.diabetes.org/p/s/the-changing-climate-of-diabetic-kidney-disease-environmental-triggers-and-vulnerabilities-1845
https://events.diabetes.org/p/s/the-many-faces-of-kidney-disease-in-diabetes-not-all-are-diabetic-nephropathy-includes-livestream-1846
https://events.diabetes.org/p/s/a-means-to-an-endpoint-establishing-meaningful-outcomes-in-clinical-neuropathy-trials-1847
https://events.diabetes.org/p/s/updates-in-autonomic-neuropathy-1848
https://events.diabetes.org/p/s/joint-diabetes-carecenters-for-disease-control-and-prevention-symposium-pressure-points-and-future-directions-in-the-prevention-of-acute-and-chronic-diabetes-related-complications-includes-livestream-1849
https://events.diabetes.org/p/s/the-highs-and-lows-of-cannabis-use-in-diabetes-behavioral-and-psychosocial-considerations-1850
https://events.diabetes.org/p/s/the-role-of-artificial-intelligence-in-transforming-nutrition-and-diabetes-care-ready-for-prime-time-or-not-quite-1851
https://events.diabetes.org/p/s/discussion-on-behavioral-medicine-and-psychology-including-the-excluded-in-behavioral-diabetes-research-1852
https://events.diabetes.org/p/s/discussion-on-exercise-physiology-syncing-up-exploring-the-interplay-of-circadian-rhythms-and-exercise-1853
https://events.diabetes.org/p/s/discussion-on-diabetes-self-management-education-and-support-dsmes-its-time-to-change-the-way-we-talk-about-dsmes-1854
https://events.diabetes.org/p/s/discussion-on-nutritional-sciences-and-metabolism-the-science-of-ultraprocessed-foods-and-impacts-on-metabolic-diseases-1855
https://events.diabetes.org/p/s/discussion-on-womens-interprofessional-network-of-the-ada-win-ada-how-to-say-no-so-you-can-say-yes-optimizing-time-management-1856
https://events.diabetes.org/p/s/social-drivers-of-health-and-advancement-towards-social-justice-1857
https://events.diabetes.org/p/s/multifaceted-insights-into-behavioral-and-psychosocial-care-for-youth-and-families-1858
https://events.diabetes.org/p/s/exploring-dimensions-of-diversity-in-diabetes-distress-with-richard-r-rubin-award-lecture-includes-livestream-1859
https://events.diabetes.org/p/s/exploring-the-impact-of-foodfood-additives-on-insulin-sensitivity-and-postprandial-glucose-with-ada-presidents-select-abstract-presentation-1860
https://events.diabetes.org/p/s/medical-nutrition-therapy-moving-beyond-traditional-outcome-measures-1861
https://events.diabetes.org/p/s/tools-for-health-care-professionals-that-assist-in-personalizing-care-1862
https://events.diabetes.org/p/s/innovative-diabetes-self-management-education-across-diverse-populations-1863
https://events.diabetes.org/p/s/back-to-the-basics-sciences-of-exercise-and-diabetes-1864
https://events.diabetes.org/p/s/clinical-contributions-in-type-1-diabetes-and-exercise-1865
https://events.diabetes.org/p/s/educating-clinicians-in-the-latest-inpatient-management-strategies-from-both-sides-of-the-pond-1866
https://events.diabetes.org/p/s/are-we-close-to-closing-the-loop-automated-insulin-delivery-during-exercise-1867
https://events.diabetes.org/p/s/the-evolution-of-diabetes-behavioral-care-includes-livestream-1868
https://events.diabetes.org/p/s/loneliness-is-a-real-heartbreaker-includes-livestream-1869
https://events.diabetes.org/p/s/survey-says-psychosocial-screening-tools-and-their-psychometric-properties-for-youth-and-adults-with-diabetes-1870
https://events.diabetes.org/p/s/consensus-or-controversy-hot-topics-in-nutrition-2024-1871
https://events.diabetes.org/p/s/optimizing-outcomes-of-glp-1-plus-gip-receptor-agonists-how-to-help-patients-succeed-1872
https://events.diabetes.org/p/s/innovative-programs-that-take-on-the-challenge-of-hard-to-reach-populations-includes-livestream-1873
https://events.diabetes.org/p/s/how-diabetes-technology-is-changing-diabetes-care-in-the-real-world-1874
https://events.diabetes.org/p/s/mind-the-gap-health-benefits-of-exercise-in-women-with-or-at-risk-for-diabetes-includes-livestream-1875
https://events.diabetes.org/p/s/type-2-diabetes-and-exercise-where-do-we-stand-1876
https://events.diabetes.org/p/s/niddk-early-career-investigator-symposium-leveraging-social-support-to-improve-diabetes-self-management-and-health-outcomes-innovative-methods-and-interventions-1877
https://events.diabetes.org/p/s/ada-education-recognition-program-erp-diversifying-diabetes-self-management-education-and-support-dsmes-delivery-models-1878
https://events.diabetes.org/p/s/the-future-of-diabetes-nutrition-interventions-innovation-in-practice-includes-livestream-1879
https://events.diabetes.org/p/s/nutrition-and-diabetes-self-management-education-and-support-dsmes-1880
https://events.diabetes.org/p/s/international-consensus-statement-and-movement-to-end-diabetes-stigma-1881
https://events.diabetes.org/p/s/cgm-expert-boards-move-beyond-hba1c-to-apply-technology-based-advances-across-the-full-spectrum-of-diabetes-care-1882
https://events.diabetes.org/p/s/clinical-conversations-on-real-time-continuous-glucose-monitoring-1883
https://events.diabetes.org/p/s/advances-in-delayed-onset-of-type-1-diabetes-strategies-to-improve-awareness-and-care-for-the-practicing-clinician-1884
https://events.diabetes.org/p/s/taking-an-obesity-centric-approach-to-care-exploring-pharmacotherapy-options-and-their-implications-in-patient-care-1885
https://events.diabetes.org/p/s/practical-management-of-thyroid-eye-disease-1886
https://events.diabetes.org/p/s/decentralizing-diabetes-care-supporting-remission-through-timely-screening-and-diabetes-specific-formula-1887
https://events.diabetes.org/p/s/how-will-artificial-intelligence-change-diabetes-clinical-practice-includes-livestream-1888
https://events.diabetes.org/p/s/early-abnormal-glucose-metabolism-in-pregnancy-to-treat-or-not-to-treat-1889
https://events.diabetes.org/p/s/keeping-up-with-hollywood-who-should-be-prioritized-for-new-antiobesity-medications-1890
https://events.diabetes.org/p/s/innovation-or-access-in-diabetes-technology-what-should-be-our-global-priority-1891
https://events.diabetes.org/p/s/diabetes-prevention-program-dpp-vs-glp-1ra-which-tool-is-best-to-battle-the-obesity-and-diabetes-epidemics-1892
https://events.diabetes.org/p/s/discussion-on-diabetes-technology-enhancing-clinic-efficiency-through-the-integration-of-diabetes-technologies-1893
https://events.diabetes.org/p/s/discussion-on-diabetes-in-primary-care-tackling-diabetes-in-primary-care-training-and-workforce-development-1894
https://events.diabetes.org/p/s/discussion-on-diabetes-in-youth-perspectives-on-universal-antibody-screening-1895
https://events.diabetes.org/p/s/discussion-on-health-care-delivery-and-quality-improvement-1896
https://events.diabetes.org/p/s/discussion-on-pregnancy-and-reproductive-health-should-continuous-glucose-monitoring-be-used-in-pregnancy-complicated-by-gestational-diabetes-1897
https://events.diabetes.org/p/s/discussion-on-clinical-centers-and-programs-challenges-in-management-of-diabetes-in-older-adults-and-in-primary-care-1898
https://events.diabetes.org/p/s/screening-for-and-delaying-vascular-complications-1899
https://events.diabetes.org/p/s/using-teams-and-technology-to-improve-outcomes-1900
https://events.diabetes.org/p/s/practicable-methods-to-improve-metabolic-parameters-1901
https://events.diabetes.org/p/s/novel-insights-from-cgm-use-during-pregnancy-1902
https://events.diabetes.org/p/s/novel-insights-into-pathophysiology-diagnosis-and-outcomes-in-gdm-1903
https://events.diabetes.org/p/s/novel-approaches-to-treatment-and-characterization-of-diabetes-in-pregnancy-with-norbert-freinkel-award-lecture-with-ada-presidents-select-abstract-presentation-includes-livestream-1904
https://events.diabetes.org/p/s/new-approaches-to-prevent-or-reverse-diabetes-1905
https://events.diabetes.org/p/s/weighing-opportunities-of-incretin-based-therapy-in-obesity-with-ada-presidents-select-abstract-presentation-1906
https://events.diabetes.org/p/s/leveling-up-incretin-based-therapy-in-type-2-diabetes-1907
https://events.diabetes.org/p/s/beyond-glucose-and-weight-reduction-additional-effects-of-incretin-based-therapies-1908
https://events.diabetes.org/p/s/diabetes-potpourri-1909
https://events.diabetes.org/p/s/sglt2-inhibition-impact-on-human-physiology-1910
https://events.diabetes.org/p/s/new-technology-whats-new-with-ada-presidents-select-abstract-presentation-1911
https://events.diabetes.org/p/s/new-technology-aid-focus-1912
https://events.diabetes.org/p/s/new-technology-continuous-glucose-monitoring-1913
https://events.diabetes.org/p/s/new-technology-the-inpatient-setting-includes-livestream-1914
https://events.diabetes.org/p/s/new-technology-equity-and-access-1915
https://events.diabetes.org/p/s/pediatric-obesity-and-type-2-diabetes-1916
https://events.diabetes.org/p/s/new-insights-and-treatments-in-management-of-youth-with-type-1-diabetes-mellitus-1917
https://events.diabetes.org/p/s/newly-diagnosed-type-2-diabetes-what-should-be-the-focus-of-management-in-2024-includes-livestream-1918
https://events.diabetes.org/p/s/noninsulin-treatment-for-type-1-diabetes-1919
https://events.diabetes.org/p/s/glp-1-plus-gip-receptor-agonists-in-the-perioperative-setting-to-stop-or-not-to-stop-1920
https://events.diabetes.org/p/s/the-role-of-the-interdisciplinary-team-in-technology-onboarding-in-primary-care-1921
https://events.diabetes.org/p/s/prioritizing-diversity-in-clinical-trials-1922
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-includes-livestream-1923
https://events.diabetes.org/p/s/metformin-reexamined-pleiotropic-effects-in-mother-and-offspring-in-humans-and-animal-models-1924
https://events.diabetes.org/p/s/controversies-in-continuous-glucose-monitoring-cgm-use-during-pregnancy-time-in-range-and-beyond-time-in-range-1925
https://events.diabetes.org/p/s/myth-busters-on-category-x-drugs-in-pregnancy-evidence-for-stopping-commonly-used-medications-during-pregnancy-preconception-and-lactation-includes-livestream-1926
https://events.diabetes.org/p/s/impact-of-precision-medicine-on-diabetes-1927
https://events.diabetes.org/p/s/important-safety-information-off-target-effects-of-new-therapies-for-diabetes-includes-livestream-1928
https://events.diabetes.org/p/s/diabetes-and-the-lung-cause-and-consequence-includes-livestream-1929
https://events.diabetes.org/p/s/how-i-feel-matters-too-the-psychosocial-aspects-of-automated-insulin-delivery-includes-livestream-1930
https://events.diabetes.org/p/s/just-do-it-incorporating-what-we-know-into-what-we-do-1931
https://events.diabetes.org/p/s/cost-and-quality-improving-diabetes-care-and-the-cost-of-ongoing-inequities-1932
https://events.diabetes.org/p/s/towards-innovative-and-equitable-care-in-youth-onset-type-2-diabetes-1933
https://events.diabetes.org/p/s/navigating-the-early-phases-of-pediatric-type-1-diabetes-1934
https://events.diabetes.org/p/s/joint-adaispad-symposium-pediatric-diabetes-insights-and-innovations-1935
https://events.diabetes.org/p/s/improving-culture-of-quality-in-pediatric-centers-lessons-from-the-type-1-diabetes-exchange-quality-improvement-collaborative-1936
https://events.diabetes.org/p/s/ada-diabetes-carediabetesdiabetologia-symposium-the-heterogeneity-of-type-1-diabetes-pathogenesis-treatment-and-prevention-includes-livestream-1937
https://events.diabetes.org/p/s/ada-diabetes-care-symposium-the-final-frontier-implementing-the-learning-from-implementation-science-1938
https://events.diabetes.org/p/s/lancet-journal-symposium-time-for-a-paradigm-shift-should-we-treat-early-gestational-diabetes-mellitus-1939
https://events.diabetes.org/p/s/heterogeneity-of-diabetes-pathophysiology-to-global-considerations-includes-livestream-1940
https://events.diabetes.org/p/s/ada-primary-care-council-what-does-a-person-with-diabetes-need-from-their-primary-care-team-includes-livestream-1941
https://events.diabetes.org/p/s/multiple-faces-of-therapeutic-inertia-in-diabetes-1942
https://events.diabetes.org/p/s/global-burden-of-cardiovascular-disease-in-people-with-diabetes-includes-livestream-1943
https://events.diabetes.org/p/s/standards-of-care-2024-updates-and-cost-of-diabetes-in-united-states-1944
https://events.diabetes.org/p/s/hyperglycemic-crises-in-diabetes-1945
https://events.diabetes.org/p/s/liver-health-in-diabetes-includes-livestream-1946
https://events.diabetes.org/p/s/the-state-of-health-equity-and-disability-supporting-diabetes-technology-usage-in-people-who-are-deafhard-of-hearing-or-blindlow-vision-1947
https://events.diabetes.org/p/s/joint-adapaho-symposium-latin-america-and-the-caribbean-regional-approach-to-prevent-and-control-diabetes-1948
https://events.diabetes.org/p/s/ada-symposium-major-advances-and-discoveries-in-diabetes-the-year-in-review-1949
https://events.diabetes.org/p/s/the-first-dedicated-kidney-outcome-trial-with-a-glp-1-receptor-agonist-once-weekly-semaglutide-and-the-flow-trial-results-includes-livestream-1950
https://events.diabetes.org/p/s/the-step-hfpef-and-step-hfpef-dm-trials-targeting-obesity-to-treat-heart-failure-includes-livestream-1951
https://events.diabetes.org/p/s/diabetes-and-organ-transplantation-pathophysiology-inpatient-and-outpatient-management-1952
https://events.diabetes.org/p/s/the-efficacy-and-safety-of-inhaled-insulin-used-with-insulin-degludec-compared-with-automated-insulin-delivery-or-multiple-daily-insulin-injections-in-adults-with-type-1-diabetes-results-of-the-inhale-1953
https://events.diabetes.org/p/s/results-from-a-randomized-trial-of-intensive-glucose-management-using-continuous-glucose-monitoring-cgm-versus-usual-care-in-hospitalized-adults-with-type-2-diabetes-the-tight-study-includes-livestrea-1954
https://events.diabetes.org/p/s/use-of-sglt2i-in-youth-with-type-1-diabetes-results-from-attempt-the-adolescent-type-1-diabetes-treatment-with-sglt2i-for-hyperglycemia-and-hyperfiltration-trial-1955
https://events.diabetes.org/p/s/prevalence-of-hypercortisolism-in-difficult-to-control-type-2-diabetes-includes-livestream-1956
https://events.diabetes.org/p/s/surmount-osa-trial-results-and-potential-role-of-tirzepatide-in-treating-obesity-related-obstructive-sleep-apnea-includes-livestream-1957
https://events.diabetes.org/p/s/improving-care-for-deaf-people-with-diabetes-who-use-asl-interpreters-a-hands-on-workshop-1958
https://events.diabetes.org/p/s/race-and-ethnicity-based-cut-points-in-diabetes-screening-and-diagnosis-benefit-or-harm-for-reducing-disparities-includes-livestream-1959
https://events.diabetes.org/p/s/discussion-on-public-health-and-epidemiology-kids-are-not-little-adults-challenges-and-opportunities-in-the-use-of-pharmacotherapy-for-youth-with-and-at-risk-for-type-2-diabetes-1960
https://events.diabetes.org/p/s/kelly-west-award-for-outstanding-achievement-in-epidemiology-lecture-includes-livestream-1961
https://events.diabetes.org/p/s/diabetes-and-the-liver-a-canary-in-the-coal-mine-1962
https://events.diabetes.org/p/s/the-safety-net-unraveled-social-and-geographical-factors-in-diabetes-disparities-1963
https://events.diabetes.org/p/s/the-new-frontier-in-risk-profiling-for-diabetes-blood-guts-and-glory-1964
https://events.diabetes.org/p/s/type-2-diabetes-and-related-trait-gwas-variant-effects-through-omics-profiles-with-ada-presidents-select-abstract-presentation-1965
https://events.diabetes.org/p/s/common-and-rare-genetic-variant-associations-and-molecularqtl-scans-in-type-2-diabetes-tissues-1966
https://events.diabetes.org/p/s/type-1-diabetes-genome-epigenome-and-crispr-screens-includes-livestream-1967
https://events.diabetes.org/p/s/when-a-box-isnt-a-box-research-frameworks-for-understanding-and-addressing-disparities-in-type-2-diabetes-1968
https://events.diabetes.org/p/s/diabetes-genome-wide-association-study-why-keep-going-1969
https://events.diabetes.org/p/s/united-states-veterans-and-diabetes-not-gone-and-not-forgotten-1970
https://events.diabetes.org/p/s/big-p-little-p-diabetes-policies-for-public-health-1971
https://events.diabetes.org/p/s/diabetes-genetic-convergence-shared-networks-of-rare-and-common-variants-1972
https://events.diabetes.org/p/s/omics-to-understand-genome-wide-association-study-whats-the-mechanism-1973
https://events.diabetes.org/p/s/ada-chief-executive-officer-and-chairman-of-the-board-fireside-chat-president-health-care-and-education-address-and-outstanding-educator-in-diabetes-award-lecture-includes-livestream-1974
https://events.diabetes.org/p/s/boosting-energy-expenditure-in-obesity-debating-the-potential-of-thermogenic-adipose-tissue-and-skeletal-muscle-bioenergetics-as-antiobesity-targets-in-humans-1975
https://events.diabetes.org/p/s/adipocyte-differentiation-and-function-1976
https://events.diabetes.org/p/s/novel-regulators-of-insulin-action-and-insulin-sensitivity-includes-livestream-1977
https://events.diabetes.org/p/s/metabolic-control-of-insulin-action-and-secretion-includes-livestream-1978
https://events.diabetes.org/p/s/revving-up-the-adipose-to-impact-insulin-sensitivity-and-glucose-homeostasis-1979
https://events.diabetes.org/p/s/secreted-factors-and-insulin-action-1980
https://events.diabetes.org/p/s/clinical-efforts-to-study-the-pathogenesis-of-insulin-resistance-1981
https://events.diabetes.org/p/s/technical-challenges-and-solutions-in-metabolomics-includes-livestream-1982
https://events.diabetes.org/p/s/the-second-act-redefining-the-signaling-mediators-of-glucose-uptake-in-muscle-1983
https://events.diabetes.org/p/s/metabolite-transport-and-molecular-metabolism-1984
https://events.diabetes.org/p/s/lipid-regulation-of-mitochondrial-metabolism-1985
https://events.diabetes.org/p/s/molecular-integration-of-amino-acid-and-fat-metabolism-in-health-and-metabolic-disease-1986
https://events.diabetes.org/p/s/setting-the-record-straight-does-sars-cov-2-cause-type-1-diabetes-includes-livestream-1987
https://events.diabetes.org/p/s/discussion-on-islet-biology-development-and-function-right-on-target-strategies-to-selectively-regenerate-and-protect-beta-cells-1988
https://events.diabetes.org/p/s/fueling-the-fire-islet-stimulus-secretion-coupling-1989
https://events.diabetes.org/p/s/islet-signal-transduction-1990
https://events.diabetes.org/p/s/beta-cell-blueprints-oral-abstracts-on-islet-development-and-postnatal-growth-1991
https://events.diabetes.org/p/s/endgame-oral-abstracts-on-beta-cell-apoptosis-with-ada-presidents-select-abstract-presentation-includes-livestream-1992
https://events.diabetes.org/p/s/islet-potpourri-oral-abstracts-includes-livestream-1993
https://events.diabetes.org/p/s/are-we-using-the-right-tools-to-establish-causality-in-islet-function-and-dysfunction-1994
https://events.diabetes.org/p/s/taking-a-closer-look-subcellular-approaches-to-islet-biology-1995
https://events.diabetes.org/p/s/channeling-mechanisms-underlying-islet-function-and-dysfunction-includes-livestream-1996
https://events.diabetes.org/p/s/the-good-the-bad-and-the-ugly-of-lipids-in-the-beta-cell-microenvironment-1997
https://events.diabetes.org/p/s/do-immune-or-beta-cells-drive-transition-from-stage-1-to-stage-3-type-1-diabetes-1998
https://events.diabetes.org/p/s/discussion-on-immunologybeta-cell-replacement-beta-cell-stressors-autoantigen-targets-and-how-this-provokes-immune-attack-1999
https://events.diabetes.org/p/s/immune-features-of-immune-therapy-and-evolution-fickle-or-fixed-2000
https://events.diabetes.org/p/s/immune-and-adipose-tissue-intersection-2001
https://events.diabetes.org/p/s/the-barrier-reef-overcoming-hurdles-to-beta-cell-replacement-therapies-2002
https://events.diabetes.org/p/s/preclinicalclinical-efforts-for-beta-cell-replacement-therapy-2003
https://events.diabetes.org/p/s/modulating-cytokines-mechanisms-underlying-type-1-diabetes-treatment-includes-livestream-2004
https://events.diabetes.org/p/s/cross-talk-between-beta-cells-and-immune-cells-2005
https://events.diabetes.org/p/s/translating-type-1-diabetes-risk-alleles-to-therapy-2006
https://events.diabetes.org/p/s/joint-adaipita-symposium-clinical-beta-cell-replacement-therapy-today-includes-livestream-2007
https://events.diabetes.org/p/s/clinical-beta-cell-replacement-therapy-in-the-near-future-includes-livestream-2008
https://events.diabetes.org/p/s/long-term-goals-and-challenges-for-beta-cell-replacement-therapy-includes-livestream-2009
https://events.diabetes.org/p/s/the-future-of-diabetes-care-as-cell-replacement-or-regeneration-therapies-includes-livestream-2010
https://events.diabetes.org/p/s/actions-of-incretins-in-the-brain-and-beyond-includes-livestream-2011
https://events.diabetes.org/p/s/research-advances-in-metabolic-liver-disease-2012
https://events.diabetes.org/p/s/novel-pathways-in-metabolic-regulation-2013
https://events.diabetes.org/p/s/new-insights-into-therapeutic-strategies-for-obesity-and-diabetes-2014
https://events.diabetes.org/p/s/emerging-new-players-in-metabolic-regulation-2015
https://events.diabetes.org/p/s/new-frontier-in-immunometabolism-2016
https://events.diabetes.org/p/s/novel-modulators-of-adipose-tissue-function-and-adiposity-2017
https://events.diabetes.org/p/s/towards-targeted-weight-loss-therapy-new-considerations-for-glp-1ra-or-surgery-2018
https://events.diabetes.org/p/s/risk-factors-reimagined-beyond-obesity-in-metabolic-risk-2019
https://events.diabetes.org/p/s/leptin-30-years-later-2020
https://events.diabetes.org/p/s/ripple-effects-after-the-advent-of-highly-effective-antiobesity-pharmacotherapy-pharmacoequity-in-the-united-states-2021
https://events.diabetes.org/p/s/weight-reducing-mechanisms-of-glp-1-based-therapies-new-insights-from-animal-studies-includes-livestream-2022
https://events.diabetes.org/p/s/metabolism-and-aging-related-diseases-2023
https://events.diabetes.org/p/s/beyond-the-scale-exploring-causes-and-consequences-of-weight-fluctuation-includes-livestream-2024
https://events.diabetes.org/p/s/mitochondria-as-a-therapeutic-target-for-diabetes-2025
https://events.diabetes.org/p/s/intermittent-fasting-in-various-forms-of-diabetes-care-includes-livestream-2026
https://events.diabetes.org/p/s/cns-effects-of-glp-1ra-beyond-diabetes-and-obesity-2027
https://events.diabetes.org/p/s/obesity-in-united-states-hispaniclatino-populations-challenges-and-strategies-2028
https://events.diabetes.org/p/s/food-noise-explained-satiety-responsiveness-and-motivation-processing-in-the-brain-includes-livestream-2029
https://events.diabetes.org/p/s/severe-glp-1ra-side-effects-in-obesity-treatment-fact-or-fiction-includes-livestream-2030
https://events.diabetes.org/p/s/ada-diabetes-journal-symposium-it-is-all-in-your-head-central-nervous-system-control-of-systemic-metabolism-2031
https://events.diabetes.org/p/s/president-medicine-and-science-address-and-national-scientific-and-health-care-achievement-awards-presentation-includes-livestream-2032
https://events.diabetes.org/p/s/outstanding-scientific-achievement-award-lecture-and-banting-medal-for-scientific-achievement-award-lectureincludes-livestream-2033
https://events.diabetes.org/p/s/creating-talks-that-are-talked-about-how-to-bring-memorability-to-your-presentations-session-cancelled-2034
https://events.diabetes.org/p/s/art-of-writing-a-winning-grant-includes-livestream-2035
https://events.diabetes.org/p/s/getting-the-career-you-envision-how-to-negotiate-for-what-you-need-and-want-includes-livestream-2036
https://events.diabetes.org/p/s/pathway-to-stop-diabetes-includes-livestream-2037
https://events.diabetes.org/p/s/welcome-to-the-84th-ada-scientific-sessions-keynote-address-by-robert-m-califf-md-and-panel-discussion-includes-livestream-2038
https://events.diabetes.org/p/s/question-and-discussion-period-2039
https://events.diabetes.org/p/s/rebuttal-2040
https://events.diabetes.org/p/s/we-need-to-stop-using-sulfonylureas-for-the-treatment-of-type-2-diabetes-2041
https://events.diabetes.org/p/s/sulfonylureas-remain-useful-agents-in-the-management-of-type-2-diabetes-2042
https://events.diabetes.org/p/s/rebuttal-2043
https://events.diabetes.org/p/s/introduction-2044
https://events.diabetes.org/p/s/question-and-discussion-period-2045
https://events.diabetes.org/p/s/real-health-diabetes-trial-2046
https://events.diabetes.org/p/s/dapagliflozin-according-to-body-mass-index-2047
https://events.diabetes.org/p/s/ketone-metabolism-and-cardiovascular-disease-2048
https://events.diabetes.org/p/s/introduction-2049
https://events.diabetes.org/p/s/question-and-discussion-period-2050
https://events.diabetes.org/p/s/current-surgical-techniques-in-diabetic-footankle-reconstruction-2051
https://events.diabetes.org/p/s/introduction-2052
https://events.diabetes.org/p/s/question-and-discussion-period-2053
https://events.diabetes.org/p/s/novel-therapies-in-clinical-trials-and-treatment-strategies-for-diabetic-retinopathy-2054
https://events.diabetes.org/p/s/therapies-in-development-for-diabetic-retinopathy-a-basic-science-2055
https://events.diabetes.org/p/s/opat-is-protective-of-major-amputation-following-hospitalization-for-diabetic-foot-infection-2056
https://events.diabetes.org/p/s/high-transepidermal-water-loss-tewl-associates-with-failure-to-maintain-wound-closure-in-diabetic-foot-ulcers-2057
https://events.diabetes.org/p/s/bacteremia-and-endocarditis-complicating-moderate-and-severe-diabetic-foot-infections-2058
https://events.diabetes.org/p/s/roger-pecoraro-award-lecture-roger-pecoraro-award-lecture-2024-2059
https://events.diabetes.org/p/s/tissue-nanotransfection-based-endothelial-targeted-epigenetic-gene-editing-in-vivo-to-rescue-diabetic-ischemic-wounds-2060
https://events.diabetes.org/p/s/lineage-tracing-of-vasculogenic-fibroblasts-in-vivo-and-their-significance-in-the-rescue-of-diabetic-ischemic-tissue-2061
https://events.diabetes.org/p/s/case-control-study-on-whole-methylome-analysis-of-monocytes-in-acute-diabetic-charcot-foot-identifying-differentially-methylated-genes-2062
https://events.diabetes.org/p/s/a-clinical-study-of-novel-antimicrobial-peptide-pl-5-topical-spray-for-mild-to-moderate-infectious-wounds-of-diabetic-foot-2063
https://events.diabetes.org/p/s/assessing-the-impact-of-hypoglycemia-among-people-with-diabetes-in-the-us-and-eu-2064
https://events.diabetes.org/p/s/level-3-hypoglycemia-in-diabetes-an-age-old-but-not-just-old-age-problem-inphorm-usa-2065
https://events.diabetes.org/p/s/time-below-range-tbr-and-its-link-to-impaired-awareness-of-hypoglycemia-iah-and-severe-hypoglycemia-sh-evidence-from-the-association-of-british-clinical-diabetologists-abcd-study-2066
https://events.diabetes.org/p/s/association-between-clustering-of-hypoglycemic-symptoms-psychological-traits-and-problem-solving-abilities-in-adults-with-type-1-diabetes-2067
https://events.diabetes.org/p/s/genetic-variation-in-glp-1r-modify-the-risk-of-hypoglycemia-in-response-to-intensive-glycemic-control-in-adults-with-type-2-diabetes-2068
https://events.diabetes.org/p/s/assessing-hypoglycemia-awareness-validating-hypoa-q-within-the-t1d-exchange-registry-2069
https://events.diabetes.org/p/s/health-related-quality-of-life-and-burden-of-type-1-diabetes-and-severe-hypoglycemia-in-adult-continuous-glucose-monitor-users-2070
https://events.diabetes.org/p/s/longitudinal-assessment-of-glycemia-and-severe-hypoglycemia-among-adults-with-type-1-diabetes-an-online-survey-2071
https://events.diabetes.org/p/s/characterization-of-behavioral-patterns-involving-hypoglycemic-episodes-in-type-1-diabetes-results-from-the-t1dexi-study-cohort-2072
https://events.diabetes.org/p/s/cgm-has-a-specific-effect-on-the-reduction-of-nocturnal-hypoglycemia-in-people-with-type-1-diabetes-on-an-mdi-treatment-regimen-2073
https://events.diabetes.org/p/s/association-of-type-1-diabetes-duration-or-duration-of-advanced-technology-utilization-with-severe-hypoglycemic-event-frequency-2074
https://events.diabetes.org/p/s/the-impact-of-glucose-threshold-on-the-number-and-duration-of-glucose-episodes-2075
https://events.diabetes.org/p/s/interoception-predicts-impaired-awareness-of-hypoglycemia-iah-in-adults-with-type-1-diabetes-t1d-2076
https://events.diabetes.org/p/s/task-induced-alterations-in-the-salience-network-amongst-patients-with-type-1-diabetes-2077
https://events.diabetes.org/p/s/metoclopramide-improves-hypoglycemic-counterregulation-in-diabetic-rats-2078
https://events.diabetes.org/p/s/a-randomized-study-of-a-gpr119-agonist-on-glucagon-counterregulation-during-hypoglycemia-in-type-1-diabetes-mellitus-t1dm-2079
https://events.diabetes.org/p/s/lipoproteina-levels-and-epicardial-adipose-tissue-in-diabetes-unraveling-novel-connections-2080
https://events.diabetes.org/p/s/fat-contents-in-pancreatic-body-and-liver-are-synergistic-risk-factors-for-impaired-glucose-regulation-in-pcos-2081
https://events.diabetes.org/p/s/the-improvement-effects-of-glucokinase-loss-of-function-mutation-on-lipid-metabolism-2082
https://events.diabetes.org/p/s/new-lipid-biomarkers-for-worsening-glucose-tolerance-in-nondiabetic-relatives-of-people-with-type-2-diabetes-2083
https://events.diabetes.org/p/s/mir103-as-a-potential-inhibitor-for-dyslipidemia-through-modulation-of-angptl8-level-2084
https://events.diabetes.org/p/s/ada-presidents-select-abstract-lower-plasma-levels-of-truncated-apolipoprotein-c-i-are-associated-with-increased-risk-of-diabetes-multiethnic-study-of-atherosclerosis-2085
https://events.diabetes.org/p/s/intervention-of-select-lipid-signaling-reduces-type-1-diabetes-incidence-2086
https://events.diabetes.org/p/s/declining-egfr-over-time-predicts-the-risk-of-a-composite-of-primary-or-secondary-major-adverse-cardiovascular-events-or-heart-failure-hospitalization-in-people-with-type-2-diabetes-exscel-post-hoc-an-2087
https://events.diabetes.org/p/s/the-triglyceride-glucose-index-and-the-presence-of-coronary-artery-disease-are-mutually-independent-predictors-for-the-development-of-type-2-diabetes-mellitus-2088
https://events.diabetes.org/p/s/association-between-composite-dietary-antioxidant-index-and-stroke-among-us-adults-with-diabetes-insights-from-nhanes-2089
https://events.diabetes.org/p/s/glycemic-markers-are-differentially-associated-with-cardiovascular-imaging-and-outcomes-in-long-duration-type-1-diabetes-2090
https://events.diabetes.org/p/s/the-role-of-optical-coherent-tomography-in-the-estimation-of-cardiovascular-risk-in-asymptomatic-patients-with-type-1-diabetes-2091
https://events.diabetes.org/p/s/risk-factors-for-combined-severe-diabetic-complications-csdc-in-patients-with-type-2-diabetes-mellitus-t2dm-2092
https://events.diabetes.org/p/s/ceramides-surpass-ldl-cholesterol-in-predicting-cardiovascular-mortality-in-diabetic-and-nondiabetic-patients-2093
https://events.diabetes.org/p/s/proteomic-analysis-of-mineralocorticoid-receptor-antagonism-in-diabetic-atherosclerosis-magma-results-and-integrated-predictors-of-response-2094
https://events.diabetes.org/p/s/cystatin-c-predicts-cardiovascular-events-in-patients-with-coronary-artery-disease-both-among-patients-with-and-among-those-without-type-2-diabetes-2095
https://events.diabetes.org/p/s/association-of-erythritol-and-erythronate-with-cardiovascular-outcomes-and-death-2096
https://events.diabetes.org/p/s/blood-monocyte-phenotype-predicts-cardiovascular-risk-in-type-2-diabetes-2097
https://events.diabetes.org/p/s/pro-b-type-natriuretic-peptide-strongly-predicts-major-cardiovascular-events-and-cardiovascular-mortality-in-cardiovascular-disease-patients-with-nafld-as-well-as-in-those-without-nafld-2098
https://events.diabetes.org/p/s/edwin-bierman-award-lecture-diabetes-and-cardiovascular-disease-the-evolution-of-cv-outcomes-assessment-of-antihyperglycemic-medications-2099
https://events.diabetes.org/p/s/metabolic-dysfunction-attenuates-d-dopachrome-tautomerase-ddt-expression-in-the-heart-a-key-mechanism-exacerbates-myocardial-post-ischemic-injury-2100
https://events.diabetes.org/p/s/vascular-sorbs2-deficiency-is-an-independent-risk-of-vascular-complications-in-diabetes-2101
https://events.diabetes.org/p/s/gpsm1-regulates-atherosclerosis-progression-by-controlling-macrophage-chemotaxis-through-pkaklf4pmp22-mapk-pathway-2102
https://events.diabetes.org/p/s/longitudinal-patterns-of-heterogeneity-in-metabolic-decompensation-among-diabetes-prevention-program-outcomes-study-dppos-participants-over-20-years-2103
https://events.diabetes.org/p/s/causal-associations-between-glyoxalase-1-expression-and-kidney-disease-in-type-1-diabetes-2104
https://events.diabetes.org/p/s/renal-hypermetabolism-in-youth-onset-type-2-diabetes-t2d-a-c-11-acetate-pet-scan-analysis-2105
https://events.diabetes.org/p/s/renal-cell-type-associated-therapeutic-effects-of-semaglutide-in-a-mouse-model-of-hypertension-accelerated-diabetic-kidney-disease-2106
https://events.diabetes.org/p/s/renoprotective-effects-of-glucagon-and-incretin-agonist-combinations-mediated-by-macula-densa-cells-2107
https://events.diabetes.org/p/s/pyruvate-kinase-m2-pkm2-activation-in-the-podocyte-prevented-subset-differentiation-of-glomerular-cells-induced-by-diabetes-2108
https://events.diabetes.org/p/s/identification-of-genetic-regulators-of-circulating-biomarkers-of-kidney-decline-in-diabetes-2109
https://events.diabetes.org/p/s/podocyte-specific-expression-of-redd1-promotes-altered-glomerular-pathology-and-renal-function-deficits-in-a-rodent-model-of-diabetic-nephropathy-2110
https://events.diabetes.org/p/s/diffusion-tensor-imaging-and-t2-mapping-of-the-tibial-nerve-can-detect-nerve-damage-in-type-2-diabetes-2111
https://events.diabetes.org/p/s/ada-presidents-select-abstract-targeting-inflammation-with-salsalate-in-type-1-diabetes-neuropathy-tinsal-t1dn-trial-2112
https://events.diabetes.org/p/s/combined-dpncheck-and-sudoscan-as-a-screening-tool-for-dpn-the-sheffield-prospective-study-2113
https://events.diabetes.org/p/s/differences-of-three-dimensional-pathology-of-dorsal-root-ganglia-in-neuropathy-of-type-1-and-type-2-diabetes-mellitus-2114
https://events.diabetes.org/p/s/increased-triglyceride-levels-are-associated-with-a-distinct-lipid-associated-protein-biomarker-profile-of-diabetic-foot-ulcers-2115
https://events.diabetes.org/p/s/identification-of-exosomal-mirna-as-a-novel-causal-biomarker-for-cognitive-impairment-in-type-2-diabetes-mellitus-triangulating-evidence-from-mendelian-randomization-analyses-and-multicenter-cohort-2116
https://events.diabetes.org/p/s/investigating-c-fiber-activity-using-depolarizing-stimuli-provides-insight-into-the-natural-course-of-diabetic-polyneuropathy-2117
https://events.diabetes.org/p/s/relationship-between-visit-to-visit-variability-of-hba1c-and-developmentprogression-of-diabetic-retinopathy-2118
https://events.diabetes.org/p/s/diabetic-retinopathy-dr-is-associated-with-markers-of-alzheimers-disease-ad-in-type-1-diabetes-t1d-2119
https://events.diabetes.org/p/s/autonomous-artificial-intelligence-diabetic-eye-exams-mitigates-disparities-in-screening-completion-for-youth-2120
https://events.diabetes.org/p/s/preadministration-of-sglt2-inhibitor-reduces-frequency-of-anti-vegf-agent-administration-in-patients-with-mild-diabetic-macular-edema-a-multicenter-randomized-controlled-open-label-trial-2121
https://events.diabetes.org/p/s/haptoglobin-hp-levels-and-phenotype-are-unrelated-to-severe-retinopathy-in-type-2-diabetes-but-lower-hp-reductions-by-fenofibrate-are-associated-with-greater-retinopathy-benefit-a-field-trial-study-2122
https://events.diabetes.org/p/s/genetic-basis-of-diabetic-macular-edema-and-proliferative-diabetic-retinopathy-insights-from-next-generation-sequencing-in-the-drgen-study-2123
https://events.diabetes.org/p/s/characterization-of-aqueous-retinol-binding-protein-3-concentrations-and-diabetic-retinopathy-progression-in-type-1-and-type-2-diabetes-2124
https://events.diabetes.org/p/s/delaying-progression-of-diabetic-retinopathy-worsens-the-risk-for-age-related-macular-degeneration-2125
https://events.diabetes.org/p/s/question-and-discussion-period-2126
https://events.diabetes.org/p/s/after-the-referral-watch-how-podiatrists-surgically-treat-foot-ulcers-2127
https://events.diabetes.org/p/s/kidney-friendly-vascular-surgery-interventions-for-diabetic-peripheral-arterial-disease-2128
https://events.diabetes.org/p/s/question-and-discussion-period-2129
https://events.diabetes.org/p/s/from-home-to-hospital-a-paramedics-perspective-on-the-diabetic-foot-2130
https://events.diabetes.org/p/s/how-it-looks-when-it-works-multidisciplinary-team-approach-to-diabetic-foot-infection-2132
https://events.diabetes.org/p/s/practicing-as-an-island-when-a-multidisciplinary-team-isnt-available-2133
https://events.diabetes.org/p/s/panel-discussion-2134
https://events.diabetes.org/p/s/new-lipid-lowering-pharmacotherapies-in-diabetes-2135
https://events.diabetes.org/p/s/lpa-therapeutics-are-we-there-yet-2136
https://events.diabetes.org/p/s/advanced-diagnostic-imaging-is-your-lipid-therapy-good-enough-2137
https://events.diabetes.org/p/s/question-and-discussion-period-2138
https://events.diabetes.org/p/s/a-multidisciplinary-approach-challenging-cases-from-the-cardiometabolic-clinic-2140
https://events.diabetes.org/p/s/a-multidisciplinary-approach-challenging-cases-from-the-cardiometabolic-clinic-2141
https://events.diabetes.org/p/s/a-multidisciplinary-approach-challenging-cases-from-the-cardiometabolic-clinic-2142
https://events.diabetes.org/p/s/a-multidisciplinary-approach-challenging-cases-from-the-cardiometabolic-clinic-2143
https://events.diabetes.org/p/s/introduction-2144
https://events.diabetes.org/p/s/question-and-discussion-period-2145
https://events.diabetes.org/p/s/the-fame-1-eye-trial-2146
https://events.diabetes.org/p/s/role-of-systemic-pharmacotherapy-in-the-prevention-and-management-of-diabetic-macular-edema-2147
https://events.diabetes.org/p/s/the-effect-of-fenofibrate-on-progression-of-diabetic-retinopathy-results-from-the-lens-trial-2148
https://events.diabetes.org/p/s/glp-1-receptor-agonist-and-diabetic-retinopathy-worsening-2149
https://events.diabetes.org/p/s/artificial-intelligence-and-novel-retinal-imaging-in-diabetic-retinopathy-screening-2150
https://events.diabetes.org/p/s/leveraging-diabetic-retinopathy-screening-programs-in-clinical-trials-2151
https://events.diabetes.org/p/s/overview-of-drcr-retina-network-studies-and-standards-of-diabetes-eye-care-2152
https://events.diabetes.org/p/s/emerging-treatment-strategies-for-diabetic-retinopathy-2153
https://events.diabetes.org/p/s/living-with-impaired-awareness-of-hypoglycemia-what-people-living-with-diabetes-wish-you-knew-2154
https://events.diabetes.org/p/s/evidence-based-interventions-to-restore-awareness-of-hypoglycemia-2155
https://events.diabetes.org/p/s/impaired-awareness-of-hypoglycemia-screening-and-diagnosis-in-clinical-practice-2156
https://events.diabetes.org/p/s/question-and-discussion-period-2157
https://events.diabetes.org/p/s/is-high-density-lipoprotein-a-risk-factor-for-men-2158
https://events.diabetes.org/p/s/sex-differences-in-lipoprotein-metabolism-2159
https://events.diabetes.org/p/s/impact-of-biological-and-chromosomal-sex-on-postprandial-lipid-metabolism-2160
https://events.diabetes.org/p/s/select-an-overview-of-the-study-and-the-weight-outcomes-2162
https://events.diabetes.org/p/s/role-of-glycemia-on-cardiovascular-outcomes-new-data-from-select-2163
https://events.diabetes.org/p/s/heart-failure-and-inflammation-outcomes-in-select-2164
https://events.diabetes.org/p/s/discussant-2165
https://events.diabetes.org/p/s/semaglutide-and-prediabetes-progressionregression-in-people-with-vascular-disease-what-have-we-learned-from-select-2166
https://events.diabetes.org/p/s/predicting-risk-for-heart-failure-in-type-2-diabetes-insights-from-the-trs-hfdm-and-watch-dm-risk-scores-2167
https://events.diabetes.org/p/s/high-risk-cardiovascular-disease-phenotypes-in-obesity-beyond-body-mass-index-2168
https://events.diabetes.org/p/s/metabolites-in-3d-how-spatial-metabolomics-revolutionizes-our-understanding-of-diabetic-kidney-disease-2170
https://events.diabetes.org/p/s/mapping-the-transcriptomic-universe-spatial-transcriptomics-in-deciphering-diabetic-nephropathy-2171
https://events.diabetes.org/p/s/a-deeper-look-at-proteins-spatial-proteomics-in-diabetic-kidney-pathogenesis-2172
https://events.diabetes.org/p/s/the-exposome-imperative-unlocking-the-full-spectrum-of-exposure-sciences-to-prevent-diabetic-kidney-disease-2173
https://events.diabetes.org/p/s/clear-waters-ahead-the-impacts-of-pfas-on-diabetic-kidney-health-2174
https://events.diabetes.org/p/s/heat-waves-and-kidneys-how-climate-change-aggravates-diabetic-nephropathy-2175
https://events.diabetes.org/p/s/acute-kidney-injury-and-its-long-term-consequences-in-diabetes-2176
https://events.diabetes.org/p/s/the-vascular-crossroads-hypertension-and-vascular-disease-in-diabetic-kidney-disease-progression-2177
https://events.diabetes.org/p/s/decoding-diabetic-kidney-disease-molecular-subtypes-and-the-future-of-nosology-2178
https://events.diabetes.org/p/s/question-and-discussion-period-2179
https://events.diabetes.org/p/s/epidemiology-overview-of-diabetic-neuropathy-2180
https://events.diabetes.org/p/s/perspectives-on-small-fiber-endpoints-2181
https://events.diabetes.org/p/s/meaningful-endpoints-in-clinical-trials-lessons-learned-2182
https://events.diabetes.org/p/s/question-and-discussion-period-2183
https://events.diabetes.org/p/s/autonomic-dysfunction-challenging-clinical-scenarios-2184
https://events.diabetes.org/p/s/gastroparesis-myths-and-facts-2185
https://events.diabetes.org/p/s/question-and-discussion-period-2186
https://events.diabetes.org/p/s/ameliorating-care-fragmentation-to-prevent-diabetes-related-microvascular-complications-2187
https://events.diabetes.org/p/s/advancing-cardiometabolic-health-and-reducing-cardiovascular-risk-in-diabetes-through-academic-community-government-industry-partnerships-2188
https://events.diabetes.org/p/s/trends-and-inequalities-in-diabetes-related-complications-among-us-adults-with-diabetes-2000-2020-2189
https://events.diabetes.org/p/s/discussant-2190
https://events.diabetes.org/p/s/the-highs-and-lows-of-cannabis-use-in-diabetes-associations-between-cbd-thc-or-cbd-plus-thc-use-vs-nonuse-on-insulin-sensitivity-inflammation-and-behavior-2191
https://events.diabetes.org/p/s/the-highs-and-lows-of-cannabis-use-in-diabetes-behavioral-and-psychosocial-considerations-2192
https://events.diabetes.org/p/s/the-highs-and-lows-of-cannabis-use-in-diabetes-overview-and-landscape-of-use-2193
https://events.diabetes.org/p/s/question-and-discussion-period-2194
https://events.diabetes.org/p/s/not-quite-but-we-are-on-our-way-to-building-the-evidence-2195
https://events.diabetes.org/p/s/rebuttal-2196
https://events.diabetes.org/p/s/introduction-2198
https://events.diabetes.org/p/s/question-and-discussion-period-2199
https://events.diabetes.org/p/s/recruitment-retention-and-engagement-of-men-from-minoritized-racial-and-ethnic-groups-in-behavioral-diabetes-research-2200
https://events.diabetes.org/p/s/recruitment-retention-and-engagement-of-lgbtqia-plus-people-in-behavioral-research-2201
https://events.diabetes.org/p/s/recruitment-retention-and-engagement-of-people-with-neurodiversity-in-behavioral-research-2202
https://events.diabetes.org/p/s/introduction-2203
https://events.diabetes.org/p/s/interaction-of-circadian-system-and-physical-activity-on-cardiovascular-health-2204
https://events.diabetes.org/p/s/exercise-timing-and-metabolic-rhythmicity-in-type-2-diabetes-2205
https://events.diabetes.org/p/s/does-timing-of-exercise-matter-time-of-day-effects-of-physical-activity-on-glycemic-outcomes-2206
https://events.diabetes.org/p/s/introduction-2207
https://events.diabetes.org/p/s/question-and-discussion-period-2208
https://events.diabetes.org/p/s/centers-for-disease-control-and-preventions-dsmes-playbook-lets-get-to-it-2209
https://events.diabetes.org/p/s/prioritizing-health-equity-in-diabetes-overview-centers-for-disease-control-and-prevention-dp23-0020-2210
https://events.diabetes.org/p/s/centers-for-disease-control-and-prevention-dsmes-toolkit-2211
https://events.diabetes.org/p/s/introduction-2212
https://events.diabetes.org/p/s/question-and-discussion-period-2213
https://events.diabetes.org/p/s/challenges-and-opportunities-of-ultraprocessed-food-research-2214
https://events.diabetes.org/p/s/ultraprocessed-foods-and-chronic-disease-across-the-lifespan-2215
https://events.diabetes.org/p/s/introduction-2216
https://events.diabetes.org/p/s/question-and-discussion-period-2217
https://events.diabetes.org/p/s/how-to-say-no-so-you-can-say-yes-optimizing-time-management-2218
https://events.diabetes.org/p/s/food-insecurity-and-inability-to-obtain-recommended-medications-diabetes-technology-and-multidisciplinary-services-in-youth-and-young-adults-with-diabetes-2220
https://events.diabetes.org/p/s/development-and-validation-of-a-social-risk-screening-tool-for-adults-with-type-2-diabetes-2221
https://events.diabetes.org/p/s/pathway-between-race-historic-and-contemporary-measures-of-structural-racism-and-prevalence-of-diabetes-in-the-us-2222
https://events.diabetes.org/p/s/symposium-on-the-international-consensus-statement-and-movement-to-end-diabetes-stigma-2223
https://events.diabetes.org/p/s/association-of-social-determinants-of-health-with-efficacy-of-metabolic-bariatric-surgery-mbs-vs-medical-therapy-mt-for-type-2-diabetes-2224
https://events.diabetes.org/p/s/longitudinal-effect-of-diabetes-fatalism-on-clinical-outcomes-and-qol-in-aa-with-type-2-diabetes-mellitus-2225
https://events.diabetes.org/p/s/the-relationship-between-daytime-child-glycemic-levels-and-parent-fear-of-hypoglycemia-2226
https://events.diabetes.org/p/s/understanding-parent-and-youth-diabetes-device-satisfaction-2227
https://events.diabetes.org/p/s/psychosocial-predictors-of-diabetes-self-efficacy-in-young-adults-with-youth-onset-type-2-diabetes-2228
https://events.diabetes.org/p/s/exploring-incorporation-of-type-1-diabetes-into-identity-and-perceptions-of-diabetes-technologies-in-adolescents-and-young-adults-ayas-2229
https://events.diabetes.org/p/s/sleep-disturbance-and-diabetes-symptom-burden-in-young-adults-with-type-1-diabetes-2230
https://events.diabetes.org/p/s/coin2dose-proof-of-concept-that-a-behavioral-economics-intervention-can-increase-mealtime-insulin-use-in-adolescents-with-type-1-diabetes-2231
https://events.diabetes.org/p/s/emotional-distress-and-insulin-initiation-in-the-grade-trial-2232
https://events.diabetes.org/p/s/individual-sources-of-diabetes-distress-a-precision-mental-health-approach-combining-ecological-momentary-assessment-and-continuous-glucose-monitoring-2233
https://events.diabetes.org/p/s/feasibility-of-a-multidisciplinary-pilot-intervention-for-parentcaregiver-diabetes-distress-2234
https://events.diabetes.org/p/s/diabetes-distress-among-persons-living-with-latent-autoimmune-diabetes-of-adults-in-the-canadian-cohort-better-a-cross-sectional-study-2235
https://events.diabetes.org/p/s/richard-r-rubin-award-lecture-life-lessons-and-diabetes-research-2236
https://events.diabetes.org/p/s/the-effect-of-a-dietary-intervention-on-insulin-sensitivity-in-type-1-diabetes-and-the-role-of-dietary-advanced-glycation-end-products-a-12-week-randomized-clinical-trial-2237
https://events.diabetes.org/p/s/sucralose-consumption-decreases-insulin-sensitivity-and-modifies-the-gut-microbiota-in-healthy-individuals-2238
https://events.diabetes.org/p/s/digital-twin-dt-technology-in-type-2-diabetes-remission-and-glycemic-improvement-eighteen-months-results-from-a-randomized-controlled-trial-2239
https://events.diabetes.org/p/s/ada-presidents-select-abstract-oral-bisphenol-a-administration-decreased-peripheral-insulin-sensitivity-in-healthy-adults-2240
https://events.diabetes.org/p/s/structured-medical-nutrition-therapy-improves-glycemia-reduces-percentage-body-fat-while-maintaining-fat-free-mass-in-individuals-with-overweightobesity-and-type-2-diabetes-2241
https://events.diabetes.org/p/s/a-multiomics-study-of-individual-responses-to-long-term-mediterranean-diet-interventions-in-the-direct-plus-trial-2242
https://events.diabetes.org/p/s/mediterranean-diet-and-gestational-diabetes-what-is-the-role-of-exposure-to-persistent-organic-pollutants-2243
https://events.diabetes.org/p/s/efficacy-of-a-culturally-tailored-mediterranean-like-diet-intervention-on-cardiometabolic-risk-factors-2244
https://events.diabetes.org/p/s/inaccurate-and-unaware-perceived-and-objective-diabetes-knowledge-among-adults-with-type-2-diabetes-2245
https://events.diabetes.org/p/s/burden-of-diabetes-survey-perspectives-from-people-living-with-diabetes-in-the-united-states-2246
https://events.diabetes.org/p/s/use-of-electronic-best-practice-advisories-bpa-to-increase-referral-to-diabetes-self-management-education-and-support-dsmes-services-2247
https://events.diabetes.org/p/s/streamlining-diabetes-device-integration-into-the-electronic-health-record-2248
https://events.diabetes.org/p/s/the-safety-and-efficacy-of-virtual-insulin-pump-initiation-in-children-and-adolescents-with-type-1-diabetes-in-the-united-states-2249
https://events.diabetes.org/p/s/the-effects-of-the-we-gdm-program-for-women-with-gestational-diabetes-mellitus-and-their-partners-on-blood-glucose-levels-and-communal-coping-a-randomised-controlled-trial-2250
https://events.diabetes.org/p/s/outcomes-of-real-world-deployment-of-the-dulce-digital-texting-education-platform-for-low-income-diverse-populations-with-diabetes-2251
https://events.diabetes.org/p/s/examining-new-onset-type-1-diabetes-educational-practices-among-centers-in-the-t1d-exchange-quality-improvement-collaborative-t1dx-qi-2252
https://events.diabetes.org/p/s/mettl3-is-essential-for-exercise-induced-cardiac-benefits-in-diabetic-cardiomyopathy-2253
https://events.diabetes.org/p/s/posttranslational-modifications-in-skeletal-muscle-direct-divergent-metabolic-responses-to-different-exercise-training-modes-2254
https://events.diabetes.org/p/s/effect-of-acute-exercise-and-exercise-training-on-the-ability-of-insulin-to-clear-branched-chain-amino-acids-from-plasma-in-obesity-and-type-2-diabetes-2255
https://events.diabetes.org/p/s/two-weeks-of-exercise-alters-neuronal-extracellular-vesicle-insulin-signaling-in-adults-with-prediabetes-2256
https://events.diabetes.org/p/s/enhancing-physical-activity-engagement-among-individuals-with-type-1-diabetes-exploring-perceived-barriers-in-the-era-of-new-technologies-2257
https://events.diabetes.org/p/s/does-exercise-in-cool-water-result-in-a-greater-decrease-in-blood-glucose-concentration-than-exercise-in-thermoneutral-water-or-on-land-in-people-with-type-1-diabetes-2258
https://events.diabetes.org/p/s/activity-feature-attenuates-drop-in-glucose-for-individuals-with-type-1-diabetes-using-omnipod-5-automated-insulin-delivery-system-2259
https://events.diabetes.org/p/s/hypoglycemia-associated-with-physical-activity-in-automated-insulin-delivery-users-frequency-and-prevention-strategies-2260
https://events.diabetes.org/p/s/question-and-discussion-period-2261
https://events.diabetes.org/p/s/the-united-kingdom-perspective-2262
https://events.diabetes.org/p/s/the-united-states-perspective-2263
https://events.diabetes.org/p/s/are-we-close-to-closing-the-loop-automated-insulin-delivery-during-exercise-2264
https://events.diabetes.org/p/s/are-we-close-to-closing-the-loop-automated-insulin-delivery-during-exercise-2265
https://events.diabetes.org/p/s/are-we-close-to-closing-the-loop-automated-insulin-delivery-during-exercise-2266
https://events.diabetes.org/p/s/are-we-close-to-closing-the-loop-automated-insulin-delivery-during-exercise-2267
https://events.diabetes.org/p/s/establishing-the-evidence-base-for-patient-empowerment-in-behavioral-diabetes-care-2268
https://events.diabetes.org/p/s/harnessing-advanced-methods-and-technologies-for-behavioral-diabetes-care-2269
https://events.diabetes.org/p/s/advancing-health-equity-in-behavioral-diabetes-care-2270
https://events.diabetes.org/p/s/the-epidemic-of-loneliness-and-isolation-2271
https://events.diabetes.org/p/s/the-psychological-toll-of-loneliness-2272
https://events.diabetes.org/p/s/the-link-between-loneliness-and-diabetes-2273
https://events.diabetes.org/p/s/screening-tools-for-anxiety-disorders-2274
https://events.diabetes.org/p/s/screening-tools-for-depression-2275
https://events.diabetes.org/p/s/screening-tools-for-executive-function-2276
https://events.diabetes.org/p/s/question-and-discussion-period-2277
https://events.diabetes.org/p/s/does-the-gut-rule-influence-of-the-microbiome-on-diabetes-and-obesity-2278
https://events.diabetes.org/p/s/protein-quantity-quality-and-timing-for-weight-management-and-glycemia-2279
https://events.diabetes.org/p/s/the-who-said-what-use-of-nonnutritive-sweeteners-for-weight-management-prediabetes-and-diabetes-2280
https://events.diabetes.org/p/s/counting-calories-or-counting-the-hours-time-restricted-eating-2281
https://events.diabetes.org/p/s/is-weight-loss-everything-nutrition-and-lifestyle-are-missing-puzzle-pieces-2282
https://events.diabetes.org/p/s/protocol-in-practice-standing-orders-for-rdrn-management-of-glp-1gip-receptor-agonists-2283
https://events.diabetes.org/p/s/delivering-diabetes-self-management-education-in-the-wild-west-2284
https://events.diabetes.org/p/s/delivering-diabetes-prevention-and-self-management-support-in-latino-communities-in-the-rockies-2285
https://events.diabetes.org/p/s/delivering-diabetes-self-management-support-in-the-diabetes-belt-2286
https://events.diabetes.org/p/s/dont-say-no-to-continuous-glucose-monitors-in-primary-care-2287
https://events.diabetes.org/p/s/implementation-of-remote-patient-monitoring-in-rural-settings-barriers-and-facilitators-2288
https://events.diabetes.org/p/s/how-connected-insulin-pens-and-caps-are-facilitating-precision-insulin-management-2289
https://events.diabetes.org/p/s/question-and-discussion-2290
https://events.diabetes.org/p/s/exercise-and-health-in-women-with-diabetes-through-the-lifespan-2291
https://events.diabetes.org/p/s/mechanism-underlying-the-benefits-of-maternal-exercise-on-offspring-health-2292
https://events.diabetes.org/p/s/exercise-for-the-preventionmanagement-of-type-2-diabetes-in-breast-cancer-survivors-2293
https://events.diabetes.org/p/s/its-about-time-the-interaction-of-exercise-and-meal-timing-2294
https://events.diabetes.org/p/s/maintaining-muscle-mass-and-metabolic-health-resistance-exercise-in-type-2-diabetes-2295
https://events.diabetes.org/p/s/incretin-based-pharmacotherapy-osteosarcopenia-and-exercise-2296
https://events.diabetes.org/p/s/panel-question-and-discussion-period-2297
https://events.diabetes.org/p/s/innovative-methods-and-analyses-to-assess-the-impact-of-supportive-others-on-diabetes-self-management-and-outcomes-evaluation-of-social-support-and-social-networks-in-rural-dwelling-older-adults-with--2298
https://events.diabetes.org/p/s/youre-not-the-boss-of-me-innovative-methods-and-analyses-to-assess-the-impact-of-caregivers-on-diabetes-management-and-psychosocial-outcomes-of-adolescents-with-diabetes-2299
https://events.diabetes.org/p/s/welcome-remarks-from-the-niddk-director-2300
https://events.diabetes.org/p/s/leveraging-social-support-to-improve-diabetes-self-management-and-outcomes-mobile-health-interventions-for-adults-with-type-2-diabetes-and-support-persons-2301
https://events.diabetes.org/p/s/interventions-leveraging-social-support-to-improve-diabetes-self-management-and-outcomes-adaptation-and-tailoring-of-a-type-1-diabetes-education-and-support-t1des-intervention-to-improve-diabetes-dist-2302
https://events.diabetes.org/p/s/question-and-discussion-period-2303
https://events.diabetes.org/p/s/innovative-approaches-to-state-funded-delivery-of-dsmes-at-scale-2304
https://events.diabetes.org/p/s/improving-diabetes-management-in-the-elderly-dsmes-in-home-health-2305
https://events.diabetes.org/p/s/providing-dsmes-within-blue-cross-and-blue-shield-2306
https://events.diabetes.org/p/s/operationalizing-delivery-of-dsmes-in-home-health-2307
https://events.diabetes.org/p/s/aligning-therapeutic-education-with-dsmes-2308
https://events.diabetes.org/p/s/produce-prescription-as-intervention-method-for-achieving-sustainable-impact-on-individual-and-community-2309
https://events.diabetes.org/p/s/gamification-of-nutrition-interventions-throughout-the-lifespan-2310
https://events.diabetes.org/p/s/nutrition-education-and-food-security-resource-for-american-indians-and-alaska-natives-a-multilevel-intervention-to-improve-type-2-diabetes-outcomes-2311
https://events.diabetes.org/p/s/question-and-discussion-period-2312
https://events.diabetes.org/p/s/collaborations-between-providers-and-dcess-bringing-standards-of-care-alive-2313
https://events.diabetes.org/p/s/collaborations-between-providers-and-dcess-bringing-standards-of-care-alive-2314
https://events.diabetes.org/p/s/integrating-multidisciplinary-team-in-diabetes-management-germany-perspective-2315
https://events.diabetes.org/p/s/culturally-sensitive-conversations-when-approaching-nutrition-changes-2316
https://events.diabetes.org/p/s/integrating-therapeutic-education-into-obesity-interventions-2317
https://events.diabetes.org/p/s/research-in-diabetes-stigma-whats-next-2318
https://events.diabetes.org/p/s/prevalence-and-impact-of-diabetes-stigma-implications-for-health-outcomes-2319
https://events.diabetes.org/p/s/international-consensus-statement-for-ending-diabetes-stigma-background-methodology-of-the-consensus-statement-and-overview-of-recommendations-for-health-professional-and-researchers-2320
https://events.diabetes.org/p/s/integration-into-care-settings-patient-perspective-and-identifying-resources-2321
https://events.diabetes.org/p/s/cgm-expert-boards-move-beyond-hba1c-to-apply-technology-based-advances-across-the-full-spectrum-of-diabetes-care-2322
https://events.diabetes.org/p/s/clinical-conversations-on-real-time-continuous-glucose-monitoring-2323
https://events.diabetes.org/p/s/advances-in-the-delayed-onset-of-type-1-diabetes-strategies-to-improve-awareness-and-care-for-the-practicing-clinician-2324
https://events.diabetes.org/p/s/taking-an-obesity-centric-approach-to-care-exploring-pharmacotherapy-options-and-their-implications-in-patient-care-2325
https://events.diabetes.org/p/s/practical-management-of-thyroid-eye-disease-2326
https://events.diabetes.org/p/s/decentralizing-diabetes-care-supporting-remission-through-timely-screening-and-diabetes-specific-formula-2327
https://events.diabetes.org/p/s/question-and-discussion-period-2328
https://events.diabetes.org/p/s/artificial-intelligence-in-health-care-and-the-future-of-diabetes-data-science-2329
https://events.diabetes.org/p/s/artificial-intelligence-and-the-future-of-the-multidisciplinary-team-2330
https://events.diabetes.org/p/s/artificial-intelligence-and-the-future-of-diabetes-devices-2331
https://events.diabetes.org/p/s/question-and-discussion-period-2332
https://events.diabetes.org/p/s/pro-early-abnormal-glucose-metabolism-in-pregnancy-should-be-treated-2333
https://events.diabetes.org/p/s/rebuttal-2334
https://events.diabetes.org/p/s/con-early-abnormal-glucose-metabolism-in-pregnancy-should-not-be-treated-2335
https://events.diabetes.org/p/s/rebuttal-2336
https://events.diabetes.org/p/s/question-and-discussion-period-2337
https://events.diabetes.org/p/s/the-person-who-has-already-benefited-from-the-medication-2338
https://events.diabetes.org/p/s/rebuttal-2339
https://events.diabetes.org/p/s/the-person-with-class-3-obesity-and-no-comorbidities-2340
https://events.diabetes.org/p/s/rebuttal-2341
https://events.diabetes.org/p/s/rebuttal-2342
https://events.diabetes.org/p/s/the-person-with-overweight-and-cardiovascular-disease-2343
https://events.diabetes.org/p/s/the-health-economics-perspective-2344
https://events.diabetes.org/p/s/question-and-discussion-period-2345
https://events.diabetes.org/p/s/access-should-be-our-top-priority-2346
https://events.diabetes.org/p/s/rebuttal-2347
https://events.diabetes.org/p/s/innovation-should-be-our-top-priority-2348
https://events.diabetes.org/p/s/rebuttal-2349
https://events.diabetes.org/p/s/question-and-discussion-period-2350
https://events.diabetes.org/p/s/rebuttal-2351
https://events.diabetes.org/p/s/the-diabetes-prevention-program-is-the-best-tool-to-battle-prediabetes-and-obesity-ndpp-2352
https://events.diabetes.org/p/s/glp-1ras-are-the-best-tools-to-battle-prediabetes-and-obesity-2353
https://events.diabetes.org/p/s/rebuttal-2354
https://events.diabetes.org/p/s/introduction-2355
https://events.diabetes.org/p/s/question-and-discussion-period-2356
https://events.diabetes.org/p/s/efficient-workflow-for-inpatient-technology-use-2357
https://events.diabetes.org/p/s/outpatient-clinic-flow-for-efficient-work-order-2358
https://events.diabetes.org/p/s/overview-of-currently-available-technologies-and-downloading-platforms-2359
https://events.diabetes.org/p/s/introduction-2360
https://events.diabetes.org/p/s/question-and-discussion-period-2361
https://events.diabetes.org/p/s/training-primary-care-providers-to-be-diabetes-specialists-2362
https://events.diabetes.org/p/s/leveraging-specialty-diabetology-within-primary-care-2363
https://events.diabetes.org/p/s/introduction-2364
https://events.diabetes.org/p/s/question-and-discussion-period-2365
https://events.diabetes.org/p/s/universal-antibody-screening-pediatric-perspective-2366
https://events.diabetes.org/p/s/universal-antibody-screening-behavioral-medicine-perspective-2367
https://events.diabetes.org/p/s/introduction-2368
https://events.diabetes.org/p/s/question-and-discussion-period-2369
https://events.diabetes.org/p/s/an-algorithm-for-preoperative-management-of-diabetes-in-elective-surgery-patients-2370
https://events.diabetes.org/p/s/designing-a-program-for-preoperative-management-of-diabetes-2371
https://events.diabetes.org/p/s/introduction-2372
https://events.diabetes.org/p/s/question-and-discussion-period-2373
https://events.diabetes.org/p/s/continuous-glucose-monitoring-should-not-yet-be-used-in-pregnancy-complicated-by-gestational-diabetes-2374
https://events.diabetes.org/p/s/rebuttal-2375
https://events.diabetes.org/p/s/continuous-glucose-monitoring-should-be-used-now-in-pregnancy-complicated-by-gestational-diabetes-2376
https://events.diabetes.org/p/s/rebuttal-2377
https://events.diabetes.org/p/s/introduction-2378
https://events.diabetes.org/p/s/question-and-discussion-period-2379
https://events.diabetes.org/p/s/success-in-suboptimally-controlled-type-2-diabetes-the-magic-of-cgm-and-collaboration-2380
https://events.diabetes.org/p/s/challenges-in-the-management-of-diabetes-in-older-adults-2381
https://events.diabetes.org/p/s/impact-of-delays-in-statin-therapy-due-to-statin-nonacceptance-on-cardiovascular-outcomes-in-patients-with-diabetes-2382
https://events.diabetes.org/p/s/effectiveness-of-telemedicine-plus-conventional-care-vs-conventional-care-alone-in-reducing-complications-of-diabetes-a-pilot-study-2383
https://events.diabetes.org/p/s/improving-diabetic-kidney-disease-screening-in-a-veterans-affairs-primary-care-clinic-2384
https://events.diabetes.org/p/s/screening-for-diabetic-retinopathy-increases-by-32-percent-with-education-and-intervention-program-in-primary-care-2385
https://events.diabetes.org/p/s/enhancing-diabetic-eye-disease-detection-through-autonomous-artificial-intelligence-implementation-in-a-federally-qualified-health-center-2386
https://events.diabetes.org/p/s/implementing-a-machine-learning-model-to-predict-risk-of-chronic-kidney-disease-ckd-progression-2387
https://events.diabetes.org/p/s/efficacy-and-feasibility-of-a-telemedicine-program-for-institutionalized-elderly-people-with-insulin-treated-diabetes-using-continuous-glucose-monitoring-and-a-connected-insulin-pen-cap-the-trescasas--2388
https://events.diabetes.org/p/s/a-scalable-application-of-artificial-intelligence-ai-to-transform-type-2-diabetes-management-in-clinical-practice-2389
https://events.diabetes.org/p/s/improved-linkage-to-the-health-system-and-better-diabetes-control-due-to-community-based-m-health-enabled-screening-and-follow-up-in-india-2390
https://events.diabetes.org/p/s/algorithmic-identification-may-improve-racial-and-ethnic-diversity-of-clinical-study-recruitment-2391
https://events.diabetes.org/p/s/effect-of-video-conferences-between-endocrinologists-and-family-doctors-on-levels-of-recommended-medication-among-persons-with-type-2-diabetes-pragmatic-rct-2392
https://events.diabetes.org/p/s/virtual-diabetes-optimization-program-vs-standard-endocrine-care-for-veterans-with-uncontrolled-diabetes-2393
https://events.diabetes.org/p/s/diabetes-rescue-engagement-and-management-d-rem-results-of-a-pragmatic-clinical-trial-of-a-community-paramedicine-program-to-improve-diabetes-care-2394
https://events.diabetes.org/p/s/rocket-type-1-diabetes-launching-diabetes-self-management-habits-in-youth-with-new-onset-type-1-diabetes-2395
https://events.diabetes.org/p/s/first-impact-on-a1c-of-medically-underserved-patients-with-type-2-diabetes-using-a-hybrid-chronic-care-model-2396
https://events.diabetes.org/p/s/analysis-of-fib-4-index-changes-in-adults-with-type-2-diabetes-in-an-effective-comprehensive-diabetes-care-program-2397
https://events.diabetes.org/p/s/postprandial-glycemic-patterns-throughout-uncomplicated-pregnancies-2398
https://events.diabetes.org/p/s/continuous-glucose-monitoring-metrics-and-suboptimal-pregnancy-outcomes-in-women-with-gestational-diabetes-secondary-analysis-of-the-digest-trial-2399
https://events.diabetes.org/p/s/using-continuous-glucose-monitoring-to-identify-neonatal-hypoglycemia-following-gestational-diabetes-the-digest-newborn-study-2400
https://events.diabetes.org/p/s/continuous-glucose-monitoring-among-pregnant-individuals-with-glucose-intolerance-2401
https://events.diabetes.org/p/s/continuous-glucose-monitoring-in-pregnancies-with-type-1-diabetes-a-retrospective-study-2402
https://events.diabetes.org/p/s/continuous-glucose-monitoring-prediction-of-gestational-diabetes-mellitus-and-adverse-pregnancy-outcomes-2403
https://events.diabetes.org/p/s/postpartum-islet-cell-function-in-individuals-with-and-without-gestational-diabetes-2404
https://events.diabetes.org/p/s/metabolic-and-clinical-outcomes-with-one-abnormal-value-on-carpenter-coustan-criteria-2405
https://events.diabetes.org/p/s/prediction-of-late-gestational-diabetes-mellitus-in-those-without-early-gdm-2406
https://events.diabetes.org/p/s/should-we-improve-or-replace-the-antenatal-oral-glucose-tolerance-test-for-diagnosis-of-gestational-diabetes-2407
https://events.diabetes.org/p/s/fasting-and-postprandial-triglycerides-in-early-pregnancy-correlate-with-mean-glucose-and-time-in-range-by-cgm-at-28-weeks-of-gestation-2408
https://events.diabetes.org/p/s/beta-cell-irs1-deficiency-predisposes-female-mice-to-developing-gestational-diabetes-2409
https://events.diabetes.org/p/s/real-time-cgm-achieves-higher-tir-among-pregnant-persons-with-gdm-2410
https://events.diabetes.org/p/s/ada-presidents-select-abstract-the-effect-of-a-reduced-energy-diet-upon-maternal-weight-and-pregnancy-outcomes-in-women-with-gestational-diabetes-the-digest-trial-2411
https://events.diabetes.org/p/s/norbert-freinkel-award-lecture-atlantic-dip-changing-the-landscape-for-better-maternal-and-infant-health-2412
https://events.diabetes.org/p/s/the-effect-of-early-initiation-of-treatment-on-glycemia-and-pregnancy-outcomes-in-women-with-early-gestational-diabetes-mellitus-2413
https://events.diabetes.org/p/s/differences-in-adipocyte-expandability-and-function-between-healthy-pregnancies-and-pregnancies-complicated-by-gestational-diabetes-mellitus-and-preeclampsia-2414
https://events.diabetes.org/p/s/the-plant-based-substance-totum-63-t63-reduces-fasting-plasma-glucose-and-hba1c-in-people-with-prediabetes-or-type-2-diabetes-t2d-a-24-week-multicenter-randomized-controlled-trial-reverse-it-2415
https://events.diabetes.org/p/s/mechanisms-of-prediabetes-remission-in-people-with-weight-gain-after-lifestyle-intervention-2416
https://events.diabetes.org/p/s/protect-per-protocol-analysis-preserving-ss-cell-function-in-children-and-adolescents-with-newly-diagnosed-stage-3-type-1-diabetes-t1d-2417
https://events.diabetes.org/p/s/influence-of-the-type-1-diabetes-genetic-risk-score-on-response-to-immunotherapies-for-type-1-diabetes-prevention-2418
https://events.diabetes.org/p/s/preclinical-studies-indicate-that-insparin-is-a-new-class-of-antidiabetes-agent-2419
https://events.diabetes.org/p/s/rates-of-remission-and-metabolic-responses-in-data-driven-high-risk-prediabetes-clusters-2420
https://events.diabetes.org/p/s/ada-presidents-select-abstract-single-dose-glp-1-based-pancreatic-gene-therapy-durably-maintains-body-composition-and-glycemia-after-semaglutide-withdrawal-in-a-murine-model-of-obesity-2421
https://events.diabetes.org/p/s/effect-of-tirzepatide-on-kidney-function-in-people-with-excess-body-weight-and-type-2-diabetes-a-post-hoc-analysis-of-the-surmount-2-trial-2422
https://events.diabetes.org/p/s/pemvidutide-a-glp-1glucagon-dual-receptor-agonist-in-subjects-with-overweight-or-obesity-a-48-week-placebo-controlled-phase-2-momentum-trial-2423
https://events.diabetes.org/p/s/retatrutide-an-agonist-of-gip-glp-1-and-glucagon-receptors-improves-markers-of-pancreatic-beta-cell-function-and-insulin-sensitivity-2424
https://events.diabetes.org/p/s/effects-of-tirzepatide-on-central-reward-and-appetite-circuits-in-the-brain-2425
https://events.diabetes.org/p/s/understanding-patterns-of-glp-1glp-1-ra-use-among-individuals-with-type-1-diabetes-a-t1d-exchange-t1dx-online-registry-analysis-2426
https://events.diabetes.org/p/s/glucagon-like-peptide-1-receptor-agonists-and-risk-of-suicideself-harm-in-us-older-adults-with-type-2-diabetes-a-population-based-cohort-study-2427
https://events.diabetes.org/p/s/comparative-effectiveness-of-semaglutide-in-type-2-diabetes-year-2-results-of-a-randomized-pragmatic-clinical-trial-2428
https://events.diabetes.org/p/s/effect-of-pemvidutide-a-glp-1glucagon-dual-receptor-agonist-on-cardioinflammatory-lipids-2429
https://events.diabetes.org/p/s/orforglipron-improves-markers-of-beta-cell-function-and-insulin-sensitivity-in-type-2-diabetes-2430
https://events.diabetes.org/p/s/differences-in-weight-reduction-efficacy-of-tirzepatide-in-adults-without-vs-with-type-2-diabetes-with-overweight-or-obesity-in-surmount-1-and-2-2431
https://events.diabetes.org/p/s/tirzepatide-reduces-hba1c-and-body-weight-significantly-more-than-placebo-regardless-of-insulin-sensitivity-and-beta-cell-function-post-hoc-analysis-from-surmount-2-2432
https://events.diabetes.org/p/s/efficacy-of-tirzepatide-in-achieving-the-composite-endpoints-of-glycemic-blood-pressure-and-lipid-goals-in-surmount-2-2433
https://events.diabetes.org/p/s/the-apelin-receptor-agonist-azelaprag-increases-weight-loss-in-diet-induced-obese-mice-on-incretin-agonists-and-restores-body-composition-and-muscle-function-to-that-of-lean-controls-2434
https://events.diabetes.org/p/s/gl0034-utreglutide-a-novel-glp-1ra-increases-liver-fgf-21-and-demonstrates-significant-efficacy-on-weight-loss-hba1c-and-triglycerides-in-dbdb-mice-2435
https://events.diabetes.org/p/s/safety-tolerability-and-metabolic-effects-of-once-weekly-gl0034-utreglutide-in-individuals-with-obesity-a-multiple-ascending-dose-study-2436
https://events.diabetes.org/p/s/effects-of-triple-hormone-receptor-agonist-retatrutide-on-lipid-profiling-in-participants-with-obesity-2437
https://events.diabetes.org/p/s/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-novel-ultra-long-acting-glp-1-receptor-agonist-zt002-in-healthy-subjects-2438
https://events.diabetes.org/p/s/the-effect-of-combined-activin-a-and-myostatin-blockade-on-body-composition-a-phase-1-trial-2439
https://events.diabetes.org/p/s/the-risk-of-heart-failure-hospitalization-after-initiation-of-sglt2i-glp-1ra-dpp-4i-or-sus-in-patients-with-type-2-diabetes-and-low-to-moderate-cv-risk-2440
https://events.diabetes.org/p/s/lantidra-first-fda-approved-cellular-therapy-to-treat-type-1-diabetes-2441
https://events.diabetes.org/p/s/modulation-of-cardiorenal-benefits-for-glp-1ras-treatment-by-glp1r-genetic-variants-2442
https://events.diabetes.org/p/s/cardioprotective-effect-of-empagliflozin-and-modification-of-sirtuins-and-their-noncoding-rnas-regulators-in-patients-with-myocardial-infarction-2443
https://events.diabetes.org/p/s/the-coronary-flow-reserve-increase-after-dapagliflozin-treatment-in-patients-with-type-2-diabetes-is-maintained-after-four-years-a-four-year-dapaheart-follow-up-study-2444
https://events.diabetes.org/p/s/pioglitazone-amplifies-the-decrease-in-hba1c-and-prevents-the-increase-in-plasma-ketone-caused-by-dapagliflozin-in-type-1-diabetes-mellitus-patients-2445
https://events.diabetes.org/p/s/empagliflozin-enhances-hepatic-glucose-production-and-reduces-total-body-norepinephrine-turnover-rate-a-randomized-trial-2446
https://events.diabetes.org/p/s/a-novel-decision-support-system-for-automated-adaptations-of-insulin-injections-in-type-1-diabetes-a-randomized-controlled-trial-2447
https://events.diabetes.org/p/s/breath-acetone-correlates-with-capillary-beta-hydroxybutyrate-in-type-1-diabetes-2448
https://events.diabetes.org/p/s/diabetes-technology-and-waste-a-real-world-study-in-a-specialized-practice-in-germany-2449
https://events.diabetes.org/p/s/time-in-range-is-associated-with-glucagonc-peptide-index-ratio-in-type-2-diabetes-patients-2450
https://events.diabetes.org/p/s/in-silico-replay-of-insulin-degludec-and-liraglutide-clinical-trial-data-in-subjects-with-type-2-diabetes-2451
https://events.diabetes.org/p/s/ada-presidents-select-abstract-cgm-metrics-from-five-studies-identify-participants-at-high-risk-of-imminent-type-1-diabetes-t1d-development-2452
https://events.diabetes.org/p/s/perioperative-fully-closed-loop-vs-standard-insulin-delivery-in-adults-undergoing-major-abdominal-surgery-a-two-center-randomized-controlled-trial-2453
https://events.diabetes.org/p/s/real-world-outcomes-with-the-omnipod-5-automated-insulin-delivery-aid-system-for-7500-users-with-high-hba1c-9-percent-at-baseline-2454
https://events.diabetes.org/p/s/glucose-control-in-free-life-under-hybrid-closed-loop-6-and-12-months-after-initiation-from-a-nationwide-survey-2455
https://events.diabetes.org/p/s/effect-of-48-months-of-closed-loop-insulin-delivery-on-residual-c-peptide-secretion-and-glycemic-control-in-newly-diagnosed-youth-with-type-1-diabetes-2456
https://events.diabetes.org/p/s/automated-hybrid-closed-loop-ahcl-systems-for-the-treatment-of-cystic-fibrosis-related-diabetes-cfrd-2457
https://events.diabetes.org/p/s/association-between-continuous-glucose-monitoring-and-diabetes-related-complications-in-children-with-type-1-diabetes-nationwide-cohort-study-2458
https://events.diabetes.org/p/s/defining-new-targets-for-interventions-to-increase-continuous-glucose-monitoring-cgm-use-in-primary-care-2459
https://events.diabetes.org/p/s/glycemic-outcomes-with-cgm-use-in-patients-with-type-2-diabetes-real-world-analysis-2460
https://events.diabetes.org/p/s/cgm-in-primary-care-practice-characteristics-and-choice-of-cgm-implementation-strategy-in-prepare-4-cgm-2461
https://events.diabetes.org/p/s/a-randomized-controlled-trial-using-continuous-glucose-monitoring-cgm-to-guide-food-choices-and-diabetes-self-care-in-people-with-type-2-diabetes-not-taking-insulin-2462
https://events.diabetes.org/p/s/remote-cgm-monitoring-in-people-with-type-2-diabetes-t2d-in-an-under-resourced-setting-2463
https://events.diabetes.org/p/s/the-association-of-continuous-glucose-monitoring-metrics-with-hospital-related-clinical-outcomes-2464
https://events.diabetes.org/p/s/implementation-of-an-ehr-integrated-hospital-wide-cgm-protocol-for-insulin-dosing-2465
https://events.diabetes.org/p/s/real-time-continuous-glucose-monitoring-guided-glucose-management-in-hospitalized-patients-with-diabetes-receiving-short-term-continuous-subcutaneous-insulin-infusion-a-randomized-clinical-trial-2466
https://events.diabetes.org/p/s/effectiveness-of-continuous-glucose-monitoring-on-short-term-in-hospital-mortality-among-frail-critically-ill-patients-with-covid-19-an-exploratory-prospective-randomized-open-label-parallel-single-ce-2467
https://events.diabetes.org/p/s/a1c-change-after-initiating-continuous-glucose-monitoring-cgm-for-people-with-diabetes-in-a-large-us-managed-health-care-plan-2468
https://events.diabetes.org/p/s/assessing-the-current-state-of-diabetes-care-in-long-term-facilities-using-continuous-glucose-monitoring-2469
https://events.diabetes.org/p/s/a1c-and-average-glucose-discordance-personalized-a1c-improves-the-discrepancy-particularly-in-black-individuals-2470
https://events.diabetes.org/p/s/a-randomized-clinical-trial-of-automated-insulin-delivery-in-elderly-with-type-1-diabetes-2471
https://events.diabetes.org/p/s/liver-health-in-adolescents-with-youth-onset-type-2-diabetes-2472
https://events.diabetes.org/p/s/clustering-pediatric-type-2-diabetes-patients-exposes-differential-responses-to-therapeutic-interventions-2473
https://events.diabetes.org/p/s/increased-insulin-secretion-and-decreased-insulin-sensitivity-in-south-asian-youth-without-diabetes-2474
https://events.diabetes.org/p/s/obesity-is-associated-with-increased-clearance-and-reduced-drug-exposure-to-metformin-in-youth-with-type-2-diabetes-2475
https://events.diabetes.org/p/s/dynamics-of-treatment-regimens-and-glycemic-outcomes-in-100000-children-from-international-pediatric-diabetes-registries-2476
https://events.diabetes.org/p/s/multiomic-profiling-of-extended-honeymoon-unveils-new-therapeutic-targets-2477
https://events.diabetes.org/p/s/narrow-variation-of-glucose-inflection-points-ips-during-progression-to-type-1-diabetes-t1d-stratified-by-demographic-and-genetic-differences-in-autoantibody-positive-ab-plus-individuals-2478
https://events.diabetes.org/p/s/clinical-and-immunologic-features-differ-in-children-at-type-1-diabetes-onset-by-ethnicity-2479
https://events.diabetes.org/p/s/panel-discussion-2480
https://events.diabetes.org/p/s/treat-obesity-first-2481
https://events.diabetes.org/p/s/its-still-about-glucose-until-proven-otherwise-2482
https://events.diabetes.org/p/s/prevent-future-complications-2483
https://events.diabetes.org/p/s/achieve-remission-2484
https://events.diabetes.org/p/s/question-and-discussion-period-2485
https://events.diabetes.org/p/s/is-there-a-place-for-sglt-inhibition-in-type-1-diabetes-mellitus-2486
https://events.diabetes.org/p/s/is-there-a-place-for-mra-in-type-1-diabetes-mellitus-2487
https://events.diabetes.org/p/s/is-there-a-place-for-glp-1ra-in-type-1-diabetes-mellitus-2488
https://events.diabetes.org/p/s/the-lived-experience-2489
https://events.diabetes.org/p/s/panel-discussion-2490
https://events.diabetes.org/p/s/anesthesia-perspective-2491
https://events.diabetes.org/p/s/gastroenterology-perspective-2492
https://events.diabetes.org/p/s/endocrinology-perspective-2493
https://events.diabetes.org/p/s/question-and-discussion-period-2494
https://events.diabetes.org/p/s/is-primary-care-the-best-place-for-continuous-glucose-monitoring-cgm-initiation-2495
https://events.diabetes.org/p/s/diabetes-care-and-education-specialists-as-technology-champions-2496
https://events.diabetes.org/p/s/what-is-the-role-of-primary-care-practices-in-automated-insulin-delivery-2497
https://events.diabetes.org/p/s/patient-perspective-2498
https://events.diabetes.org/p/s/question-and-discussion-period-2499
https://events.diabetes.org/p/s/equitable-science-is-good-science-the-importance-of-diversity-from-the-pis-perspective-2500
https://events.diabetes.org/p/s/the-importance-of-diversity-from-the-regulatory-perspective-2501
https://events.diabetes.org/p/s/the-importance-of-diversity-from-the-advocacy-perspective-2502
https://events.diabetes.org/p/s/lack-of-equitable-representation-in-clinical-trials-compounds-disparities-2503
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-2504
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-2505
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-2506
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-2507
https://events.diabetes.org/p/s/question-and-discussion-period-2509
https://events.diabetes.org/p/s/first-do-no-harm-potential-fetal-programming-perils-with-maternal-metformin-use-in-pregnancy-2510
https://events.diabetes.org/p/s/effects-of-metformin-and-maternal-overnutrition-on-fetal-pancreas-and-islet-mitochondria-in-nonhuman-primates-2511
https://events.diabetes.org/p/s/effects-and-consequences-of-metformin-action-in-the-fetal-liver-from-nonhuman-primates-and-sheep-2512
https://events.diabetes.org/p/s/evidence-for-long-term-effects-of-in-utero-metformin-exposure-where-do-we-go-from-here-2513
https://events.diabetes.org/p/s/question-and-discussion-period-2514
https://events.diabetes.org/p/s/time-in-range-and-beyond-time-in-range-which-continuous-glucose-monitoring-metrics-to-follow-during-pregnancy-and-what-should-the-targets-be-2515
https://events.diabetes.org/p/s/confronting-a1c-in-the-era-of-continuous-glucose-monitoring-cgm-2516
https://events.diabetes.org/p/s/glycemic-targets-in-early-vs-late-gestation-as-a-predictor-of-fetal-overgrowth-2517
https://events.diabetes.org/p/s/time-in-range-vs-conventional-fastingpostprandial-targets-which-should-take-precedence-2518
https://events.diabetes.org/p/s/question-and-discussion-period-2519
https://events.diabetes.org/p/s/lipid-lowering-drugs-the-good-the-bad-and-the-not-that-ugly-2520
https://events.diabetes.org/p/s/pharmacology-overview-which-types-of-medications-are-most-likely-to-cause-problems-in-pregnancy-2521
https://events.diabetes.org/p/s/ace-inhibitors-and-arbs-timing-is-everything-2522
https://events.diabetes.org/p/s/glp-1-receptor-agonists-how-should-we-counsel-our-patients-2523
https://events.diabetes.org/p/s/how-is-precision-medicine-changing-the-paradigm-in-type-1-diabetes-2524
https://events.diabetes.org/p/s/how-is-precision-medicine-changing-the-paradigm-in-type-2-diabetes-2525
https://events.diabetes.org/p/s/how-is-precision-medicine-changing-the-paradigm-in-monogenic-diabetes-2526
https://events.diabetes.org/p/s/question-and-discussion-period-2527
https://events.diabetes.org/p/s/new-insulin-formulations-2528
https://events.diabetes.org/p/s/fixed-ratio-insulin-combinations-2529
https://events.diabetes.org/p/s/sglt2-inhibitors-2530
https://events.diabetes.org/p/s/glp-1-receptor-agonists-2531
https://events.diabetes.org/p/s/question-and-discussion-period-2532
https://events.diabetes.org/p/s/glp-1-receptor-agonists-and-the-respiratory-outcomes-in-patients-with-asthma-and-chronic-obstructive-pulmonary-disease-2533
https://events.diabetes.org/p/s/what-do-we-know-about-diabetes-and-the-lung-2534
https://events.diabetes.org/p/s/immunometabolic-pathways-in-lung-inflammation-novel-therapeutic-opportunities-2535
https://events.diabetes.org/p/s/insulin-resistance-as-a-treatable-trait-in-asthma-2536
https://events.diabetes.org/p/s/its-still-a-lot-of-work-mitigating-diabetes-technology-burnout-2537
https://events.diabetes.org/p/s/psychosocial-considerations-of-automated-insulin-delivery-2538
https://events.diabetes.org/p/s/question-and-discussion-period-2539
https://events.diabetes.org/p/s/ehr-based-tools-to-overcome-therapeutic-inertia-and-improve-health-equity-in-diabetes-technology-prescriptions-2540
https://events.diabetes.org/p/s/screening-for-type-1-diabetes-from-evidence-2541
https://events.diabetes.org/p/s/the-michigan-collaborative-for-type-2-diabetes-2542
https://events.diabetes.org/p/s/reality-check-preventing-diabetes-in-the-real-world-early-findings-of-the-real-world-effectiveness-of-interventions-of-the-type-2-diabetes-mellitus-prevention-network-2543
https://events.diabetes.org/p/s/question-and-discussion-period-2544
https://events.diabetes.org/p/s/virtual-peer-groups-in-adolescents-and-young-adults-with-type-1-diabetes-2545
https://events.diabetes.org/p/s/improving-diabetes-outcomes-and-reducing-inequities-through-collaboration-perspective-from-the-t1d-exchange-2547
https://events.diabetes.org/p/s/disparities-in-diabetes-prevalence-and-management-2548
https://events.diabetes.org/p/s/question-and-discussion-period-2549
https://events.diabetes.org/p/s/the-genetics-of-youth-onset-type-2-diabetes-where-are-we-and-what-lies-ahead-2550
https://events.diabetes.org/p/s/diabetes-care-technology-use-and-barriers-in-youth-onset-type-2-diabetes-2551
https://events.diabetes.org/p/s/new-insights-into-pathophysiology-and-screening-of-early-microvascular-complications-in-youth-onset-type-2-diabetes-2552
https://events.diabetes.org/p/s/advances-in-pathophysiology-and-novel-treatments-in-youth-onset-type-2-diabetes-2553
https://events.diabetes.org/p/s/question-and-discussion-period-2554
https://events.diabetes.org/p/s/patient-perspective-2555
https://events.diabetes.org/p/s/continuous-glucose-monitoring-cgm-and-early-stage-type-1-diabetes-2556
https://events.diabetes.org/p/s/pediatric-type-1-diabetes-screening-programs-2557
https://events.diabetes.org/p/s/the-economics-of-early-stage-type-1-diabetes-detection-and-treatment-2558
https://events.diabetes.org/p/s/question-and-discussion-period-2559
https://events.diabetes.org/p/s/innovations-in-diabetes-education-app-based-diabetes-technology-education-and-more-2560
https://events.diabetes.org/p/s/what-is-new-in-treatment-of-preschool-children-with-type-1-diabetes-mellitus-2561
https://events.diabetes.org/p/s/inpatient-pediatric-diabetes-technology-use-2562
https://events.diabetes.org/p/s/rethinking-first-line-therapy-in-pediatric-type-2-diabetes-2563
https://events.diabetes.org/p/s/increasing-insulin-pump-utilization-in-public-insured-patients-2564
https://events.diabetes.org/p/s/data-driven-predictions-to-determine-high-risk-patients-with-type-1-diabetes-2565
https://events.diabetes.org/p/s/current-approaches-to-addressing-racial-equity-insights-from-the-t1d-exchange-q1-collaborative-2566
https://events.diabetes.org/p/s/question-and-discussion-period-2567
https://events.diabetes.org/p/s/endotypes-clusters-fuzzy-clusters-whatever-2568
https://events.diabetes.org/p/s/beyond-autoantibody-number-and-hla-2569
https://events.diabetes.org/p/s/heterogeneity-creates-therapeutic-challenges-in-t1d-interventions-and-clinical-trials-2570
https://events.diabetes.org/p/s/question-and-discussion-period-2571
https://events.diabetes.org/p/s/diabetes-prevention-what-do-we-know-now-that-we-didnt-know-20-years-ago-2572
https://events.diabetes.org/p/s/multifactorial-cardiovascular-risk-reduction-the-coordinate-diabetes-implementation-example-2573
https://events.diabetes.org/p/s/using-telehealth-to-improve-diabetes-control-in-real-world-practice-2574
https://events.diabetes.org/p/s/commentary-and-future-direction-2575
https://events.diabetes.org/p/s/question-and-discussion-period-2576
https://events.diabetes.org/p/s/how-should-we-diagnose-early-gestational-diabetes-mellitus-2577
https://events.diabetes.org/p/s/epidemiology-of-early-gestational-diabetes-mellitus-2578
https://events.diabetes.org/p/s/pathophysiology-of-early-gestational-diabetes-mellitus-2579
https://events.diabetes.org/p/s/further-considerations-for-the-early-diagnosis-of-gestational-diabetes-mellitus-2580
https://events.diabetes.org/p/s/panel-discussion-2581
https://events.diabetes.org/p/s/heterogeneity-of-diabetes-a-global-perspective-2582
https://events.diabetes.org/p/s/heterogeneity-in-treatment-strategies-for-diabetes-2583
https://events.diabetes.org/p/s/heterogeneity-in-type-2-diabetes-2584
https://events.diabetes.org/p/s/heterogeneity-from-social-determinants-of-health-2585
https://events.diabetes.org/p/s/team-based-care-2586
https://events.diabetes.org/p/s/team-based-care-2587
https://events.diabetes.org/p/s/team-based-care-2588
https://events.diabetes.org/p/s/team-based-care-2589
https://events.diabetes.org/p/s/question-and-discussion-period-2590
https://events.diabetes.org/p/s/therapeutic-inertia-is-not-just-about-medications-lifestyle-counseling-in-diabetes-2591
https://events.diabetes.org/p/s/therapeutic-inertia-in-treatment-of-diabetes-are-we-making-progress-2592
https://events.diabetes.org/p/s/the-other-end-of-the-spectrum-therapeutic-inertia-in-treatment-of-hypoglycemia-2593
https://events.diabetes.org/p/s/when-patients-decline-diabetes-treatment-recommendations-2594
https://events.diabetes.org/p/s/question-and-discussion-period-2595
https://events.diabetes.org/p/s/cardiometabolic-disease-introduction-and-united-kingdom-region-2596
https://events.diabetes.org/p/s/cardiometabolic-disease-in-arabian-gulf-region-2597
https://events.diabetes.org/p/s/cardiovascular-disease-in-india-2598
https://events.diabetes.org/p/s/cardiovascular-disease-in-china-2599
https://events.diabetes.org/p/s/question-and-discussion-period-2600
https://events.diabetes.org/p/s/team-based-care-2601
https://events.diabetes.org/p/s/team-based-care-2602
https://events.diabetes.org/p/s/team-based-care-2603
https://events.diabetes.org/p/s/team-based-care-2604
https://events.diabetes.org/p/s/team-based-care-2605
https://events.diabetes.org/p/s/team-based-care-2606
https://events.diabetes.org/p/s/economic-costs-of-diabetes-in-the-united-states-2607
https://events.diabetes.org/p/s/economic-costs-of-diabetes-in-the-united-states-2608
https://events.diabetes.org/p/s/question-and-discussion-period-2609
https://events.diabetes.org/p/s/complications-and-discharge-protocol-2610
https://events.diabetes.org/p/s/epidemiology-global-trends-costs-mortality-2611
https://events.diabetes.org/p/s/welcome-and-introduction-rationale-and-methods-2612
https://events.diabetes.org/p/s/pathogenesis-and-diagnostic-criteria-2613
https://events.diabetes.org/p/s/management-acute-and-transition-protocol-2614
https://events.diabetes.org/p/s/question-and-discussion-period-2615
https://events.diabetes.org/p/s/primary-care-2616
https://events.diabetes.org/p/s/physical-activity-and-exercise-2617
https://events.diabetes.org/p/s/nutrition-2618
https://events.diabetes.org/p/s/introduction-new-nomenclature-and-team-based-care-2619
https://events.diabetes.org/p/s/endocrinology-and-obesity-2620
https://events.diabetes.org/p/s/team-based-care-2621
https://events.diabetes.org/p/s/epidemiologyhepatology-2622
https://events.diabetes.org/p/s/question-and-discussion-period-2623
https://events.diabetes.org/p/s/enhancing-diabetes-technology-accessibility-for-individuals-who-are-blind-or-have-low-vision-2624
https://events.diabetes.org/p/s/real-world-challenges-using-diabetes-technology-as-a-person-with-low-vision-2625
https://events.diabetes.org/p/s/fostering-inclusivity-advancing-diabetes-technology-for-deaf-and-hard-of-hearing-individuals-2626
https://events.diabetes.org/p/s/hacks-to-address-the-lack-of-diabetes-technology-accessible-for-deaf-and-hard-of-hearing-people-with-diabetes-2627
https://events.diabetes.org/p/s/question-and-discussion-period-2628
https://events.diabetes.org/p/s/the-growing-burden-of-diabetes-in-latin-america-and-the-caribbean-2629
https://events.diabetes.org/p/s/mexicos-experience-to-address-obesity-and-improve-diabetes-control-2630
https://events.diabetes.org/p/s/improving-diabetes-care-in-jamaica-2631
https://events.diabetes.org/p/s/question-and-discussion-period-2632
https://events.diabetes.org/p/s/translational-2633
https://events.diabetes.org/p/s/clinical-2635
https://events.diabetes.org/p/s/flow-results-by-baseline-use-of-sglt2i-2636
https://events.diabetes.org/p/s/flow-results-summary-and-clinical-implication-2637
https://events.diabetes.org/p/s/flow-cv-outcomes-2638
https://events.diabetes.org/p/s/current-treatment-strategies-unmet-medical-need-flow-rationale-2639
https://events.diabetes.org/p/s/flow-trial-design-and-baseline-characteristics-glycemic-control-and-body-weight-2640
https://events.diabetes.org/p/s/flow-results-independent-commentary-2641
https://events.diabetes.org/p/s/flow-kidney-outcomes-2642
https://events.diabetes.org/p/s/question-and-discussion-period-2643
https://events.diabetes.org/p/s/step-hfpef-dm-a-deep-dive-into-the-metabolic-outcomes-2645
https://events.diabetes.org/p/s/step-hfpef-and-step-hfpef-dm-trials-why-and-what-2646
https://events.diabetes.org/p/s/clinical-implications-of-the-step-hfpef-program-and-defining-the-next-steps-forward-2647
https://events.diabetes.org/p/s/discussant-2648
https://events.diabetes.org/p/s/question-and-discussion-period-2649
https://events.diabetes.org/p/s/diabetes-and-organ-transplantation-an-overview-2651
https://events.diabetes.org/p/s/management-of-diabetes-following-liver-transplantation-2652
https://events.diabetes.org/p/s/question-and-discussion-period-2653
https://events.diabetes.org/p/s/study-results-ii-primary-efficacy-safety-and-quality-of-life-outcomes-2654
https://events.diabetes.org/p/s/study-results-iii-effect-of-inhaled-insulin-degludec-compared-with-automated-insulin-delivery-and-in-subgroups-according-to-participant-characteristics-2655
https://events.diabetes.org/p/s/inhaled-insulins-history-and-study-rationale-2656
https://events.diabetes.org/p/s/critique-of-study-design-and-results-2657
https://events.diabetes.org/p/s/study-results-i-comparison-of-inhaled-insulin-vs-rapid-acting-analogue-insulin-in-users-of-automated-insulin-delivery-or-multiple-daily-insulin-injections-during-standardized-in-clinic-meal-challenges-2658
https://events.diabetes.org/p/s/use-of-inhaled-insulin-in-clinical-practice-2659
https://events.diabetes.org/p/s/study-methods-and-participant-baseline-characteristics-2660
https://events.diabetes.org/p/s/question-and-discussion-period-2661
https://events.diabetes.org/p/s/study-background-and-rationale-2662
https://events.diabetes.org/p/s/study-results-2663
https://events.diabetes.org/p/s/discussion-of-results-and-conclusions-2664
https://events.diabetes.org/p/s/study-methods-2665
https://events.diabetes.org/p/s/question-and-discussion-period-2666
https://events.diabetes.org/p/s/attempt-study-renal-and-glycemic-outcomes-2667
https://events.diabetes.org/p/s/attempt-study-commentary-sglt2i-in-youth-with-type-1-diabetes-2668
https://events.diabetes.org/p/s/rationale-for-sglt2i-adjunctive-therapy-in-youth-with-type-1-diabetes-2669
https://events.diabetes.org/p/s/attempt-study-patient-perspectives-of-sglt2i-for-diabetes-management-2670
https://events.diabetes.org/p/s/question-and-discussion-period-2671
https://events.diabetes.org/p/s/rationale-for-and-design-of-the-catalyst-trial-2672
https://events.diabetes.org/p/s/clinical-implications-of-the-catalyst-trial-part-1-2673
https://events.diabetes.org/p/s/pathologic-mechanisms-of-hypercortisolism-in-type-2-diabetes-2674
https://events.diabetes.org/p/s/the-spectrum-of-hypercortisolism-an-evolution-of-understanding-2675
https://events.diabetes.org/p/s/results-of-the-catalyst-trial-part-1-2676
https://events.diabetes.org/p/s/question-and-discussion-period-2677
https://events.diabetes.org/p/s/surmount-osa-efficacy-and-safety-2678
https://events.diabetes.org/p/s/cardiometabolic-consequences-of-osa-towards-personalized-treatment-2679
https://events.diabetes.org/p/s/putting-surmount-osa-results-in-context-and-implications-regarding-treatment-of-patients-with-obesity-related-osa-2680
https://events.diabetes.org/p/s/tirzepatide-and-surmount-osa-rationale-hypotheses-and-study-design-2681
https://events.diabetes.org/p/s/current-therapeutic-landscape-for-treating-sleep-apnea-and-potential-role-of-incretins-2682
https://events.diabetes.org/p/s/hands-on-simulation-of-working-with-deaf-populations-and-asl-interpreters-2683
https://events.diabetes.org/p/s/language-access-disparity-the-link-between-being-deaf-and-having-diabetes-2684
https://events.diabetes.org/p/s/hands-on-simulation-of-working-with-deaf-populations-and-asl-interpreters-2685
https://events.diabetes.org/p/s/best-practices-for-working-with-deaf-populations-and-asl-interpreters-2686
https://events.diabetes.org/p/s/question-and-discussion-period-2687
https://events.diabetes.org/p/s/rebuttal-2688
https://events.diabetes.org/p/s/using-race-and-ethnicity-based-cut-points-has-the-potential-to-increase-health-disparities-in-the-diagnosis-of-diabetes-2689
https://events.diabetes.org/p/s/rebuttal-2690
https://events.diabetes.org/p/s/using-race-and-ethnicity-based-cut-points-has-the-potential-to-reduce-health-disparities-in-the-diagnosis-of-diabetes-2691
https://events.diabetes.org/p/s/introduction-2692
https://events.diabetes.org/p/s/question-and-discussion-period-2693
https://events.diabetes.org/p/s/moving-beyond-insulin-and-metformin-learning-from-adult-experience-to-improve-care-for-youth-with-type-2-diabetes-2694
https://events.diabetes.org/p/s/role-of-antiobesity-pharmacotherapy-in-youth-with-and-at-risk-for-type-2-diabetes-2695
https://events.diabetes.org/p/s/lessons-learnt-from-epidemiology-of-diabetes-in-south-asians-the-kelly-west-lecture-2024-2696
https://events.diabetes.org/p/s/comparison-of-screening-pathways-of-advanced-fibrosis-due-to-masld-in-diabetology-2697
https://events.diabetes.org/p/s/the-impact-of-type-2-diabetes-t2d-on-the-outcomes-of-liver-transplantation-in-the-united-states-from-2007-2022-2698
https://events.diabetes.org/p/s/association-of-diabetic-complications-and-various-comorbidities-with-major-adverse-cardiovascular-events-in-type-2-diabetes-and-their-development-over-time-a-danish-registry-based-case-control-study-2699
https://events.diabetes.org/p/s/performance-of-fib-4-score-in-predicting-mortality-among-patients-with-nonalcoholic-2700
https://events.diabetes.org/p/s/association-of-nonalcoholic-fatty-liver-disease-and-liver-fibrosis-with-cardiovascular-disease-all-cause-and-cause-specific-mortality-in-individuals-with-type-2-diabetes-2701
https://events.diabetes.org/p/s/metabolic-dysfunction-associated-steatotic-liver-disease-and-nonalcoholic-fatty-liver-disease-have-similar-clinical-profiles-and-mortality-2702
https://events.diabetes.org/p/s/food-insecurity-patterns-and-mental-health-among-youth-and-young-adults-with-diabetes-2703
https://events.diabetes.org/p/s/social-vulnerability-rurality-and-prevalence-of-obesity-and-inactivity-in-us-counties-2004-2019-2704
https://events.diabetes.org/p/s/association-of-geographic-factors-with-use-of-metabolic-disease-specialty-care-among-adults-with-type-2-diabetes-and-ascvd-2705
https://events.diabetes.org/p/s/direct-and-indirect-effects-of-redlining-on-diabetes-prevalence-via-food-access-2706
https://events.diabetes.org/p/s/impact-of-carbohydrate-restricted-nutrition-therapy-and-continuous-remote-care-among-people-with-type-2-diabetes-in-rural-vs-urban-areas-2707
https://events.diabetes.org/p/s/assessing-connection-to-outpatient-care-among-patients-screening-positive-for-previously-undiagnosed-diabetes-in-the-emergency-department-2708
https://events.diabetes.org/p/s/gut-microbiota-blood-metabolome-and-incident-type-2-diabetes-in-us-hispanics-2709
https://events.diabetes.org/p/s/gut-microbial-metabolism-of-bile-acids-mediterranean-diet-and-cardiometabolic-risk-in-the-direct-plus-trial-2710
https://events.diabetes.org/p/s/metabolomics-profiles-underlying-development-of-microvascular-complications-in-the-diabetes-prevention-project-outcome-study-dppos-2711
https://events.diabetes.org/p/s/sex-differences-in-metabolomics-and-risk-of-coronary-heart-disease-in-type-2-diabetes-2712
https://events.diabetes.org/p/s/human-genetic-study-of-triglyceride-to-hdl-c-ratio-adjusted-for-bmi-identifies-new-insulin-resistance-associated-loci-genes-pathways-and-disease-subtypes-2713
https://events.diabetes.org/p/s/ada-presidents-select-abstract-discovering-stimulatory-state-specific-type-2-diabetes-gwas-mechanisms-with-single-cell-multiomics-on-ipsc-derived-fibro-adipogenic-progenitor-cell-villages-2714
https://events.diabetes.org/p/s/differential-cell-type-specific-gene-expression-and-chromatin-accessibility-by-type-2-diabetes-status-and-physical-activity-levels-in-human-skeletal-muscle-2716
https://events.diabetes.org/p/s/widespread-age-associated-changes-in-the-chromatin-architecture-of-skeletal-muscle-cell-types-2717
https://events.diabetes.org/p/s/massively-parallel-characterization-of-thousands-of-type-2-diabetes-associated-variants-in-multiple-cell-types-nominates-candidate-causal-regulatory-alleles-and-mechanisms-2718
https://events.diabetes.org/p/s/common-variant-polygenic-risk-score-influences-penetrance-of-rare-variants-in-monogenic-diabetes-genes-2719
https://events.diabetes.org/p/s/single-nucleus-multiomics-profiling-across-49-individuals-of-hispanic-ancestry-reveals-cell-specific-skeletal-muscle-insulin-responsive-gene-regulatory-signatures-2720
https://events.diabetes.org/p/s/associations-of-combined-genetic-and-lifestyle-risks-with-incident-type-2-diabetes-in-the-uk-biobank-2721
https://events.diabetes.org/p/s/whole-genome-sequencing-identifies-a-rare-noncoding-variant-proximal-to-metrn-associated-with-hba1c-levels-2722
https://events.diabetes.org/p/s/initial-eqtl-discovery-in-individual-pancreatic-cell-types-from-the-human-pancreas-analysis-program-2723
https://events.diabetes.org/p/s/population-scale-single-nucleus-skeletal-muscle-chromatin-dynamics-and-nucleosome-positioning-in-the-context-of-type-2-diabetes-2724
https://events.diabetes.org/p/s/genetic-variation-and-time-to-progression-in-tn10-teplizumab-2725
https://events.diabetes.org/p/s/genetic-predictors-of-response-to-oral-insulin-for-type-1-diabetes-prevention-2726
https://events.diabetes.org/p/s/epigenome-wide-discovery-of-the-maternal-effect-in-type-1-diabetes-risk-2727
https://events.diabetes.org/p/s/genome-wide-crispr-screen-identified-that-alternative-splicing-regulates-in-insulin-secretion-2728
https://events.diabetes.org/p/s/question-and-discussion-period-2729
https://events.diabetes.org/p/s/a-pragmatic-action-based-framework-to-address-global-inequities-in-diabetes-2730
https://events.diabetes.org/p/s/adapting-the-nimhd-research-framework-for-diabetes-disparities-across-the-lifespan-2731
https://events.diabetes.org/p/s/applying-implementation-science-frameworks-to-advance-diabetes-prevention-efforts-2732
https://events.diabetes.org/p/s/national-policy-frameworks-for-addressing-type-2-diabetes-2733
https://events.diabetes.org/p/s/question-and-discussion-period-2734
https://events.diabetes.org/p/s/type-2-diabetes-genome-wide-association-studies-in-underrepresented-populations-2735
https://events.diabetes.org/p/s/type-2-diabetes-global-genetics-initiative-2736
https://events.diabetes.org/p/s/type-2-diabetes-genome-wide-association-study-cluster-partitioning-2737
https://events.diabetes.org/p/s/type-1-diabetes-multiancestry-genome-wide-association-study-2738
https://events.diabetes.org/p/s/question-and-discussion-period-2739
https://events.diabetes.org/p/s/diabetes-and-complications-in-veterans-2740
https://events.diabetes.org/p/s/telehealth-interventions-to-improve-outcomes-in-veterans-with-diabetes-2742
https://events.diabetes.org/p/s/mental-health-and-diabetes-in-veterans-2743
https://events.diabetes.org/p/s/question-and-discussion-period-2744
https://events.diabetes.org/p/s/working-to-prevent-diabetes-workplace-polices-in-canada-that-promote-health-2746
https://events.diabetes.org/p/s/state-level-policies-that-promote-diabetes-prevention-and-successful-disease-management-2748
https://events.diabetes.org/p/s/genetic-convergence-in-rare-and-common-diabetes-hnf1a-and-rfx6-mpra-2749
https://events.diabetes.org/p/s/diabetes-genetic-convergence-rare-to-common-variants-in-networks-2750
https://events.diabetes.org/p/s/single-cell-transcriptomics-networks-genetic-convergence-hnf1a-2751
https://events.diabetes.org/p/s/leveraging-omics-in-the-study-of-type-2-diabetes-in-underrepresented-populations-2752
https://events.diabetes.org/p/s/genome-wide-association-study-from-variant-to-function-2753
https://events.diabetes.org/p/s/genome-wide-association-study-functional-follow-up-at-a-single-locus-2754
https://events.diabetes.org/p/s/ada-chief-executive-officer-and-chairman-of-the-board-fireside-chat-2755
https://events.diabetes.org/p/s/meeting-people-where-they-are-improving-diabetes-care-and-outcomes-through-education-and-collaboration-2756
https://events.diabetes.org/p/s/lessons-learned-diabetes-education-for-one-and-for-all-2757
https://events.diabetes.org/p/s/question-and-discussion-period-2758
https://events.diabetes.org/p/s/brown-fat-is-a-regulator-of-energy-balance-in-humans-2759
https://events.diabetes.org/p/s/rebuttal-2760
https://events.diabetes.org/p/s/rebuttal-2761
https://events.diabetes.org/p/s/the-role-of-bat-in-obesity-and-weight-loss-2762
https://events.diabetes.org/p/s/a-pka-to-mtorc1-signaling-axis-controls-metabolic-homeostasis-via-phosphorylation-of-raptor-2763
https://events.diabetes.org/p/s/neddylation-targets-cullin-3-to-regulate-adipocyte-differentiation-2764
https://events.diabetes.org/p/s/gpsm1-regulates-er-ca2-plus-myosin-ii-axis-and-promotes-adipocyte-browning-and-metabolic-health-2765
https://events.diabetes.org/p/s/selenite-induced-glutathione-peroxidase-3-in-the-control-of-insulin-receptor-expression-in-adipocytes-2766
https://events.diabetes.org/p/s/glucose-regulation-of-adipose-tissue-browning-by-cbpp300-and-hdac3-mediated-reversible-acetylation-of-crebzf-2767
https://events.diabetes.org/p/s/skeletal-muscle-insulin-resistance-the-rate-limiting-step-in-humans-is-at-the-level-of-the-vasculature-2768
https://events.diabetes.org/p/s/reduced-apolipoprotein-c-i-truncation-is-associated-with-worsening-of-insulin-resistance-and-risk-of-diabetes-in-persons-with-impaired-glucose-tolerance-2769
https://events.diabetes.org/p/s/disrupted-circadian-glucocorticoid-rhythms-and-high-fat-diet-drive-obesity-and-insulin-resistance-through-distinct-mechanisms-2770
https://events.diabetes.org/p/s/depalmitoylation-inhibition-improves-glucose-tolerance-by-promoting-endothelial-insulin-transcytosis-2771
https://events.diabetes.org/p/s/loss-of-insulin-signaling-in-microglia-impairs-cellular-uptake-of-ass-and-neuroinflammatory-response-exacerbating-alzheimer-like-neuropathology-2772
https://events.diabetes.org/p/s/creg1-promotes-insulin-receptor-recycling-to-enhance-insulin-signaling-in-hepatocytes-2773
https://events.diabetes.org/p/s/pyruvate-carboxylase-flux-is-increased-in-the-type-1-diabetic-exocrine-pancreas-2774
https://events.diabetes.org/p/s/fbln7-in-pre-adipocytes-promotes-adipose-tissue-fibrosis-and-disrupts-metabolic-homeostasis-in-obesity-2775
https://events.diabetes.org/p/s/manganese-regulates-hepatic-insulin-sensitivity-and-glucose-tolerance-2776
https://events.diabetes.org/p/s/adipose-stromal-cells-increase-insulin-sensitivity-and-decrease-liver-gluconeogenesis-in-a-type-1-dm-mouse-model-2777
https://events.diabetes.org/p/s/nod1-plays-a-causal-role-in-western-diet-induced-insulin-resistance-and-glucose-intolerance-in-microbiota-deficient-conditions-2778
https://events.diabetes.org/p/s/androgen-dependent-tissue-factor-pathway-inhibitor-regulating-protein-adtrp-regulates-macrophage-polarization-and-migration-to-adipocytes-2779
https://events.diabetes.org/p/s/a-multiomics-approach-to-identify-genes-important-for-the-regulation-of-antidiabetic-and-anti-inflammatory-lipids-2780
https://events.diabetes.org/p/s/maladaptive-sensory-plasticity-via-a2d1-subunit-promotes-adipose-tissue-lipolysis-after-spinal-cord-injury-2781
https://events.diabetes.org/p/s/divergent-roles-of-mettl14-mediated-m6a-in-regulating-brown-and-white-adipose-tissue-transcriptomes-and-systemic-metabolism-2782
https://events.diabetes.org/p/s/matrix-metalloprotease-2-as-a-novel-regulator-of-glucose-utilization-by-adipocytes-and-high-fat-diet-induced-glucose-intolerance-2783
https://events.diabetes.org/p/s/beta-cell-sf1-as-a-thermogenic-regulator-against-diet-induced-obesity-in-mice-elucidating-its-role-in-islet-adipose-cross-talk-2784
https://events.diabetes.org/p/s/cell-intrinsic-alterations-in-mirna-expression-and-secretion-in-muscle-in-type-2-diabetes-2785
https://events.diabetes.org/p/s/insulin-regulates-exosomal-microrna-secretion-from-adipocytes-completing-a-novel-feedback-loop-2786
https://events.diabetes.org/p/s/endothelial-cell-regeneration-by-secretome-secreted-from-p53-silenced-bone-marrow-derived-bmscs-2787
https://events.diabetes.org/p/s/a-small-intestinal-bile-acid-modulates-the-gut-microbiome-to-improve-glucose-regulation-following-bariatric-surgery-2788
https://events.diabetes.org/p/s/relationship-between-obesity-sarcopenia-and-insulin-resistance-in-older-adults-2789
https://events.diabetes.org/p/s/pi3k-inhibition-with-single-dose-alpelisib-as-a-model-of-insulin-resistance-in-healthy-adults-2790
https://events.diabetes.org/p/s/type-a-insulin-resistance-can-be-misdiagnosed-as-type-1-or-type-2-diabetes-a-cautionary-tale-2791
https://events.diabetes.org/p/s/sequential-measurements-of-insulin-resistance-in-the-assessment-of-individuals-participating-in-diabetes-prevention-programs-2792
https://events.diabetes.org/p/s/question-and-discussion-period-2793
https://events.diabetes.org/p/s/new-metabolite-id-in-metabolomics-2794
https://events.diabetes.org/p/s/subcellular-metabolomics-for-mapping-nutrient-responses-2795
https://events.diabetes.org/p/s/nuclear-magnetic-resonance-based-metabolism-2796
https://events.diabetes.org/p/s/stable-isotope-tracing-in-vivo-and-imaging-mass-spec-2797
https://events.diabetes.org/p/s/question-and-discussion-period-2798
https://events.diabetes.org/p/s/regulation-of-glut4-by-tug-proteins-2799
https://events.diabetes.org/p/s/control-of-muscle-glucose-metabolism-by-the-adipokine-isthmin-1-2800
https://events.diabetes.org/p/s/control-of-glucose-transport-by-novel-insulin-signaling-pathways-2801
https://events.diabetes.org/p/s/linking-mitochondrial-energetics-to-insulin-sensitivity-and-glucose-metabolism-2802
https://events.diabetes.org/p/s/question-and-discussion-period-2803
https://events.diabetes.org/p/s/mitochondrial-pyruvate-transport-and-liver-metabolism-2804
https://events.diabetes.org/p/s/fumarate-and-mitochondrial-energetics-2805
https://events.diabetes.org/p/s/lipid-transport-and-metabolism-2806
https://events.diabetes.org/p/s/insulin-signaling-and-bile-acid-transport-and-metabolism-2807
https://events.diabetes.org/p/s/question-and-discussion-period-2808
https://events.diabetes.org/p/s/mitochondrial-phospholipid-metabolism-2810
https://events.diabetes.org/p/s/structurefunction-of-regulators-of-lipid-droplet-formation-2811
https://events.diabetes.org/p/s/mitochondria-association-with-lipid-droplets-regulation-and-function-2812
https://events.diabetes.org/p/s/question-and-discussion-period-2813
https://events.diabetes.org/p/s/mitochondrial-branched-chain-amino-acid-oxidation-and-metabolism-2814
https://events.diabetes.org/p/s/pleotropic-effects-of-exercise-on-amino-acid-and-fat-metabolism-in-metabolic-disease-2815
https://events.diabetes.org/p/s/amino-acid-signaling-and-glucose-regulation-2816
https://events.diabetes.org/p/s/amino-acid-metabolism-and-brown-fat-activation-2817
https://events.diabetes.org/p/s/question-and-discussion-period-2818
https://events.diabetes.org/p/s/infection-does-not-equal-causation-unraveling-the-complicated-relationship-between-sars-cov-2-and-diabetes-2819
https://events.diabetes.org/p/s/rebuttal-2820
https://events.diabetes.org/p/s/rebuttal-2821
https://events.diabetes.org/p/s/sars-cov-2-infects-human-beta-cells-and-compromises-beta-cell-function-2822
https://events.diabetes.org/p/s/introduction-2823
https://events.diabetes.org/p/s/question-and-discussion-period-2824
https://events.diabetes.org/p/s/islet-cell-targeting-using-a-znt8-ab-for-beta-cell-mass-imaging-and-regeneration-2825
https://events.diabetes.org/p/s/nanoparticle-targeting-of-the-beta-cell-2826
https://events.diabetes.org/p/s/zinc-targeting-of-the-beta-cell-2827
https://events.diabetes.org/p/s/signaling-mechanisms-underlying-islet-compensation-in-a-novel-mouse-model-of-ss-cell-replication-deficiency-2828
https://events.diabetes.org/p/s/slc7a2-dependent-arginine-transport-in-a-cells-signals-arginine-tone-to-regulate-insulin-secretion-2829
https://events.diabetes.org/p/s/a-novel-strategy-for-detecting-in-vivo-functional-ss-cells-using-positron-emission-tomography-pet-imaging-2830
https://events.diabetes.org/p/s/investigating-the-mechanisms-of-cross-talk-between-endocrine-beta-cells-and-pericytes-in-pancreatic-islets-2831
https://events.diabetes.org/p/s/revelations-in-regulation-sodiumpotassium-atpase-subunit-control-of-beta-cell-cation-handling-and-insulin-secretion-2832
https://events.diabetes.org/p/s/ss-cell-dysfunction-and-mitochondrial-loss-occur-independently-of-insulitis-in-type-1-diabetes-pathogenesis-2833
https://events.diabetes.org/p/s/traf6-directs-a-noncanonical-role-for-innate-immune-signaling-in-pancreatic-ss-cells-2834
https://events.diabetes.org/p/s/acetylation-induces-a-sumoylation-phosphorylation-switch-to-enhance-mafa-transactivation-2835
https://events.diabetes.org/p/s/m6a-carrna-methylation-regulates-chromatin-state-and-transcription-in-islets-from-humans-with-type-2-diabetes-2836
https://events.diabetes.org/p/s/jnk3-a-key-downstream-target-of-incretin-responses-in-ss-cells-2837
https://events.diabetes.org/p/s/inflammation-induced-repression-of-insulin-production-by-targeting-its-mrna-to-stress-granules-via-adp-ribosylation-machinery-2838
https://events.diabetes.org/p/s/autophagy-promotes-islet-a-cell-function-by-maintaining-er-proteostasis-and-glucagon-production-2839
https://events.diabetes.org/p/s/parturition-event-regulates-endocrine-genesis-during-pancreas-differentiation-2840
https://events.diabetes.org/p/s/reduction-of-rna-editing-enzyme-adar1-in-human-islets-triggers-an-interferon-response-and-impairs-beta-cell-function-2841
https://events.diabetes.org/p/s/role-of-mef2a-in-beta-cell-differentiation-and-function-during-er-stress-2842
https://events.diabetes.org/p/s/chd3-helicase-modulates-pancreatic-ss-cell-function-in-absence-of-chd4-2843
https://events.diabetes.org/p/s/the-role-of-clic-like-chloride-channel-1-in-the-pancreatic-beta-cell-2844
https://events.diabetes.org/p/s/selective-loss-of-the-spliced-form-of-xbp1-causes-early-onset-diabetes-in-male-but-not-female-mice-2845
https://events.diabetes.org/p/s/enhanced-expression-of-zinc-finger-protein-385d-leads-to-type-2-diabetes-phenotype-in-human-beta-cells-2846
https://events.diabetes.org/p/s/regulation-of-pancreatic-beta-cell-survival-and-function-during-aging-2847
https://events.diabetes.org/p/s/ada-presidents-select-abstract-the-lonp1-protease-maintains-pancreatic-ss-cell-survival-by-governing-mitochondrial-protein-folding-2848
https://events.diabetes.org/p/s/transcriptional-activation-in-beta-cells-during-er-stress-linking-ipla2beta-with-nfkb-2849
https://events.diabetes.org/p/s/lc3-plus-extracellular-vesicles-evs-are-associated-with-altered-ss-cell-autophagy-islet-inflammation-and-diabetes-2850
https://events.diabetes.org/p/s/targeting-alpha-cells-to-treat-hypoglycemia-in-type-1-diabetes-2851
https://events.diabetes.org/p/s/perilipin-2-regulates-fatty-acid-trafficking-to-mitochondria-through-microlipophagy-in-beta-cells-2852
https://events.diabetes.org/p/s/the-alpha-catenin-cholesterol-biosynthesis-axis-regulates-tight-junction-formation-in-pancreatic-islets-2853
https://events.diabetes.org/p/s/question-and-discussion-period-2854
https://events.diabetes.org/p/s/transgenic-mouse-models-can-be-used-to-study-in-vivo-beta-cell-biology-2855
https://events.diabetes.org/p/s/of-mice-and-mankind-why-human-samples-are-necessary-to-advance-understanding-of-pancreatic-islet-pathophysiology-2856
https://events.diabetes.org/p/s/large-omics-data-sets-allow-for-key-insights-into-beta-cell-biology-2857
https://events.diabetes.org/p/s/a-new-open-resource-for-the-islet-community-towards-causality-by-connecting-omics-and-function-2858
https://events.diabetes.org/p/s/new-models-are-needed-for-optimal-testing-of-beta-cell-biology-2859
https://events.diabetes.org/p/s/contributions-of-the-microtubule-cytoskeleton-to-beta-cell-biology-2860
https://events.diabetes.org/p/s/cilia-microvilli-and-membrane-localized-glycolysis-in-the-beta-cell-2861
https://events.diabetes.org/p/s/metabolic-control-of-beta-cell-secretory-capacity-2862
https://events.diabetes.org/p/s/channeling-euglycemia-talk-1-channel-modulation-of-islet-hormone-secretion-and-glucose-homeostasis-2863
https://events.diabetes.org/p/s/impact-of-intracellular-calcium-flux-on-beta-cell-insulin-secretion-2864
https://events.diabetes.org/p/s/impacts-of-swell-channels-on-insulin-secretion-2865
https://events.diabetes.org/p/s/cholesterol-redistribution-in-pancreatic-beta-cells-a-flexible-path-to-regulate-insulin-secretion-2866
https://events.diabetes.org/p/s/glucose-metabolism-primes-lipogenesis-in-the-v-cell-through-epigenomic-signaling-2867
https://events.diabetes.org/p/s/lipoproteins-induced-beta-cell-impairment-and-impact-on-the-action-of-beta-cell-derived-exosomes-2868
https://events.diabetes.org/p/s/question-and-discussion-period-2869
https://events.diabetes.org/p/s/rebuttal-2872
https://events.diabetes.org/p/s/type-1-diabetes-progression-is-precipitated-by-immune-cells-2873
https://events.diabetes.org/p/s/introduction-2874
https://events.diabetes.org/p/s/question-and-discussion-period-2875
https://events.diabetes.org/p/s/stress-induced-pathways-in-beta-cells-increase-immune-perception-of-pancreatic-islets-implications-for-type-1-diabetes-2876
https://events.diabetes.org/p/s/dissecting-the-autoimmune-t-cell-repertoires-in-type-1-diabetes-2877
https://events.diabetes.org/p/s/beta-cell-adaptive-stress-response-and-immune-system-cross-talk-in-diabetes-2878
https://events.diabetes.org/p/s/defining-type-1-diabetes-endtypes-2879
https://events.diabetes.org/p/s/preclinical-characterization-of-mtx-101-a-novel-kirxcd8-targeting-bispecific-cd8-treg-modulator-2880
https://events.diabetes.org/p/s/pathogenic-action-of-gad65-autoantibodies-on-islet-function-in-type-1-diabetes-2881
https://events.diabetes.org/p/s/clonal-expansion-of-islet-reactive-cd4-t-cells-with-early-disease-progression-in-type-1-diabetes-2882
https://events.diabetes.org/p/s/diurnal-variation-of-islet-autoantibodies-in-established-type-1-diabetes-2883
https://events.diabetes.org/p/s/pancreatic-adverse-events-and-mortality-in-patients-with-immune-checkpoint-inhibitor-associated-diabetes-mellitus-a-10-year-follow-up-study-2884
https://events.diabetes.org/p/s/lipid-signaling-in-macrophages-contributes-to-inflammatory-transcriptome-in-immune-cells-2885
https://events.diabetes.org/p/s/rnaseq-analysis-reveals-temporal-dynamics-of-colonic-immune-response-to-high-fat-diet-in-mice-2886
https://events.diabetes.org/p/s/macrophage-ucp1-deficiency-inhibits-cold-exposure-induced-insulin-sensitivity-in-high-fat-diet-mice-2887
https://events.diabetes.org/p/s/sustained-tnf-a-transcription-triggered-in-obesity-through-h3k9k18-acetylation-is-associated-with-metabolic-impairments-2888
https://events.diabetes.org/p/s/sequential-islet-transplants-for-type-1-diabetes-do-not-cumulatively-increase-hepatic-portal-venous-pressure-2889
https://events.diabetes.org/p/s/immunoprivileged-hydrogels-recover-normoglycemia-for-extended-duration-in-immunocompetent-diabetic-animals-2890
https://events.diabetes.org/p/s/characterization-of-regenerative-adult-islet-progenitor-cells-from-human-pancreatic-tissue-2891
https://events.diabetes.org/p/s/overcoming-islet-scarcity-through-in-vitro-differentiation-of-human-pluripotent-stem-cells-2892
https://events.diabetes.org/p/s/effect-of-pd-l1-overexpression-on-autoreactive-t-cell-responses-toward-stem-cell-derived-beta-cells-2893
https://events.diabetes.org/p/s/females-undergoing-islet-transplantation-with-cni-based-immunosuppression-may-be-at-higher-risk-of-renal-function-decline-2894
https://events.diabetes.org/p/s/allogeneic-neo-islets-reduce-insulin-need-by-up-to-12-ukg-bw-in-autoimmune-type-1-diabetes-dogs-over-three-years-without-requiring-antirejection-drugs-enough-to-meet-human-type-1-diabetes-mellitus-nee-2895
https://events.diabetes.org/p/s/preliminary-results-of-islet-survival-in-a-novel-biovascular-pancreas-implanted-in-primates-2896
https://events.diabetes.org/p/s/hypoimmune-islet-cells-mediate-insulin-independence-after-allogeneic-transplantation-in-a-fully-immunocompetent-nonhuman-primate-without-immunosuppression-2897
https://events.diabetes.org/p/s/question-and-discussion-period-2898
https://events.diabetes.org/p/s/how-does-il-2-treatment-prevent-type-1-diabetes-progression-2900
https://events.diabetes.org/p/s/how-does-ustekinumab-prevent-type-1-diabetes-progression-2901
https://events.diabetes.org/p/s/question-and-discussion-period-2902
https://events.diabetes.org/p/s/imaging-beta-cell-immune-cell-interactions-2903
https://events.diabetes.org/p/s/what-do-immune-cells-see-in-the-pancreas-2904
https://events.diabetes.org/p/s/profiling-islet-immune-cell-interactions-in-the-human-pancreas-2905
https://events.diabetes.org/p/s/mining-spatial-transcriptomics-for-beta-cell-immune-cell-cross-talk-2906
https://events.diabetes.org/p/s/question-and-discussion-period-2907
https://events.diabetes.org/p/s/hla-as-a-target-not-a-predictor-2908
https://events.diabetes.org/p/s/targeting-tyk2-for-treatment-of-type-1-diabetes-2909
https://events.diabetes.org/p/s/il2ra-variation-shapes-type-1-diabetes-risk-2910
https://events.diabetes.org/p/s/fixing-foxp3-plus-cells-in-type-1-diabetes-2911
https://events.diabetes.org/p/s/question-and-discussion-period-2912
https://events.diabetes.org/p/s/evaluation-of-the-patient-with-diabetes-for-beta-cell-replacement-2913
https://events.diabetes.org/p/s/the-psychological-impact-of-islet-or-pancreas-transplantation-2914
https://events.diabetes.org/p/s/monitoring-and-treatment-of-recipients-for-rejection-or-type-1-diabetes-recurrence-2915
https://events.diabetes.org/p/s/update-on-clinical-trials-using-stem-cell-replacement-2916
https://events.diabetes.org/p/s/question-and-discussion-period-2917
https://events.diabetes.org/p/s/materials-to-prevent-immune-rejection-2918
https://events.diabetes.org/p/s/islet-vascularization-2919
https://events.diabetes.org/p/s/how-to-design-the-optimal-beta-cell-surrogate-2920
https://events.diabetes.org/p/s/integration-of-tools-for-monitoring-therapeutic-success-2921
https://events.diabetes.org/p/s/question-and-discussion-period-2922
https://events.diabetes.org/p/s/role-for-basic-scienceanimal-models-2923
https://events.diabetes.org/p/s/sites-for-delivery-2924
https://events.diabetes.org/p/s/induction-of-long-term-tolerance-2925
https://events.diabetes.org/p/s/question-and-discussion-period-2927
https://events.diabetes.org/p/s/beta-cell-regeneration-strategies-2928
https://events.diabetes.org/p/s/designing-the-next-generation-of-beta-cells-for-stem-cell-rx-2929
https://events.diabetes.org/p/s/insulin-resistance-is-associated-with-alterations-in-the-dynamics-of-incretin-secretion-2930
https://events.diabetes.org/p/s/semaglutide-reduces-tumor-burden-in-the-gan-diet-induced-obese-and-biopsy-confirmed-mouse-model-of-mash-with-advanced-fibrosis-and-hcc-2931
https://events.diabetes.org/p/s/state-dependent-activity-in-hindbrain-glucagon-like-peptide-1-producing-neurons-regulates-consummatory-and-valence-behavior-through-functionally-interconnected-hypothalamic-and-limbic-circuits-2932
https://events.diabetes.org/p/s/gip-acutely-blunts-insulin-and-glp-1-induced-muscle-microvascular-perfusion-2933
https://events.diabetes.org/p/s/brain-glp-1r-is-likely-required-for-peripheral-liraglutide-treatment-on-stimulating-hepatic-fgf21-2934
https://events.diabetes.org/p/s/single-cell-multiomic-analysis-of-the-effect-of-gip-and-gip-1-mono-and-multi-agonism-on-the-hypothalamus-and-hindbrain-2935
https://events.diabetes.org/p/s/coenzyme-a-synthase-knockdown-alleviates-metabolic-dysfunction-associated-steatohepatitis-via-decreasing-cholesterol-in-liver-lipid-droplets-2936
https://events.diabetes.org/p/s/the-role-of-inositol-polyphosphate-multikinase-in-progression-of-nonalcoholic-steatohepatitis-2937
https://events.diabetes.org/p/s/the-pnpla3-g-allele-reduces-the-beneficial-effects-of-a-healthy-diet-on-hepatic-lipid-content-in-type-2-diabetes-2938
https://events.diabetes.org/p/s/glucagon-and-insulin-cross-talk-regulates-hepatic-glycogen-metabolism-2939
https://events.diabetes.org/p/s/improvement-of-tissue-specific-insulin-sensitivity-after-bariatric-surgery-does-not-restore-hepatic-oxphos-capacity-2940
https://events.diabetes.org/p/s/a-noninvasive-index-for-significant-liver-fibrosis-and-stratifying-risk-of-cirrhosis-in-patients-with-type-2-diabetes-mellitus-in-primary-care-2941
https://events.diabetes.org/p/s/systemic-identification-of-functionally-conserved-lncrna-metabolic-regulators-between-humans-and-mice-2942
https://events.diabetes.org/p/s/the-mots-cck2-pathway-is-a-novel-molecular-target-for-type-2-diabetes-in-east-asians-2943
https://events.diabetes.org/p/s/identifying-nogo-b-receptor-as-a-resilience-factor-in-preventing-obesity-associated-type-2-diabetes-2944
https://events.diabetes.org/p/s/discovery-of-long-acting-unimolecular-peptide-tetra-agonists-targeting-glp-1-gip-amylin-and-calcitonin-receptors-for-enhanced-metabolic-benefits-in-animal-models-of-obesity-2945
https://events.diabetes.org/p/s/precision-engineered-activin-and-gdf-ligand-trap-hs235-a-novel-lean-mass-preserving-treatment-for-obesity-2946
https://events.diabetes.org/p/s/the-antimyostatin-antibody-srk-439-promotes-healthy-body-composition-in-combination-with-glp-1ras-in-a-mouse-model-of-obesity-2947
https://events.diabetes.org/p/s/synergistic-effects-of-dapagliflozin-and-tirzepatide-combination-treatment-on-weight-loss-and-glucose-regulation-in-diet-induced-obese-animals-2948
https://events.diabetes.org/p/s/beneficial-effect-of-the-combination-therapy-of-cagrilintide-a-dual-amylincalcitonin-agonist-and-tirzepatide-a-dual-glp-1gip-agonist-on-body-weight-loss-in-obese-rats-2949
https://events.diabetes.org/p/s/a-novel-glp-1fgf21-dual-agonist-zt003-has-therapeutic-potential-for-obesity-diabetes-and-nonalcoholic-steatohepatitis-2950
https://events.diabetes.org/p/s/lipocalin-2-a-mitokine-that-mediates-white-to-brown-fat-cross-talk-2951
https://events.diabetes.org/p/s/a-novel-function-of-endothelial-insulin-like-growth-factor-1-receptor-regulation-of-gastrointestinal-microbiota-as-a-defensive-mechanism-against-obesity-induced-metabolic-dysfunction-2952
https://events.diabetes.org/p/s/paternal-metabolism-modulates-the-metabolome-of-offspring-during-the-early-embryonic-period-2953
https://events.diabetes.org/p/s/adipose-m6a-reader-ythdf2-regulates-white-adipose-tissue-growth-and-metabolism-2954
https://events.diabetes.org/p/s/vascular-endothelium-specific-rock2-deficiency-inhibits-the-progression-of-obesity-via-adipocyte-browning-2955
https://events.diabetes.org/p/s/proteome-wide-analysis-of-usp2-substrates-revealed-its-role-in-thermogenesis-via-stabilization-of-ebf2-2956
https://events.diabetes.org/p/s/opa1-reprograms-macrophage-metabolism-to-enforce-tolerance-of-inflammation-in-obesity-2957
https://events.diabetes.org/p/s/novel-lipidated-interleukin-22-reduces-body-weight-and-improves-glucose-homeostasis-in-mice-2958
https://events.diabetes.org/p/s/palmitic-acid-coordinates-impaired-adipose-tissue-icoshigh-treg-immunosuppression-and-systemic-metabolic-disturbance-during-obesity-2960
https://events.diabetes.org/p/s/defective-g-csf-in-the-secretome-of-epicardial-adipose-cells-favors-apoptosis-and-cellular-stress-of-cardiac-progenitor-cells-in-human-obesity-2961
https://events.diabetes.org/p/s/adipose-tissue-perilipin-1-insulin-responsiveness-in-obesity-2962
https://events.diabetes.org/p/s/diet-induced-hyperlipidation-of-adiponectin-contributes-to-adiponectin-dysfunction-2963
https://events.diabetes.org/p/s/notch-signaling-inhibitor-adpo-002-promotes-browning-in-human-adipose-tissue-explants-2964
https://events.diabetes.org/p/s/the-obesity-related-natriuretic-handicap-involves-the-coordinated-regulation-of-multiple-genes-in-adipose-tissue-to-blunt-natriuretic-peptide-signaling-2965
https://events.diabetes.org/p/s/quality-of-life-and-health-utility-12-years-after-randomization-to-bariatric-surgery-vs-medical-therapy-in-patients-with-type-2-diabetes-and-obesity-the-armms-t2d-study-2966
https://events.diabetes.org/p/s/performance-of-a-machine-learning-gene-risk-score-biomarker-to-predict-weight-loss-response-to-tirzepatide-and-semaglutide-2967
https://events.diabetes.org/p/s/short-term-effects-of-semaglutide-and-tirzepatide-on-body-composition-in-patients-with-obesity-undergoing-a-low-calorie-diet-2968
https://events.diabetes.org/p/s/effect-of-baseline-antihyperglycemic-medications-on-weight-reduction-with-tirzepatide-surmount-2-subgroup-analysis-2969
https://events.diabetes.org/p/s/beyond-size-matters-the-impact-of-pancreatic-volume-and-pancreatic-fat-on-type-2-diabetes-2970
https://events.diabetes.org/p/s/hypothalamic-gliosis-is-associated-with-cvd-risk-factors-in-the-framingham-heart-study-fhs-2971
https://events.diabetes.org/p/s/plasma-lipidome-in-people-with-insulin-sensitive-and-insulin-resistant-obesity-2972
https://events.diabetes.org/p/s/multiancestry-whole-genome-sequencing-wgs-meta-analysis-to-identify-loci-associated-with-imaging-measured-hepatic-steatosis-2973
https://events.diabetes.org/p/s/leptin-30-years-later-2974
https://events.diabetes.org/p/s/leptin-30-years-later-2975
https://events.diabetes.org/p/s/leptin-30-years-later-2976
https://events.diabetes.org/p/s/leptin-30-years-later-2977
https://events.diabetes.org/p/s/economic-and-public-policy-considerations-in-the-united-states-2978
https://events.diabetes.org/p/s/antiobesity-medication-access-on-the-clinical-frontlines-2979
https://events.diabetes.org/p/s/principles-of-pharmacoequity-2980
https://events.diabetes.org/p/s/question-and-discussion-period-2981
https://events.diabetes.org/p/s/unraveling-the-distributed-neural-circuits-underlying-food-intake-and-body-weight-effects-of-glp-1-and-its-analogues-2982
https://events.diabetes.org/p/s/systemically-administered-glp-1-receptor-agonists-vs-brain-derived-glp-1-does-it-matter-for-weight-reducing-therapy-2983
https://events.diabetes.org/p/s/novel-insights-into-regulation-of-energy-metabolism-by-gipr-agonism-and-gipr-glp-1r-coagonism-2984
https://events.diabetes.org/p/s/strategies-for-mitigating-nausea-and-emesis-side-effects-of-glp-1r-agonism-2985
https://events.diabetes.org/p/s/question-and-discussion-period-2986
https://events.diabetes.org/p/s/aging-dependent-regulatory-cells-emerge-in-subcutaneous-fat-to-inhibit-adipogenesis-2987
https://events.diabetes.org/p/s/skeletal-aging-the-role-of-cellular-senescence-in-aging-and-endocrine-disease-2988
https://events.diabetes.org/p/s/caloric-restriction-and-aging-in-nonhuman-primates-2989
https://events.diabetes.org/p/s/lrp1-is-a-major-link-between-obesity-memory-and-neurodegenerative-diseases-2990
https://events.diabetes.org/p/s/immune-cell-memory-and-weight-cycling-2991
https://events.diabetes.org/p/s/signs-of-antiaging-in-lifestyle-interventions-2992
https://events.diabetes.org/p/s/nutrient-uptake-and-metabolism-during-weight-loss-2993
https://events.diabetes.org/p/s/exercise-and-skeletal-muscle-mitochondrial-adaptations-in-type-1-diabetes-2994
https://events.diabetes.org/p/s/harnessing-amino-acid-metabolism-for-diabetic-therapy-2995
https://events.diabetes.org/p/s/targeting-mitochondria-via-probiotics-to-restore-microbiota-health-in-type-2-diabetes-2996
https://events.diabetes.org/p/s/can-time-restricted-eating-inhibit-the-progression-of-prediabetes-2997
https://events.diabetes.org/p/s/possibilities-of-fasting-in-patients-with-diabetes-2998
https://events.diabetes.org/p/s/can-time-restricted-eating-treat-polycystic-ovary-syndrome-2999
https://events.diabetes.org/p/s/glp-1ra-and-thirst-3000
https://events.diabetes.org/p/s/glp-1ra-in-alcohol-use-disorder-3001
https://events.diabetes.org/p/s/glp-1-actions-on-neurodegeneration-and-neuroinflammation-3002
https://events.diabetes.org/p/s/question-and-discussion-period-3003
https://events.diabetes.org/p/s/neighborhood-determinants-of-health-and-policy-changes-lessons-outside-the-united-states-3004
https://events.diabetes.org/p/s/obesity-inequity-among-hispaniclatino-adults-and-children-in-the-united-states-drivers-and-implications-3005
https://events.diabetes.org/p/s/tailoring-obesity-treatments-to-the-united-states-hispaniclatino-population-success-and-challenges-3006
https://events.diabetes.org/p/s/metabolic-dysfunction-associated-steatotic-liver-disease-among-hispaniclatino-children-and-adults-3007
https://events.diabetes.org/p/s/effect-of-behavioral-weight-loss-on-satiety-and-food-motivation-3008
https://events.diabetes.org/p/s/gut-brain-signaling-underlying-motivational-behavior-3009
https://events.diabetes.org/p/s/genetic-and-environmental-influences-on-satiety-and-food-motivation-in-obesity-3010
https://events.diabetes.org/p/s/question-and-discussion-period-3011
https://events.diabetes.org/p/s/fine-tuning-the-patients-glp-1-experience-3012
https://events.diabetes.org/p/s/pancreatitis-and-gall-bladder-disease-3013
https://events.diabetes.org/p/s/thyroid-cancer-3014
https://events.diabetes.org/p/s/suicide-risk-3015
https://events.diabetes.org/p/s/question-and-discussion-period-3016
https://events.diabetes.org/p/s/central-nervous-system-regulation-of-systemic-glucose-lessons-learned-from-the-adaptation-to-exercise-3018
https://events.diabetes.org/p/s/neural-signaling-to-and-from-adipose-tissue-in-the-regulation-of-metabolic-health-3019
https://events.diabetes.org/p/s/brain-defense-of-glycemia-in-health-and-diabetes-3020
https://events.diabetes.org/p/s/fighting-diabetes-a-journey-that-began-in-childhood-3021
https://events.diabetes.org/p/s/the-science-of-diabetes-and-a-life-of-trials-3023
https://events.diabetes.org/p/s/insulin-and-instructions-how-the-epigenome-directs-diabetes-3024
https://events.diabetes.org/p/s/creating-talks-that-are-talked-about-how-to-bring-memorability-to-your-presentations-3025
https://events.diabetes.org/p/s/question-and-discussion-period-3026
https://events.diabetes.org/p/s/clinicaltranslational-science-perspective-3028
https://events.diabetes.org/p/s/question-and-discussion-period-3029
https://events.diabetes.org/p/s/getting-the-career-you-envision-how-to-negotiate-for-what-you-need-and-want-3030
https://events.diabetes.org/p/s/decoding-the-puzzle-unveiling-type-2-diabetes-genetics-via-multi-omic-insights-3031
https://events.diabetes.org/p/s/is-there-such-a-thing-as-good-fat-3033
https://events.diabetes.org/p/s/innovation-challenge-includes-livestream-note-continuing-education-credit-is-not-awarded-for-this-session-3035
https://events.diabetes.org/p/s/rebuttal-3037
https://events.diabetes.org/p/s/yes-the-future-is-now-harness-the-benefits-artificial-intelligence-has-to-offer-3038
https://events.diabetes.org/p/s/team-based-care-3039
https://events.diabetes.org/p/s/team-based-care-3042
https://events.diabetes.org/p/s/rebuttal-3045
https://events.diabetes.org/p/s/type-1-diabetes-progression-is-precipitated-by-beta-cells-3046
https://events.diabetes.org/p/s/national-scientific-and-health-care-achievement-awards-presentation-3047
https://events.diabetes.org/p/s/keynote-address-the-dissociation-between-technology-advances-and-health-outcomes-for-diabetes-in-the-us-what-should-we-do-differently-3049
https://events.diabetes.org/p/s/diabetes-and-kidney-transplantation-3051
https://events.diabetes.org/p/s/early-encounters-diabetes-exposure-before-birth-shapes-brain-pathways-and-metabolic-risk-3053
https://events.diabetes.org/p/s/striking-a-balance-the-role-of-glucagon-agonism-to-improve-obesity-and-metabolic-care-3054
https://events.diabetes.org/p/s/striking-a-balance-the-role-of-glucagon-agonism-to-improve-obesity-and-metabolic-care-3055
https://events.diabetes.org/p/s/team-based-care-3056
https://events.diabetes.org/p/s/basic-3057
https://events.diabetes.org/p/s/global-policies-for-diabetes-prevention-successful-policies-and-proposed-action-plans-3058
https://events.diabetes.org/p/s/how-does-baricitinib-block-type-1-diabetes-progression-3060
https://events.diabetes.org/p/s/what-the-gut-says-the-brain-about-food-3061
https://events.diabetes.org/p/s/closing-remarks-3063
https://events.diabetes.org/p/s/introduction-3064
https://events.diabetes.org/p/s/panel-discussion-3065
https://events.diabetes.org/p/s/welcome-to-the-84th-ada-scientific-sessions-3066
https://events.diabetes.org/p/s/panel-discussion-3067
https://events.diabetes.org/p/s/panel-discussion-3068
https://events.diabetes.org/p/s/panel-discussion-3069
https://events.diabetes.org/p/s/consensus-monitoring-guidance-in-early-stage-type-1-diabetes-includes-livestream-3070
https://events.diabetes.org/p/s/predicting-risk-for-atherosclerotic-cardiovascular-disease-in-type-2-diabetes-insights-from-score2-diabetes-risk-score-3071
https://events.diabetes.org/p/s/panel-discussion-3072
https://events.diabetes.org/p/s/psychosocial-and-educational-considerations-3073
https://events.diabetes.org/p/s/overview-of-pediatric-advice-3074
https://events.diabetes.org/p/s/coming-consensus-3075
https://events.diabetes.org/p/s/why-do-we-need-monitoring-guidance-3076
https://events.diabetes.org/p/s/overview-of-adult-advice-3077
https://events.diabetes.org/p/s/next-steps-and-real-world-applications-3078
https://events.diabetes.org/p/s/sex-and-gender-specific-cardiovascular-disease-risk-factors-3100
https://events.diabetes.org/p/s/panel-3101
https://events.diabetes.org/p/s/panel-3102
https://events.diabetes.org/p/s/panel-3103
https://events.diabetes.org/p/s/panel-3104
https://events.diabetes.org/p/s/panel-3105
https://events.diabetes.org/p/s/porcinexeno-approaches-3106
https://events.diabetes.org/p/s/basic-science-perspective-3107
https://events.diabetes.org/p/s/health-care-policy-and-diabetes-how-to-improve-population-health-from-multiple-perspectives-3108
https://events.diabetes.org/p/s/meet-tandem-mobi-tiny-pump-big-control-the-future-of-aid-presented-by-tandem-diabetes-care-3112
https://events.diabetes.org/p/s/empowering-people-with-type-2-diabetes-early-utilization-of-dexcom-cgm-to-support-behavior-change-and-improve-health-outcomes-presented-by-dexcom-3113
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3114
https://events.diabetes.org/p/s/omnipod-r-5-advancing-automated-insulin-delivery-for-all-presented-by-insulet-3115
https://events.diabetes.org/p/s/explore-advancements-in-type-1-diabetes-management-presented-by-sanofi-3116
https://events.diabetes.org/p/s/revolutionizing-cgm-technology-a-journey-through-mindful-innovation-presented-by-abbott-3117
https://events.diabetes.org/p/s/how-soon-should-aid-be-offered-success-in-high-risk-individuals-with-the-minimedtm-780g-system-3118
https://events.diabetes.org/p/s/product-theater-for-zepboundtm-tirzepatide-injection-presented-by-lilly-usa-llc-3119
https://events.diabetes.org/p/s/from-awareness-to-action-the-importance-of-screening-for-type-1-diabetes-presented-by-sanofi-3120
https://events.diabetes.org/p/s/perspectives-in-hyperglycemia-secondary-to-hypercortisolism-a-path-to-diagnosis-presented-by-corcept-therapeutics-3121
https://events.diabetes.org/p/s/discover-the-tempo-personalized-diabetes-management-platform-presented-by-lilly-usa-llc-3122
https://events.diabetes.org/p/s/championing-ldl-c-lowering-in-diabetes-care-presented-by-amgen-3123
https://events.diabetes.org/p/s/jardiance-r-empagliflozin-tablets-a-review-of-multiple-clinical-trials-and-approved-indications-presented-by-boehringer-ingelheim-pharmaceuticals-inc-and-lilly-usa-llc-3124
https://events.diabetes.org/p/s/discover-a-new-treatment-option-that-is-available-for-patients-with-nash-with-liver-fibrosis-madrigal-pharmaceuticals-inc-3125
https://events.diabetes.org/p/s/hepatitis-b-you-hold-the-key-to-prevention-the-importance-of-hepatitis-b-vaccination-among-adults-with-diabetes-presented-by-gsk-3126
https://events.diabetes.org/p/s/meet-tandem-mobi-tiny-pump-big-control-the-future-of-aid-presented-by-tandem-diabetes-care-3128
https://events.diabetes.org/p/s/meet-tandem-mobi-tiny-pump-big-control-the-future-of-aid-presented-by-tandem-diabetes-care-3129
https://events.diabetes.org/p/s/meet-tandem-mobi-tiny-pump-big-control-the-future-of-aid-presented-by-tandem-diabetes-care-3130
https://events.diabetes.org/p/s/empowering-people-with-type-2-diabetes-early-utilization-of-dexcom-cgm-to-support-behavior-change-and-improve-health-outcomes-presented-by-dexcom-3131
https://events.diabetes.org/p/s/empowering-people-with-type-2-diabetes-early-utilization-of-dexcom-cgm-to-support-behavior-change-and-improve-health-outcomes-presented-by-dexcom-3132
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3133
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3134
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3135
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3136
https://events.diabetes.org/p/s/creating-the-next-chapter-in-diabetes-management-by-leveraging-interoperability-and-dynamic-collaboration-introducing-the-twiist-aid-system-for-personalized-flexible-control-presented-by-sequel-3137
https://events.diabetes.org/p/s/omnipod-r-5-advancing-automated-insulin-delivery-for-all-presented-by-insulet-3138
https://events.diabetes.org/p/s/omnipod-r-5-advancing-automated-insulin-delivery-for-all-presented-by-insulet-3139
https://events.diabetes.org/p/s/omnipod-r-5-advancing-automated-insulin-delivery-for-all-presented-by-insulet-3140
https://events.diabetes.org/p/s/explore-advancements-in-type-1-diabetes-management-presented-by-sanofi-3141
https://events.diabetes.org/p/s/explore-advancements-in-type-1-diabetes-management-presented-by-sanofi-3142
https://events.diabetes.org/p/s/revolutionizing-cgm-technology-a-journey-through-mindful-innovation-presented-by-abbott-3144
https://events.diabetes.org/p/s/revolutionizing-cgm-technology-a-journey-through-mindful-innovation-presented-by-abbott-3145
https://events.diabetes.org/p/s/how-soon-should-aid-be-offered-success-in-typically-hard-to-manage-populations-with-the-minimed-780g-system-presented-by-medtronic-3146
https://events.diabetes.org/p/s/how-soon-should-aid-be-offered-success-in-typically-hard-to-manage-populations-with-the-minimed-780g-system-presented-by-medtronic-3147
https://events.diabetes.org/p/s/how-soon-should-aid-be-offered-success-in-typically-hard-to-manage-populations-with-the-minimed-780g-system-presented-by-medtronic-3148
https://events.diabetes.org/p/s/how-soon-should-aid-be-offered-success-in-typically-hard-to-manage-populations-with-the-minimed-780g-system-presented-by-medtronic-3149
https://events.diabetes.org/p/s/product-theater-for-zepboundtm-tirzepatide-injection-presented-by-lilly-usa-llc-3150
https://events.diabetes.org/p/s/from-awareness-to-action-the-importance-of-screening-for-type-1-diabetes-presented-by-sanofi-3151
https://events.diabetes.org/p/s/from-awareness-to-action-the-importance-of-screening-for-type-1-diabetes-presented-by-sanofi-3152
https://events.diabetes.org/p/s/perspectives-in-hyperglycemia-secondary-to-hypercortisolism-a-path-to-diagnosis-presented-by-corcept-therapeutics-3153
https://events.diabetes.org/p/s/perspectives-in-hyperglycemia-secondary-to-hypercortisolism-a-path-to-diagnosis-presented-by-corcept-therapeutics-3154
https://events.diabetes.org/p/s/perspectives-in-hyperglycemia-secondary-to-hypercortisolism-a-path-to-diagnosis-presented-by-corcept-therapeutics-3155
https://events.diabetes.org/p/s/discover-the-tempo-personalized-diabetes-management-platform-presented-by-lilly-usa-llc-3156
https://events.diabetes.org/p/s/championing-ldl-c-lowering-in-diabetes-care-presented-by-amgen-3157
https://events.diabetes.org/p/s/jardiance-r-empagliflozin-tablets-a-review-of-multiple-clinical-trials-and-approved-indications-presented-by-boehringer-ingelheim-pharmaceuticals-inc-and-lilly-usa-llc-3158
https://events.diabetes.org/p/s/jardiance-r-empagliflozin-tablets-a-review-of-multiple-clinical-trials-and-approved-indications-presented-by-boehringer-ingelheim-pharmaceuticals-inc-and-lilly-usa-llc-3159
https://events.diabetes.org/p/s/discover-a-new-treatment-option-that-is-available-for-patients-with-nash-with-liver-fibrosis-madrigal-pharmaceuticals-inc-3160
https://events.diabetes.org/p/s/hepatitis-b-you-hold-the-key-to-prevention-the-importance-of-hepatitis-b-vaccination-among-adults-with-diabetes-presented-by-gsk-3161
https://events.diabetes.org/p/s/eversense-long-term-cgm-addressing-traditional-cgm-usage-barriers-presented-by-ascensia-diabetes-care-3162
https://events.diabetes.org/p/s/eversense-long-term-cgm-addressing-traditional-cgm-usage-barriers-presented-by-ascensia-diabetes-care-3163
https://events.diabetes.org/p/s/eversense-long-term-cgm-addressing-traditional-cgm-usage-barriers-presented-by-ascensia-diabetes-care-3164
https://events.diabetes.org/p/s/does-weight-reduction-modulate-heart-failure-benefit-insights-from-step-hfpef-3166
https://events.diabetes.org/p/s/million-veterans-program-3167
https://events.diabetes.org/p/s/medicaid-expansion-or-lack-thereof-and-diabetes-health-outcomes-3168
https://events.diabetes.org/p/s/omnipod-5-unusual-suspects-for-aid-3169
https://events.diabetes.org/p/s/early-incorporation-of-a-noninvasive-in-office-treatment-for-painful-diabetic-peripheral-neuropathy-of-the-feet-3170
https://events.diabetes.org/p/s/attention-on-mash-the-hepatic-manifestation-of-the-metabolic-syndrome-presented-by-novo-nordisk-3171
https://events.diabetes.org/p/s/introduction-new-nomenclature-and-team-based-care-3172
https://events.diabetes.org/p/s/omnipod-5-unusual-suspects-for-aid-3173
https://events.diabetes.org/p/s/early-incorporation-of-a-noninvasive-in-office-treatment-for-painful-diabetic-peripheral-neuropathy-of-the-feet-3174
https://events.diabetes.org/p/s/the-minimed-780g-system-algorithm-explained-3176
https://events.diabetes.org/p/s/revolutionizing-diabetic-eye-screening-introducing-the-optomed-aurora-aeye-empowering-early-detection-with-ai-3177
https://events.diabetes.org/p/s/the-minimed-780g-system-algorithm-explained-3178
https://events.diabetes.org/p/s/revolutionizing-diabetic-eye-screening-introducing-the-optomed-aurora-aeye-empowering-early-detection-with-ai-3179
https://events.diabetes.org/p/s/introduction-of-outstanding-educator-award-3180
https://events.diabetes.org/p/s/introduction-of-president-health-care-and-education-award-3181
https://events.diabetes.org/p/s/conclude-3182
https://events.diabetes.org/p/s/introduction-of-president-medicine-and-science-3183
https://events.diabetes.org/p/s/conclude-3184
https://events.diabetes.org/p/s/introduction-of-banting-award-winner-3185
https://events.diabetes.org/p/s/introduction-of-outstanding-scientific-achievement-awardee-3186
https://events.diabetes.org/p/s/introduction-3187
https://events.diabetes.org/p/s/introduction-of-panel-3188
https://events.diabetes.org/p/s/ada-chief-executive-officer-and-chairman-of-the-board-fireside-chat-3189
https://events.diabetes.org/p/s/cardiovascular-disease-in-china-3190
https://events.diabetes.org/p/s/team-based-care-3191
https://events.diabetes.org/p/s/attention-on-mash-the-hepatic-manifestation-of-the-metabolic-syndrome-presented-by-novo-nordisk-3192
https://events.diabetes.org/p/s/join-the-hosts-of-adas-podcasts-for-a-dynamic-live-podcast-recording-3193
https://events.diabetes.org/p/s/heterogeneity-in-cellular-therapy-for-t1d-3194
https://events.diabetes.org/p/cf/2025-ada-clinical-update-conference-3199
https://events.diabetes.org/p/s/hands-on-training-presented-by-abbott-3200
https://events.diabetes.org/p/s/special-event-beyond-prescriptions-the-role-of-nutrition-in-patient-care-3201
https://events.diabetes.org/p/s/product-theater-presented-by-medtronic-3202
https://events.diabetes.org/p/s/welcome-to-the-2025-ada-clinical-update-conference-3203
https://events.diabetes.org/p/s/keynote-address-3204
https://events.diabetes.org/p/s/standards-of-care-2025-updates-and-practice-implications-3205
https://events.diabetes.org/p/s/case-study-discussion-and-implementation-conversation-3206
https://events.diabetes.org/p/s/breakexhibits-3207
https://events.diabetes.org/p/s/mens-health-in-diabetes-3208
https://events.diabetes.org/p/s/womens-health-hormonal-health-and-aging-well-with-diabetes-3209
https://events.diabetes.org/p/s/panel-discussion-3210
https://events.diabetes.org/p/s/call-to-action-3211
https://events.diabetes.org/p/s/networking-receptionexhibits-3212
https://events.diabetes.org/p/s/opening-comments-3213
https://events.diabetes.org/p/s/hyperglycemic-crisis-dka-3214
https://events.diabetes.org/p/s/the-diabetes-dilemma-differentiating-type-1-and-type-2-diabetes-what-to-do-if-diabetes-type-is-unclear-and-why-does-it-matter-3215
https://events.diabetes.org/p/s/ckd-screening-and-maintenance-3216
https://events.diabetes.org/p/s/panel-discussion-3217
https://events.diabetes.org/p/s/breakexhibits-3218
https://events.diabetes.org/p/s/diabetes-in-underserved-communities-strategies-for-improvement-3219
https://events.diabetes.org/p/s/updates-in-psychosocial-care-and-diabetes-3220
https://events.diabetes.org/p/s/panel-discussion-3221
https://events.diabetes.org/p/s/lunch-3222
https://events.diabetes.org/p/s/beyond-education-outpatient-cdces-adding-value-to-your-practice-3223
https://events.diabetes.org/p/s/using-patient-education-resources-in-clinical-practice-3224
https://events.diabetes.org/p/s/panel-discussion-3225
https://events.diabetes.org/p/s/breakexhibits-3226
https://events.diabetes.org/p/s/update-on-obesity-medications-3227
https://events.diabetes.org/p/s/exercise-and-nutrition-for-preserving-muscle-mass-on-glp1-3228
https://events.diabetes.org/p/s/psychology-and-behavioral-health-in-obesity-care-3229
https://events.diabetes.org/p/s/panel-discussion-3230
https://events.diabetes.org/p/s/call-to-action-team-based-care-spotlight-3231
https://events.diabetes.org/p/s/opening-comments-3232
https://events.diabetes.org/p/s/expanded-uses-of-glp-1-and-glp-1gip-ras-recommendations-safety-considerations-and-issues-related-to-compounding-3233
https://events.diabetes.org/p/s/current-cardiology-updates-in-primary-care-3234
https://events.diabetes.org/p/s/panel-discussion-3235
https://events.diabetes.org/p/s/breakexhibits-3236
https://events.diabetes.org/p/s/ai-in-diabetesprimary-care-delivery-3237
https://events.diabetes.org/p/s/technology-update-review-latest-developments-3238
https://events.diabetes.org/p/s/behavioral-considerations-for-cgm-and-aid-in-primary-care-3239
https://events.diabetes.org/p/s/panel-discussion-3240
https://events.diabetes.org/p/s/call-to-action-3241